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ABSTRACT OF DISSERTATION

LOCALIZATION AND FUNCTIONAL CHARACTERIZATION OF OATP4C1
TRANSPORTER IN IN VITRO CELL SYSTEMS AND HUMAN/RAT TISSUES
The organic anion transporting polypeptide 4c1 (Oatp4c1) was previously identified
as a novel uptake transporter predominantly expressed at the basolateral membrane in
the rat kidney proximal tubules. Its functional role was suggested to be a vectorial
transport partner of an apically-expressed efflux transporter for the efficient translocation
of physiological substrates into urine, some of which were suggested to be uremic
toxins. In vitro studies in polarized cell lines showed that upon transfection rat Oatp4c1
localizes at the apical membrane. The objectives of this project were to further validate
the subcellular localization of Oatp4c1/OATP4C1 in rat and human tissues as well as
their localization and function in polarized cells.
Using several complementary biochemical, molecular and proteomic methods as
well as antibodies amenable to immunohistochemistry, immunofluorescence, and
immunoblotting, we investigated the expression pattern of Oatp4c1 in epithelial cell lines
and in the rat kidney and mammary gland (MG). Collectively, these data demonstrated
that rat Oatp4c1 localized at the apical cell surface of polarized epithelium and primarily
in the proximal straight tubules, the S3 segment of proximal tubule, in the juxtamedullary
cortex.
Drug uptake studies in Oatp4c1-expressing cells demonstrated that Oatp4c1mediated estrone-3-sulfate (E3S) uptake was ATP-independent and pH-dependent. The
increased E3S transport activity at acidic extracellular pH was ascribed to the increased
maximum transport rate (Vmax). In addition, E3S transport inhibition by various substrates
suggests that Oatp4c1 possesses multiple substrate binding sites.
The apical localization of Oatp4c1 in the rat kidney and MG is a novel finding and
implies that this transporter protein plays a role in the reabsorption, not vectorial
secretion, of its substrates. In addition, the upregulation of Oatp4c1 expression during
lactation indicates that it is involved in reuptake of xenobiotic from the milk, resulting in
their reduced exposure to the suckling infants, or that it functions as a scavenger
system. Further, studies to identify physiological substrates are needed to better
understand the significance of Oatp4c1 function in renal and mammary epithelium.
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CHAPTER 1 : BACKGROUND
A. Drug transporters in lactating mammary epithelium
Breast milk offers the most complete nutrition for infant growth and
development, and breastfeeding is widely advocated because of numerous benefits
for infants and mothers. For infants, breastfeeding enhances cognitive development
and immune system function, thus decreasing the risk of contracting infectious
diseases. For mothers, breastfeeding promotes postpartum recovery, and decreases
the risk of osteoporosis and incidences of both breast cancer and ovarian cancer (1,
2). However, maternal medications may pose exposure risks to nursing infants. The
limited information regarding drug transfer into the milk makes patients and
physicians hesitate when deciding between maternal therapeutic benefit and infant
drug exposure risk. A better understanding of the mechanism of drug transfer into
the milk will facilitate these therapeutic decisions regarding drug use during lactation.
The mammary gland is the organ that produces milk. It is comprised of
epithelium and stroma (mammary fat pad), which is connective tissue. The
epithelium consists of ducts and milk production unit, alveoli. Mammary epithelial
cells are luminal secretory cells, which undergo extensive proliferation and
differentiation during pregnancy and lactation to produce breast milk and secrete it
into a central lumen, which opens to the body surface through the nipple. The luminal
secretory cells form the barrier between the breast milk and the maternal circulation
with an apical surface facing the lumen (milk) and a basolateral surface facing the
blood. They are surrounded by basal myoepithelial cells, which are contractile
following oxytocin stimuli, and subsequently eject the milk (3, 4).
During lactation, the mammary gland is responsible for delivering essential
nutrients, as well as xenobiotics, to suckling infants via breast milk. Many substances
1

enter into breast milk by passive diffusion, and their exposure risks can therefore be
predicted using mathematical models incorporating drug protein binding, ionization,
and fat partitioning (5, 6). Nevertheless, some water soluble substances need
transporters to efficiently cross the lactating mammary epithelial cells (LMEC).
Several adenosine triphosphate (ATP)-binding cassette (ABC) transporters and
solute carrier (SLC) have been reported to be expressed on the mammary
epithelium. However, to date, only ABCG2 has been demonstrated to be important
for drug transfer into the milk.

1. ATP-binding cassette (ABC) transporter superfamily
The ABC transporter superfamily consists of 7 subfamilies categorized A G, based on membrane topology and sequence homology. ABC transporters
consist of a pair of cytoplasmic ATP-binding domains, also known as nucleotide
binding domains (NBD), and two sets of transmembrane domains (TMD). The
NBD contain three conserved sequences: Walker A and B motifs and a signature
C motif. Walker A and B motifs can be found in all ATP-binding proteins, but the
C motif is specific to ABC transporters. ABC transporters are organized as either
full transporters containing two NBD and TMD or half transporters containing one
of each domain. Half transporters assemble as either a homodimer or a
heterodimer to be functional. ABC transporters are called primary active efflux
transporters because they utilize energy derived from ATP hydrolysis to
unidirectionally efflux a wide range of molecules against their concentration
gradient (7).

2

Several ABC transporters have been identified in mammary gland. The
prototypical ABC transporter is ABCB1, which is also known as multidrug
resistance protein 1 (MDR1) or P-glycoprotein (P-gp). P-gp is a full length
transporter with 12 TMD with cytoplasmic N- and C- terminals. P-gp was
identified in human mammary gland by immunohistochemistry (8, 9), and mRNA
and protein expression appears to be down-regulated during lactation in humans
and mice (10, 11).
The ABCC family encodes multidrug resistance-associated proteins
(MRPs). Larger MRPs (1, 2, 3, 6 and 7) contain 17 TMD with extracellular Nterminal and intracellular C-terminal. Smaller MRPs (4 and 5) consist of 12 TMD
with intracellular N- and C-terminals (12). ABCC1, ABCC2, and ABCC5 mRNA
were detected in both LMEC isolated from human breast milk and non-lactating
mammary epithelial cells (MEC) isolated from reduction mammoplasty
specimens, while ABCC3 and ABCC4 were not detected in either tissues.
ABCC1 expression is lower in LMEC relative to MEC at mRNA and protein levels
in humans and mice, respectively (10, 11). During lactation, mRNA expression of
ABCC2 is not changed, whereas ABCC5 is increased 1.7-fold in LMEC as
compared to MEC (11).
ABCG2 (Human: ABCG2; rodent: Abcg2), also known as breast cancer
resistance protein (BCRP), is a half-transporter containing only 6 TMD, and
forms a homodimer to acquire transport activity. ABCG2/Abcg2 localizes at the
apical membrane in mouse, rat, cow, and human lactating mammary tissues. Its
expression increases during mammary gland development and achieves highest
levels during lactation (10, 13). Several studies using the Abcg2 knockout mouse
model have demonstrated that Abcg2 plays an important role in xenobiotics as

3

well as riboflavin (vitamin B2) transfer into the milk (Table 1-1) (14-17). It is
interesting to note that milk secretion of riboflavin in Abcg2 knockout mice is
reduced 60-fold compared to wild-type mice. This suggests that Abcg2 is
involved in nutrient transfer from mother to suckling infant via breast milk (14). In
addition, drugs such as nitrofurantoin, cimetidine, acyclovir, and ciprofloxacin, for
which milk to plasma ratio cannot be explained by passive diffusion, are shown to
be ABCG2/Abcg2 substrates (16-19). This suggests that ABCG2/Abcg2 may be
a major factor in facilitating drug transfer into the milk.

4

Table 1-1: Milk to plasma AUC ratios for certain drugs in wild-type and
Abcg2 knockout (Abcg2-/-) mice.
Wild-type

Abcg2-/-

Ratio

Reference

Riboflavin

25.0

0.37

67.6

(14)

Nitrofurantoin

45.7

0.6

76.2

(15)

PhIP

12.8

0.5

28.1

(16)

Topotecan

6.7

0.7

10.1

Cimetidine

13.7

2.3

6.0

Aflatoxin B1

0.7

0.2

3.8

IQ

0.9

0.3

3.4

Acyclovir

1.3

0.4

3.3

Trp-P-1

1.1

0.4

2.6

Ciprofloxacin

4.44

2.19

2

(17)

2. Solute carrier (SLC) superfamily
The SLC family consists of 52 subfamilies, with over 410 family members
(20, 21). SLC family members have varied biochemical properties, including Gprotein coupling receptors, voltage gated ion channels, tyrosine kinase receptors,
and various transporters for small molecules or organic anions/cations. Among
SLC family members, SLC15, 21 and 22 families are relevant for xenobiotics
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transport in the mammary gland. Many of these transporters transfer their
substrates bidirectionally by facilitated diffusion down a concentration gradient or
by secondary active transport coupled with endogenous ions to exchange or
cotransport across cell membranes, but are typically considered as uptake
transporters.
The peptide transporters (SLC15) contain 12 TMD, a large extracellular
loop between TMD 9 and 10, and intracellular N- and C-terminals. Both
SLC15A1 (PEPT1) and SLC15A2 (PEPT2) transporters have similar substrate
selectivity, but PEPT1 is a low-affinity, high-capacity transporter, while PEPT2 is
a high-affinity, low-capacity carrier (22). Both PEPT1 and PEPT2 are expressed
in LMEC by RT-PCR analysis. During lactation, mRNA expression of SLC15A1 is
downregulated, while SLC15A2 increased 28-fold in the LMEC as compared to
the MEC (11). In situ hybridization analysis showed that Slc15a2 mRNA localize
at the apical side of rat ductal epithelium (23). The apical localization suggests
PEPT2/Pept2 may function as a scavenger system to transport the product of
milk protein hydrolysis back into the mammary epithelium driven by an inwarddirected proton gradient from breast milk (pH 6.8-7.2 (24)). It may also reuptake
some peptide-like drugs such as cephalosporins back into the mammary
epithelium, thus reducing the burden of the milk. (23).
Organic anion or cation transport is mediated mostly by solute carrier
organic anion transporter family (SLCO) (previously SLC21) and SLC22 families.
SLCO family encodes for organic anion transporting polypeptides (rodents:
Oatps, human: OATPs). They contain 12 TMD with cytoplasmic N- and Cterminals and a large extracellular loop between TMD 9 and 10 (25). SLC22
family includes organic cation transporters (OCT, SLC22A1-3), zwitterion/cation
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transporters (OCTN, SLC22A4-5), and organic anion transporters (OAT,
SLC22A6-20). They all consist of 12 TMD with cytoplasmic N- and C-terminals,
a large extracellular loop between TMD 1 and 2, and a large intracellular loop
between TMD 6 and 7 (26). For organic anion transport, OATs

transport

relatively small organic anions (generally <400 Da) such as PAH, probenecid and
fluorescein, while OATPs transport comparably bulky compounds (generally >
500 Da) such as conjugated steroids, bile acids, thyroid hormone, eicosanoids,
peptides, cardiac glycosides (digoxin, ouabain), and numerous drugs (27).
OATPs currently comprise six families (OATP1-6), containing 11 human
isoforms and 14 rat isoforms. They transport a wide range of amphipathic
compounds generally by a bidirectional, sodium-independent, pH-dependent,
electroneutral mechanism (28). SLCO1A2 (OATP1A2, previously: OATP-A),
SLCO2B1 (OATP2B1, previously: OATP-B), SLCO3A1 (OATP3A1, previously:
OATP-D), and SLCO4A1 (OATP4A1, previously: OATP-E) mRNA were detected
in both LMEC and MEC by RT-PCR or Northern blot analysis (11, 29). During
lactation, mRNA expression of both SLCO1A2 and SLCO2B1 increases about
1.5-fold in LMEC relative to MEC, whereas SLCO3A1 and SLCO4A1 are
downregulated. Immunohistochemical analysis showed that OATP2B1 localizes
in the contractile myoepithelial cells rather than the luminal secretory cells (29).
Interestingly, microarray analysis has shown that SLCO4C1 (OATP4C1) mRNA
expression increases 70-fold in LMEC relative to MEC (30). This suggests a
potential role of OATP4C1 in drug transfer into breast milk. The characterization
of OATP4C1 is discussed in greater detail in the section D.
SLC22A1 (OCT1) and SLC22A3 (OCT3), but not SLC22A2 (OCT2), mRNA
were detected in both LMEC and MEC by RT-PCR analysis (11, 31). During
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lactation, mRNA expression of SLC22A1 increases 7.8-fold in LMEC as
compared to MEC, whereas SLC22A3 is downregulated. OCTN1 (SLC22A4) and
OCTN2 (SLC22A5) were both detected in human mammary tissue by Western
blotting, and OCTN2 was detected in the ductal-lobular-alveolar structures, as
demonstrated by immunohistochemical analysis (32). During lactation, mRNA
expression of SLC22A4 increases about 6-fold in LMEC relative to MEC,
whereas SLC22A5 is downregulated. SLC22A6 - 8 (OAT1 - 3) were not detected
in lactating or non-lactating human and rat mammary tissue (11, 29, 31).

B. Renal physiology
The kidney plays a critical role in maintaining homeostasis in body fluid
composition, conserving essential nutrients, and eliminating natural byproducts,
toxins, drugs and drug metabolites from the body. A simple diagram of the structure
of the kidney is shown in Figure 1-1. Each kidney is covered by an inelastic capsule,
which confines the volume of the kidney despite changes in blood pressure. Each
kidney comprises two regions: a dark brown outer region named the cortex, and a
pale inner region, which is divided into the medulla and the renal pelvis. The medulla
consists of 7 to 18 large conical masses (usually 7 in humans) known as the renal
pyramids. The broad base of each pyramid faces the cortex and their apex, papilla,
is at renal pelvis. The renal pelvis contains the major renal blood vessels and ureter
origin.
Each human kidney contains about 1.25 million functional units, which are
called nephrons. Each nephron is composed of a renal corpuscle attached to a long
thin convoluted tube and its associated blood supply. The renal corpuscle consists of
Bowman’s capsule and glomerulus which is a capillary tuft that receives the blood
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supply from an afferent arteriole of the renal circulation. The proximal tubule arises
directly from Bowman’s capsule and connects with the descending loop of Henle.
The thin descending limb turns and ascends towards the cortex, and connects to the
thick segment. The terminal segment of the thick ascending limb of the loop of Henle
and the initial part of the distal tubule contact the afferent arteriole close to the
glomerulus and form the juxtaglomerular apparatus, which is responsible for
regulation of sodium balance. The distal tubules of a number of nephrons merge via
connecting tubules to form collecting ducts and pass through the cortex and medulla
to the renal pelvis.
These structures are comprised of epithelial cells, which are rich in
mitochondria suggesting a major role in active transport. These cells are joined via
tight junctions near the apical surface, which is densely covered by microvilli forming
a brush border. The brush border (apical) membrane faces the urine, and the
basolateral membrane faces the blood. The renal excretory systems consist of three
major processes: glomerular filtration, tubular secretion, and tubular reabsorption.
The sum of the three processes for a compound undergoing in the nephrons
determines its net renal excretion rate. The glomerular blood pressure provides the
driving force to filter water and solute out from the blood to Bowman’s capsule. About
20% of the renal blood flow undergoes filtration at the glomerulus and passes along
to the proximal tubule. Low molecular weight substances which are not bound to
plasma protein (e.g., albumin) are more likely to be filtered. The filtered substances,
including glucose, amino acids, sodium, chloride, bicarbonate and exogenous
substances (e.g., β-lactam antibiotics), may be reabsorbed from the glomerular
filtrate to the blood. The reabsorption is accompanied by an osmotic equivalent of
water so that about two-thirds of the filtered fluid has been reabsorbed by the end of
the proximal tubule. In addition to reabsorbing solutes, the proximal tubule actively
9

secretes some organic anions and cations into the lumen. The homeostasis of
endogenous and exogenous substances is achieved by tubular secretion and
reabsorption, which are mediated by multiple transporters localized at both sides of
the plasma membranes, mainly in the proximal tubular cells. Tubular secretion and
reabsorption can occur as a facilitated transport to transfer substances down a
concentration gradient or as an active transport requiring energy to move substances
against a concentration gradient (33, 34).

Figure 1-1: Cross-sectional view of the kidney (34).
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C. Drug transporters in the kidney
The kidney is responsible for homeostasis of endogenous and exogenous
substances through tubular secretion and reabsorption. Many of the urinaryeliminated drugs and metabolites are water soluble and cannot easily cross the lipid
bilayer of cell membranes. Transporters are needed for selective and efficient
transport in renal tubular cells, including the ABC and SLC transporters (Figure 1-2).
Several studies have demonstrated that overlapping substrate specificity among
uptake and efflux transporters is likely to accelerate the translocation of endogenous
and exogenous substances across epithelial or endothelial barriers, and this process
is often called vectorial transport (35, 36). Thus, it is important to obtain detailed
knowledge regarding transporters expressed in the kidney and their substrates to
better understand renal tubular secretion and reabsorption of drugs and/or their
metabolites. In the long term, such information will be important in predicting renal
drug excretion and transporter-mediated drug-drug interactions. The detailed
information of ABC transporter superfamily and SLC superfamily expressed in the
kidney is described below.

11

Figure 1-2: ABC and SLC transporters in proximal tubular cells (adapted from
literature (37-39)).

1. ABC transporters
Among ABC transporters, ABCB1, ABCC1-6 and ABCG2 are relevant for
xenobiotic transport in the kidney. Because of unidirectional transport, function of
ABC transporters in the kidney is determined by their subcellular localization. The
12

apical transporters are responsible for renal tubular secretion, while the
basolateral transporters are important in renal tubular reabsorption.
ABCB1 is expressed at the apical membrane in proximal tubules (40). It
plays an important role in tubular secretion of digoxin, and may be responsible
for clinically important drug-drug interactions, such as digoxin-quinidine or
digoxin-verapamil (41).
ABCC1 localizes at the basolateral membranes of the limb of Henle, distal
tubules and collecting ducts, but not proximal tubules in mouse kidney (42).
ABCC1 along with an apical uptake transporter may facilitate the tubular
reabsorption of substances from fluids in the distal tubules. ABCC1 substrates
include a variety of physiological substances such as glutathione, glucuronide
and sulfate conjugates as well as xenobiotics, such as methotrexate (MTX),
doxorubicin, topotecan and vinblastine (12).
ABCC2 is expressed apically in proximal tubules (43, 44) and plays an
important role in tubular secretion of its substrates. ABCC2 shares considerable
substrate specificity with ABCC1, but has a distinct function in the body because
of different subcellular localization (12). In a patient with a heterozygous ABCC2
mutation, nephrotoxicity was reported due to reduced MTX elimination (45).
ABCC3 localizes at the basolateral membranes in rat distal tubules, thick
ascending loop of Henle, and in human proximal tubules (46, 47). ABCC3 may
be involved in tubular reabsorption of its substrates, which are similar to ABCC1
(12).
ABCC4 localizes at the apical membrane of renal proximal tubules (48, 49).
Studies in Abcc4 knockout mice revealed the importance of this protein in the
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tubular secretion of various drugs, such as antivirals (adefovir, tenofovir),
diuretics (hydrochlorothiazide, furosemide) and cephalosporin antibiotics (50).
ABCC4 may also facilitate the tubular secretion of other substrates, such as
cyclic nucleotides, MTX, topotecan, prostaglandins, urate, para-aminohippurate
(PAH) and several anionic conjugates (50).
ABCC5 is expressed in the kidney (51, 52), but the localization in the
kidney has not been determined yet. Nevertheless, ABCC5 polarizes to
basolateral membrane when stably transfected in MDCKII cells, and mediates
the transport of nucleotide analogues, such as adefovir, mercaptopurine,
thioguanine, cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP) (53, 54). The role of ABCC5 in the kidney remains to be
investigated.
ABCC6 is highly expressed in kidney and liver and is localized at the
basolateral membrane in the proximal tubules (55, 56). It has a limited substrate
specificity, which includes the endothelin receptor antagonist BQ123 (cyclo [TrpAsp-Pro-Val-Leu]), S-(dinitrophenyl)-glutathione and leukotriene C4. Its role in
renal elimination of its substrates remains to be clarified.
ABCG2 is expressed at the apical membrane in proximal tubules (57, 58).
The apical localization suggests its role in facilitating the elimination of its
substrates into the urine. ABCG2 transports a wide range of substrates, including
uncharged or amphiphilic compounds, particularly anticancer drugs, such as
topotecan, MTX, doxorubicin (12).

14

2. SLC transporters
Among SLC family members, SLC15, 17, 21 and 22 families are relevant
for xenobiotics transport in the kidney. These transporters are typically
considered as uptake transporters. Therefore, the apical SLC transporters are
mostly responsible for renal tubular reabsorption, while the basolateral SLC
transporters are important in renal tubular secretion.
Pept1 and Pept2 localize at the apical membrane in the S1 segments and
S2/S3 segments in the rat proximal tubules, respectively (59). They are proton
oligopeptide cotransporters and mediate the renal reabsorption of small anionic
peptides and various peptide-like drugs, such as the β-lactam antibiotic
cephalosporin (22).
Sodium-dependent phosphate cotransporter 1 (NPT1) (SLC17A1) belongs
to type I phosphate/vesicular glutamate transporters (SLC17) containing at least
6 (perhaps 8) TMD (60). It localizes at the apical membrane in all segments of
rabbit renal proximal tubules (61), and handles the tubular secretion of urate,
PAH and various anionic drugs (62).
Among OATPs, only Oatp1a1, Oatp1a3v1, Oatp1a3v2, Oatp1a5, Oatp2a1,
OATP1A2 and Oatp4c1/OATP4C1 have been detected in rodents/human kidney.
Oatp1a1 (previously: Oatp1, Oatp) is expressed at the apical membrane of the
proximal tubule S3 segment in the outer medulla (63). Oatp1a1 has broad
substrate specificity, including anionic, cationic, and neutral compounds. It is
expressed predominantly in males and its expression has been related to the
longer half-life of perfluorocarboxylates (PFO) as compared to female rats, which
indicates an important role in renal reabsorption of PFO (64). The transport
mechanisms of Oatp1a1 have been proposed as solute/HCO3- exchange and
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solute/GSH exchange (65, 66). OATP1A2 (previously: OATP-A) localizes at the
apical membrane in human distal tubules (67) and probably participates in the
saturable reabsorption of MTX (68). Oatp1a3v1 (previously: OAT-K1) and
Oatp1a3v2 (previously: OAT-K2) are expressed exclusively in the kidney (69).
Oatp1a3v1 was detected in the brush-border membranes isolated from rat kidney
by Western blotting. In addition, both Oatp1a3v1 and Oatp1a3v2 showed a
functionally apical uptake or efflux in cell systems (70-72), which suggests that
they function as bidirectional organic anion transporters at the apical membrane.
Oatp1a3v1 and Oatp1a3v2 have also been implicated as the major exceretory
route of MTX and may be responsible for the folinic acid rescue for high-dose
MTX treatment of acute lymphocytic leukemia by exchanging extracellular folinic
acid for intracellular MTX (73, 74). Oatp1a5 (previously: Oatp3) mRNA is highly
expressed in rat kidney (75), but its localization has not been determined yet.
Endogenous

or

exogenous

substances

(e.g.,

thyroid

hormones,

E3S,

fexofenadine, digoxin) have been reported to interact with rat Oatp1a5 (76, 77),
but the role of Oatp1a5 in renal drug elimination remains to be clarified. Oatp2a1
(previously: PGT) localizes at the apical surface of rat collecting ducts,
glomerular endothelial and mesangial cells and is responsible for renal
reabsorption of prostanoids (78). OATP4C1/Oatp4c1 (previously: OATP-H) was
reported to be expressed at the basolateral membrane of the proximal tubules
(79). The expression and functional characterization of OATP4C1 is discussed in
greater detail in section D.
Oct1, Oct2 and Oct3 all localize at basolateral membrane of rat proximal
tubules (80-82). Oct1 is mainly expressed in S1/S2 segments of rat proximal
tubules. Oct2 is predominantly expressed in S2/S3 segments of rat proximal
tubules, and in all segments of human proximal tubules. OCTs are facilitative and
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bidirectional diffusion transporters mediating electrogenic and Na+-independent
flux of small organic cations with a molecular weight up to about 400-500 Da
(83). The transport direction is determined by concentration gradients and the
electrical potential across the membrane. OCT1, OCT2 and OCT3 have a broad
overlap of substrate and inhibitor specificities. OCTs mediate the renal excretion
of neurotransmitters dopamine, epinephrine, and many organic cation drugs such
as desipramine, metformin, cimetidine and cisplatin. OCTs also mediate the renal
reabsorption of choline (26).
OCTN1 and OCTN2 are strongly expressed at the apical membranes of
proximal tubules (84, 85). OCTN1 is a bidirectional proton/organic cation
antiporter (86, 87), whereas OCTN2 may function as a unidirectional sodium/Lcarnitine cotransporter or a bidirectional sodium-independent organic cation
transporter (88, 89). OCTN1 and OCTN2 mediate the renal secretion of organic
cations, such as verapamil, choline, whereas OCTN2 can also mediate the
reabsorption of L-carnitine following exchange with cationic compounds (26).
OATs

are

organic

anion/dicarboxylate

(favorably

α-ketoglutarate)

exchangers. OAT1 s predominantly expressed in the kidney (90). It localizes at
the basolateral membrane in S2 segment of rat proximal tubules and all
segments of human proximal tubules (82, 91). OAT2 is highly expressed in the
liver and to a lesser extent in the kidney (90). Its localization in the kidney is
controversial. It was detected at the basolateral membrane of human proximal
tubules (92), but it has also been reported at the apical surface of rat medullary
thick ascending limb of Henle’s loop and the collecting ducts (91) or proximal
tubule S3 segments (93). Therefore, the role of OAT2 in kidney is still unclear.
OAT3 is exclusively expressed in the kidney and its mRNA expression is
considerably higher than OAT1 in human kidney (82). OAT3 is expressed at the
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basolateral membrane in all segments of rat or human proximal tubules (82, 91,
94). OAT1 and OAT3 mediate the first step of renal tubular excretion of their
substrates. They have wide overlapping substrate specificities, including
endogenous substrates such as PAH, cyclic nucleotides, prostaglandins, urate,
uremic toxins, as well as anionic drugs, such as β-lactam antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), antiviral drugs, antidiabetic and
anticancer drugs. In addition, OAT1 has a larger contribution to low-molecular
weight drugs, whereas OAT3 transports more bulky amphipathic anions, such as
hepatic hydroxymethylglutaryl –Coenzyme A (HMG-CoA) reductase inhibitors
(statins), and even some cationic drugs, including H2 receptor antagonists (95).
OAT4 is highly expressed in the kidney and to a lesser extent in the placenta. It
localizes at the apical membrane of the proximal tubules (96, 97), and is involved
in renal reabsorption of organic anions, such as E3S, MTX and PAH, driven by
an outwardly directed dicarboxylate gradient (84, 98). Urate transporter 1
(URAT1 is mainly expressed in the kidney, and is localized at the apical
membrane of proximal tubules (99, 100). OAT4 and URAT1 are urate anion
exchangers that play a key role in urate homeostasis via a renal reabsorption
mechanism. OAT10 is predominantly expressed in human kidney, and was
exclusively detected in the brush-border membrane isolated from the rat kidney.
It is responsible for renal reabsorption of nicotinate and urate (101). Oat5
expression is restricted to the kidney, and is localized at the apical membrane in
the S2/S3 segment of mouse and rat proximal tubules. It may be involved in
renal reabsorption of E3S (102, 103).
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D. OATP4C1 (Human: OATP4C1; rodent: Oatp4c1)
OATP4C1 (SLCO4C1) was first isolated from human kidney in 2004 (79). It
was initially called OATP-H and renamed as OATP4C1 according to the HUGO
Gene Nomenclature Committee (28). It is located on chromosome 5q21, and is
about 62 kb long including 13 exons and 12 introns. It consists of 724 amino acids,
and the predicted molecular weight is 79 kDa. OATP4C1 was predicted to contain 12
TMD with intracellular N- and C-terminals, by hydrophobicity analysis. There are four
putative N-glycosylation sites in the predicted extracellular loop and five potential
phosphorylation sites in the intracellular portions. Interestingly, the intracellular loop
between TMD 6 and 7 of human OATP4C1 and rat Oatp4c1 contain two and one,
respectively, potential ATP binding sites characteristic of the Walker A motif found in
ABC transporters but not in other OATP family proteins. The overall homology
between human and rat Oatp4c1 is 80.4% at the amino acid level.
Microarray expression studies show that human SLCO4C1 mRNA is highly
expressed in the kidney, neutrophils, liver, moderately in mammary gland, and
slightly in lung, skin, peripheral leukocytes and mononuclear cells (104). Rat Slco4c1
is detected mainly in the kidney and lung, and slightly in the brain by Northern
analysis (79), while mouse Slco4c1 is detected in the kidney and lung by bDNA
assay (105). There is no gender difference of Slco4c1 expression in the rat kidney,
but higher Slco4c1 expression was observed in male mouse kidney as compared to
females (79, 105). In addition, Slco4c1 expression in kidney increases with age in
mice(105). RT-PCR from microdissected rat nephron segments showed that rat
Slco4c1 is detected mainly in the proximal convoluted tubule, proximal straight
tubule, and slightly in the glomerulus, cortical thick ascending limb and cortical
collecting duct. Immunohistochemical analyses has shown that Oatp4c1 localizes at
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the basolateral membrane in the rat proximal tubules (79) as well as human
OATP4C1 in the transgenic rat harboring human SLCO4C1 (106). In the 5/6
nephrectomized renal failure model, Slco4c1 expression was significantly decreased
by Northern blot analysis. This may be related to the changes of pharmacokinetics of
its substrates in renal failure. Interestingly, microarray analysis showed that
SLCO4C1 is highly expressed in lung tumors and its mRNA expression is 18-fold
higher than that in the normal human lung (104). This suggests a potential vital role
of OATP4C1 in lung cancer. SLCO4C1 was also detected in several cancer cell
lines, including renal carcinoma cells (ACHN, SN12C), ovarian cancer cells
(OVCAR-8, OVCAR-3), leukemia cells (HL-60, RPMI-8226, CCRF-CEM), lung
cancer cells (H322M, H23, HOP-62, H460), glioblastoma (SF-539) and breast cancer
cells (BT-549) (107).
A promoter analysis showed that SLCO4C1 promoter region has xenobioticresponsive element (XRE) motifs, which are generally recognized by aryl
hydrocarbon receptors (AhR) and AhR nuclear translocator heterodimer (108). The
promoter activities are enhanced by nuclear AhR inducers, 3-methylcholanthrene
and HMG-CoA reductase inhibitors (pravastatin, fluvastatin, simvastatin, lovastatin,
cerivastatin, itavastatin, mevastatin, atorvastatin, rosuvastatin and pitavastatin).
Following pravastatin treatment in ACHN cells, SLCO4C1 mRNA expression is
upregulated 1.73-fold, and uptake of an OATP4C1 substrate, triiodothyronine (T3), is
increased 1.4-fold (106).
The reported substrates of OATP4C1 include cardiac glycosides [digoxin (Km
7.8 μM) and ouabain (Km 0.38 μM)], thyroid hormones [T3 (Km 5.9 μM) and
thyroxine (T4)], cAMP, MTX (79), sitagliptin (109), and E3S (110). The transport
direction appears to be unidirectional uptake from outside to inside (79), but the
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driving force has not been elucidated. Sodium, chloride, and pH did not affect
OATP4C1-mediated uptake, while ATP depletion partially inhibits T3 uptake to 40%
(79). However, Leuthold et al. demonstrated that OATP4C1-mediated E3S or T4
uptake is significantly higher at extracellular pH 6.5 than pH 8.0 (111). In addition,
OATP4C1 has been suggested to possess multiple substrate recognition sites,
because digoxin does not inhibit OATP4C1-mediated T3 (79) or E3S (110) uptake
and vice versa, while E3S and T3 have mutual inhibition.
Furthermore, the physiological role of OATP4C1, reportedly a basolateral
uptake transporter, has been postulated to couple with P-glycoprotein, an apical
efflux transporter, to facilitate the renal clearance of common substrates, such as
digoxin (79) and uremic toxins (106). In studies with transgenic rats harboring human
SLCO4C1, the hypertension and renal inflammation were ameliorated in renal failure
models. The decreased plasma concentrations of uremic toxins (guanidino
succinate, asymmetric dimethylarginine, and trans-aconitate) suggest that OATP4C1
may facilitate the excretion of uremic toxins in renal failure models and, by extension,
in patients with chronic kidney disease. The enhancement of the uremic toxins
excretion and the amelioration of end-organ damage were also observed by
pravastatin-induced Slco4c1 up-regulation in rat renal failure models (106). However,
direct evidence that these toxins are OATP4C1 substrates is lacking.

E. Summary
The well documented benefits of breastfeeding and the limited data regarding
drug transfer into breast milk, make it difficult for patients and their doctors to weigh
the benefits and risks between maternal treatment and infant drug exposure. For
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most of the drugs that have been studied, the exposure risks can be predicted by
passive diffusion using mathematical models that incorporate easily measured
parameters such as drug protein binding, ionization, and fat partitioning. However,
several reports showed that certain drugs accumulate in breast milk at substantially
higher levels than predicted by passive diffusion and in particular, drugs that are
substrates for xenobiotic transporters. A comprehensive microarray analysis was
performed to measure the expression of 55 xenobiotic transporter genes in LMEC
isolated from human breast milk and MEC isolated from reduction mammoplasty
specimens and to identify the genes that are upregulated during lactation (30). In
accord with a previous study (10), ABCG2 expression was upregulated during
lactation by 164-fold in LMEC relative to MEC. A novel finding showed a 70-fold
increase of SLCO4C1 expression in LMEC as compared to MEC, suggesting a
potential role in drug transfer into the milk.
Human OATP4C1 and rat Oatp4c1 have been demonstrated to localize at the
basolateral membrane in the kidney (79, 106). Therefore, we hypothesized that
OATP4C1/Oatp4c1 localizes at the basolateral membrane in the mammary gland
and couples with ABCG2/Abcg2, an apical efflux transporter, to facilitate the transfer
of common substrates into breast milk. To study the role of Oatp4c1 in drug
disposition, we sought to generate stably transfected cell lines expressing rat
Oatp4c1. Initial attempts to generate Oatp4c1-expressing MDCKII cells produced
unexpected results as the transporter localized at the apical rather than the
basolateral membranes.
This dissertation work aims to validate the subcellular localization of
OATP4C1/Oatp4c1 in the in vitro models and in human/rat tissues and to explore
their transport characteristics. We used a comprehensive approach, including
multiple antibodies amenable to immunohistochemistry, immunofluorescence, and
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immunoblotting to probe the expression of Oatp4c1 in intact tissues and cells as well
as biochemically separated and enriched apical and basolateral membranes isolated
from polarized cells and rat renal proximal tubules. Furthermore, proteomic analysis
was used to qualitatively validate the specificity of these antibodies. Functional
activity of Oatp4c1 in MDCKII-Oatp4c1 was probed with E3S and MTX. The
expression and subcellular localization of human OATP4C1 in the in vitro model,
human kidney, lung tumor specimens and cancer cells were also examined.
Functional activity of OATP4C1 in MDCKII-OATP4C1 and Sf9-OATP4C1 was
probed with ouabain and E3S.

Copyright © Kuei-Ling Kuo 2012
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CHAPTER 2 : PLAN OF WORK
Hypothesis 1: Oatp4c1 is upregulated in mammary gland during lactation. It functions
as a basolateral uptake transporter, and couples with apically-expressed efflux
transporter Abcg2 to facilitate the transfer of common substrates into the milk.
Specific Aim 1a: To develop and validate rat Oatp4c1 antibodies amenable for
immunoblotting, immunohistochemistry and immunofluorescence.
Specific Aim 1b: To create and validate a stably transfected rat Oatp4c1expressing cell line with appropriate characteristics for uptake studies.
Specific Aim 1c: To determine the expression and subcellular localization of
Oatp4c1 in rat tissues (liver, kidney, lactating and non-lactating mammary gland).
To explore the xenobiotic transporters responsible for drug transport into the milk,
a microarray study was performed by Dr. Philip Empey and showed a 70-fold increase of
SLCO4C1 mRNA expression in human lactating mammary epithelial cells relative to
non-lactating mammary epithelial cells (30). The upregulation of SLCO4C1 expression
during lactation suggested a potential role of OATP4C1 in drug transfer into the milk. To
determine the subcellular localization of Oatp4c1 in mammary epithelium, rat Oatp4c1
antibodies will be developed in Specific Aim 1a. The antibody specificities will be
validated using a stably transfected rat Oatp4c1-expressing cell line established in
Specific Aim 1b by Western blotting, immunohistochemistry and immunofluorescence.
To investigate the role of Oatp4c1 in drug disposition, a single clone with the highest
Oatp4c1 expression will be obtained and will be used in Specific Aim 3a and 3b. Specific
Aim 1c will investigate the expression and subcellular localization of Oatp4c1 in rat liver,
kidney, lactating and non-lactating mammary gland by Western blotting and
immunochemical analysis.
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Hypothesis 2: Oatp4c1 localizes at the apical membrane in the rat kidney cortex.
Specific Aim 2a: To verify the apical localization of Oatp4c1 in the rat kidney cortex
by proteomic analysis in the isolated brush-border membrane (BBM) and
basolateral membrane (BLM).
Specific Aim 2b: To determine the precise expression pattern of Oatp4c1 at the
organ and nephron level.
A previous study reported that Oatp4c1 localizes to the basolateral membrane in
the rat kidney cortex (79). However, results from Specific Aim 1c showed that Oatp4c1
localizes at the apical membrane of polarized epithelial cells grown in vitro. In Specific
Aim 2a we will isolate BBM and BLM from rat kidney cortex to elucidate these
contradictory results. The proteins in BBM and BLM preparations will be analyzed by
Western blotting and LC-MS/MS to validate the localization of Oatp4c1 in rat kidney.
Specific Aim 2b will determine the precise location of Oatp4c1 at the organ and nephron
level by double immunofluorescence with proximal tubule marker or distal tubule marker.
Double immunofluorescence staining will also be used to access the location of Oatp4c1
relative to major apical efflux transporters in the rat kidney.

Hypothesis 3: Oatp4c1 functions as an uptake transporter involved in renal tubular
reabsorption. The in vitro cell systems can be used to identify potential substrates and
explore the physiological role of Oatp4c1.
Specific Aim 3a: To investigate Oatp4c1 transport characteristics and driving force.
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Specific Aim 3b: To identify potential Oatp4c1 substrates.
The kidney is responsible for homeostasis of endogenous and exogenous
substances through tubular secretion and reabsorption, which in part is mediated by
various membrane transporters, including those in the SLC superfamily. The results from
Specific Aim 1c showed that Oatp4c1 localizes at the apical membrane in rat kidney
inner cortex, suggesting a potential role in renal reabsorption of its substrates. To have a
better understanding of the physiological role of Oatp4c1, its substrates and transport
characteristics will be explored. In Specific Aim 3a we will verify E3S, a human
OATP4C1 substrate (110, 111), as a rat Oatp4c1 substrate and will investigate the
transport kinetic and driving force of Oatp4c1-mediated E3S transport using the
Oatp4c1-expressing cells developed in Specific Aim 1a. In Specific Aim 3b we will
determine the interaction of Oatp4c1 with potential physiological substrates by studying
their capacity to inhibit transport of E3S.

Hypothesis 4: OATP4C1 is localized at the apical membrane in the in vitro cell systems
and human kidney, and is highly expressed in lung cancer. The in vitro cell systems can
be used to study the role of OATP4C1 in drug disposition.
Specific Aim 4a: To develop and validate human OATP4C1 antibodies amenable
for immunoblotting, immunohistochemistry and immunofluorescence.
Specific Aim 4b: To create and validate human OATP4C1-expressing cells with
appropriate characteristics for functional studies.
Specific Aim 4c: To determine the expression and subcellular localization of
OATP4C1 in the human kidney.
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Specific Aim 4d: To determine the expression of OATP4C1 in cancer cells.
The

subcellular

localization

of

membrane

transporters

determines

their

physiological function. The novel finding of the apical localization of rat Oatp4c1 in this
project suggests its physiological role is tubular reabsorption not tubular secretion. To
validate the subcellular localization of OATP4C1 in human kidney, human OATP4C1
antibodies will be developed in Specific 4a. The antibody specificities will be validated in
a stably transfected OATP4C1-expressing cell line established in Specific Aim 4b by
Western blotting, immunohistochemistry and immunofluorescence. The functional
activity of OATP4C1 in the transfected cell line will also be validated using ouabain and
E3S as substrates in uptake studies. OATP4C1 will also be overexpressed in insect cells
for substrate screening and its functional activity will be probed with ouabain and E3S. In
Specific Aim 4c we will determine the subcellular localization of OATP4C1 in human
kidney. In Specific Aim 4d we will examine SLCO4C1/OATP4C1 expression in several
cancer cell lines, lung tumor and adjacent normal lung tissue sections.

Copyright © Kuei-Ling Kuo 2012
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CHAPTER 3 : MATERIALS AND METHODS
A. Materials
Madin-Darby canine kidney II (MDCKII) cells were purchased from European
Collection of Cell Cultures (Salisbury, UK). LLC-PK1 cells (porcine kidney proximal
tubule epithelial cells) were purchased from American Type Culture Collection
(ATCC, Manassas, VA).
Transwells #3414, and snapwells #3407 were obtained from Corning Costar
(Cambridge, MA). All cell culture media were purchased from Mediatech (Manassas,
VA). Fetal bovine serum was from Atlanta Biologicals (Lawrenceville, GA). Penicillinstreptomycin, blasticidin, geneticin were obtained from Invitrogen (Carlsbad, CA).
RNeasy Kit, Qiashredder columns, RNase-free DNase set, and QIAprep Spin
Miniprep Kit were obtained from Qiagen (Valencia, CA). ThermoScriptTM RT-PCR
kit, LR ClonaseTM II Enzyme Mix, Tag-On-DemandTM Suppressor System and
ethidium bromide were purchased from Invitrogen. RecoverALLTM Total nucleic acid
isolation kit was from Invitrogen Ambion. XL1-Blue Supercompetent cell was from
Stratagene (Santa Clara, CA). ZymocleanTM Gel DNA Recovery kit was from Zymo
Research (Irvine, CA). Phusion High-Fidelity PCR kit, restriction enzymes (KpnI,
SspI, EcoRV, SalI), and PNGase F were purchased from New England Biolabs
(Ipswich, MA). The SYBR® Green PCR Core Reagents kit was obtained from
Applied Biosystems (Foster City, CA). All primers were purchased from Integrated
DNA Technologies (Coralville, IA). Fluorescein calibration dye was obtained from
Bio-Rad (Hercules, CA). Sea-Kem LE agarose was from Cambrex (Rockland, ME).
FuGENE 6 transfection reagent and Complete Mini EDTA-free protease inhibitor
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tablets were obtained from Roche Diagnostics (Indianapolis, IN). Sodium butyrate
was from Sigma-Aldrich (St. Louis, MO).
LDS sample buffer, Magic MarkTM XP protein ladder, Prolong Gold antifade
reagent containing DAPI were purchased from Invitrogen. Polyvinylidene difluoride
membrane was from Millipore (Billerica, MA). HistoGelTM was obtained from Thermo
Scientific Richard-Allan Scientific (Kalamazoo, MI). Sulfo-NHS-SS-Biotin, streptavidin
agarose beads, BCA Protein Assay kit and Supersignal West Pico chemiluminescent
kit were obtained from Thermo Scientific Pierce (Rockford, IL). Avidin/biotin blocking
kit, normal goat serum, NovaRED kit, hematoxylin, and Vecta Mount were purchased
from Vector Laboratories (Burlingame, CA). Streptavidin-HRP reagent was from
Dakota (Carpinteria, CA).
Rat monoclonal antibody against E-cadherin (DECMA-1), mouse monoclonal
antibodies against calbindin-D28k (CB-955) and aquaporin 1 (1/22) were obtained
from Abcam (Cambridge, MA). Mouse monoclonal antibody against Zo-1 (zo1-1A12),
Alexa Fluor® 488 goat anti-mouse IgG (H+L) and Alexa Fluor® 568 goat anti-rabbit
IgG (H+L), Alexa Fluor® 488 goat anti-rabbit IgG (H+L), and Alexa Fluor® 568 goat
anti-rat IgG (H+L) were from Invitrogen. Mouse monoclonal antibody against β-actin
(AC-15) was from Sigma-Aldrich. Mouse monoclonal antibody against P-gp (C219)
was from Signet (Dedham, MA). Mouse monoclonal antibody against human BCRP
(BXP-21), rat monoclonal antibody against rat Abcg2 (BXP-53) and Mrp4 (M4I-10)
were from Kamiya (Seattle, WA). Rabbit polyclonal antibody against Na+/K+-ATPase
(#3010) was obtained from Cell Signaling (Danvers, MA). HRP-conjugated goat antimouse IgG (H+L), HRP-conjugated goat anti-rabbit IgG (H+L), HRP-conjugated goat
anti-rat IgG (H+L) were purchased from Thermo Scientific Pierce (Rockford, IL).
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[3H]-E3S (45.6 Ci/mmol) was purchased from Perkin Elmer (Waltham, MA) and
[3H]-MTX (40 Ci/mmol) from American Radiolabeled Chemicals (St. Louis, MO). Biosafe® II scintillation cocktail was obtained from Research Products International
(Mount Prospect, IL). GF120918 was a gift from GlaxoSmithKline (Research Triangle
Park, NC). Hoechst 33342 was obtained from Invitrogen. OE67 membrane filters
were from Millipore Corporation (Bedford, MA). RC55 membrane filters were from
Schleicher and Schuell (Keene, NJ).

B. Creation and validation of a rat Oatp4c1-expressing cell line
1. Development of rat Oatp4c1 antibody
Rabbit polyclonal antibodies against rat Oatp4c1 were generated using an
extracellular loop [SPDFEARAGKC (PA1556) (79)], two amino-terminus
[KGVENPAFVPSSPDTPRR (PA1254); QPRESEDPQKSTEPS (F3608)], and two
carboxyl-terminus

[STITVEEDLNKIENEG

(PA1343);

TVEEDLNKIENEG

(PA1562)] sequence peptides (Figure 3-1). The antigen sequence specificities
were confirmed with NCBI’s BLAST. The antigen preparation, immunization and
serum collection were performed by Open Biosytems (Rockford, IL). The rabbits
were immunized with 0.5 mg of antigen on Day 1 and boosted with 0.25 mg of
antigen on Days 14, 28 and 42. The terminal sera were collected on Day 90. The
antibody specificities were validated by Western blotting, immunohistochemical
analysis and immunofluorescence as described in Section B-8, Section B-9 and
Section B-10. PA1343 was affinity-purified.
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Figure 3-1: Rat Oatp4c1 antibody antigen peptide sequence and location.

2. Construction of plasmid vector
Total RNA was isolated from a frozen kidney of a Sprague-Dawley rat using
RNeasy Kit as directed by the manufacture with sample disruption using
Qiashredder and on-column DNA digestion. Total RNA concentration was
determined by the measurement of optical density at 260 nm with a UV-Vis
Spectrophotometer (ND-1000, NanoDrop, Wilmington, DE). Total RNA quality
was verified by an OD260/OD280 absorption ratio greater than 2.0. Reversetranscription of 1 μg RNA to cDNA was performed with reverse ThermoScriptTM
RT-PCR kit with oligo (dT)20 primers using Peltier Thermal Cycler (Waltham, MA).
Rat Slco4c1 cDNA was amplified using Phusion High-Fidelity PCR kit with
forward

(5’-CACCATGCAGGGTTCCAAGGGAG-3’)

and

reverse

(5’-

CTATCCTTCGTTCTCTATTTTGTTG-3’) primers. The amplification protocol
included an initial denaturation (98 ºC for 1 min) followed by 40 cycles of a
denaturation step (98 ºC for 10 sec), an annealing step (64°C for 30 sec) and an
extension step (72 ºC for 35 sec), and a final extension step (72 ºC for 10 min).
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To confirm the amplified fragment was of appropriate size, amplification products
were separated by 0.8% agarose gel electrophoresis in 1 x TBE running buffer
(89 mM Tris-Borate, 2 mM EDTA, pH 8.0) for 1 hr at 80 V. The gel was visualized
by staining with 0.5 µg/ml ethidium bromide, and imaged on an Image Station
2000 MM (Eastman Kodak, New Haven, CT). The single band at appropriate size
was cut from the gel on a UV lamp transilluminator (Fisher Scientific, Pittsburgh,
PA) and purified using ZymocleanTM Gel DNA Recovery kit following the
manufacture’s protocol. The subsequent sequence (Slco4c1) was cloned into the
vector pENTR using pENTR Directional TOPO Cloning kit and the construct was
transformed into competent One Shot TOP10 E. coli. The competent cells were
grown in an agar plate with 50 µg/ml kanamycin. The plasmid DNA was isolated
from positive transformants using QIAprep Spin Miniprep Kit according to the
manufacturer’s protocol. The plasmid construct (500 ng) was validated by
EcoRV, SalI or KpnI restriction enzyme digestion for 2 hr at 37°C and 0.8%
agarose gel electrophoresis. The sequence was confirmed (Davis sequencing,
Davis, CA) to share 100% identity with rat Slco4c1 sequence (GeneBank
accession number NM_001002024). The plasmid DNA (150 ng, pENTR/Slco4c1)
was then subcloned into the multiple cloning site of the mammalian expression
vector pcDNA6.2/GFP-DEST using Gateway® LR Clonase® II enzyme mix as
directed by the manufacturer’s protocol. The construct was transformed into XL1Blue Supercompetent cells and the competent cells were grown in an agar plate
with 100 µg/ml carbenicillin. The plasmid DNA (pcDNA6.2/GFP-DEST/Slco4c1,
Figure 3-2) from positive transformants was validated by EcoRV, SspI and KpnI
restriction enzyme digestion for 2 hr at 37°C and 0.8% agarose gel
electrophoresis.
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Figure 3-2: pcDNA6.2/GFP-DEST/ Slco4c1 plasmid construct.

3. Cell culture and transfection
MDCKII cells were cultured in minimum essential medium (MEM)
supplemented with 5% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml
streptomycin at 37°C in a humidified incubator with 5% CO2. LLC-PK1 cells were
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. The
pcDNA6.2/GFP-DEST/Slco4c1

and

pcDNA6.2/GFP-DEST

(vector)

were

transfected into MDCKII and LLC-PK1 cells at 50% confluence with the lipidbased FuGENE 6 transfection reagent at a 3:1 ratio as directed by
manufacturer’s protocol. The transfected cells were selected with 5 µg/ml of
blasticidin. Success of transfection was evaluated by Western blot analysis of cell
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lysates and immunohistochemical analysis of paraformaldehyde-fixed paraffinembedded cell pellet sections for rat Oatp4c1 following procedures described in
Section B-8 Western blot and Section B-9 Immunohistochemistry. The
subcellular localization in pooled cells was examined by confocal microscopy and
surface

protein

biotinylation

assay

as

described

in

Section

B-10

Immunofluorescence microscopy and Section B-11 Surface protein biotinylation
assay.

4. Single clone selection by fluorescence-activated cell sorting (FACS) with
transiently expressed C-terminal-tagged green fluorescent protein (GFP)
MDCKII-Oatp4c1 (1 x 106 cells/well) were grown in a 6-well plate and
allowed to become 90% confluent overnight. Cells were treated with Tag-OnDemandTM Suppressor System for 6 hr at 37°C, and then replaced with fresh
growth medium. After 48 hr, cells were trypsinized, pelleted by centrifugation at
300 g for 5 min, resuspended in growth medium and filtered with a 35 µm cell
strainer to remove cell clumps and debris. FACS analyses were performed at UK
Flow Cytometry Core Facility. Cells were sorted into individual wells in 96-well
plates with excitation at 478 nm and emission at 507 nm using FACSCalibur
cytofluorimeter (BD Biosciences, San Jose, CA) and MoFloTM High-Performance
Cell Sorter (DakoCytomation, Fort Collins, CO). Cells in 96-well plates were
immediately transferred to the incubator. Cell medium was replaced every three
days. Upon confluence, cells were transferred to 24-well plate, 12-well plate, 6well plate, T-25 and T-75 serially. Oatp4c1 expression was evaluated by
immunofluorescence staining as described in Section B-10 Immunofluorescence
microscopy.
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5. Single clone selection by immunofluorescence labeling and FACS
The immunofluorescence labeling of viable cells was according to
procedures described by Cunningham with some modifications (112). MDCKIIOatp4c1 cells (1 × 106 cells) were trypsinized, pelleted by centrifugation at 300 g
for 5 min, resuspended in 10% BSA/PBS containing 110 µg/ml PA1343 (for rat
Oatp4c1) and incubated for 1 hr at room temperature. Cells were washed with
PBS and centrifuged twice. Cell pellets were labeled with 4 µg/ml Alexa Fluor
488 goat anti-rabbit IgG in 10% BSA/PBS for 30 min at 4°C. Following two
washes with PBS and centrifugation, cells were resuspended in growth medium.
At UK Flow Cytometry Core Facility, cells were sorted into individual wells in 96well plates with excitation at 495 nm and emission at 519 nm. Cells in 96-well
plates were immediately transferred to the incubator. Cell medium was replaced
every three days. Upon confluence, cells were transferred to 24-well plates, 12well plates, 6-well plates, T-25 and T-75 flasks serially. Oatp4c1 expression was
evaluated by immunofluorescence staining as described in Section B-10
Immunofluorescence microscopy.

6. Single clone selection by serial dilution
MDCKII-Oatp4c1 cells were plated in 96-well plates as shown in Figure
3-3. Cells were trypsinized, centrifuged, resuspended in growth medium. Cell
suspension (5 x 103 cells/ml; 200 μl) was added in A1 and growth medium (100
μl) was added to all the other wells. Cell suspension (100 μl) was transferred
from A1 to B1 and mixed by gently pipetting and repeated down the entire
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column. Cell suspension (100 μl) from H1 was discarded to have the same
volume as the wells above it. Growth medium (100 μl) was added to the first
column to achieve final volume of 200 μl. Cell suspension (100 μl) was
transferred from the first column to the second column and mixed by gently
pipetting and repeated across entire plate. Cell suspension (100 μl) from each
well in the last column was discarded. The final volume was brought to 200 μl by
adding 100 μl of growth medium. Cell medium was replaced every three days.
Upon confluence, cells were transferred to 24-well plates, 12-well plates, 6-well
plates, T-25 and T-75 flasks serially. Oatp4c1 expression was evaluated by
immunofluorescence staining as described in Section B-10 Immunofluorescence
microscopy.

Figure 3-3: Plate setup for serial dilution.
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7. Regulation of Oatp4c1 expression by sodium butyrate, blasticidin, simvastatin,
glycerol, and MG132
MDCKII-Oatp4c1 cells were grown in 6-well plates (5 x 105 cells/well) or
Lab-TekTM 8-well chamber slides (1.4 x 104 cells/well, Thermo Scientific Nunc,
Rochester, NY) allowed to become 50% confluent overnight, and then incubated
with 0.1 - 5 mM of sodium butyrate for 24 hr. Cells grown in 6-well plates were
washed with ice-cold PBS, scraped with cell scrapers and centrifuged at 300 g
for 5 min. Cell lysates were prepared and subjected to Western blot to evaluate
Oatp4c1 expression as described in Section B-8 Western blot. Total RNA was
isolated from cell pellets and subjected to qRT-PCR analysis to assess Slco4c1
mRNA expression as described in Section C-1 Quantitative real time polymerase
chain reaction (qRT-PCR). Cells grown in chamber slides were stained for
immunofluorescence analysis to evaluate Oatp4c1 expression as described in
Section B-10 Immunofluorescence microscopy.
Cells were also grown in 10 and 30 μg/ml of blasticidin for two passages or
treated with 10 and 20 μM simvastatin for 24 hr, 0 – 1.5 M glycerol for 48 hr, or
0.1 and 10 μM MG132 for 12 and 24 hr, respectively, to evaluate their effects on
Slco4c1/Oatp4c1 expression in MDCKII-Oatp4c1 cells.

8. Western blot
MDCKII-Oatp4c1 and MDCK-pcDNA cells were grown in a T-75 flask to
confluence. Following a wash with ice-cold PBS, cells were scraped and pelleted
by centrifugation at 300 g for 5 min. Cell pellets were resuspended in RIPA buffer
(50 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 1 mM EDTA,
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0.1% SDS, pH 8.0) with protease inhibitor cocktail (Complete Mini tablets) and
shaken at 4°C for 30 minutes. Cell lysates were stored at -80°C until use.
Cell lysates were mixed with NuPAGE LDS sample buffer and 0.1 M
dithiothreitol (DTT) before heating to 70°C for 10 min. Proteins were separated
on a 10% SDS-polyacrylamide gel with 5% stacking gel and Tris-Glycine SDS
running buffers (25 mM Tris, 192 mM glycine, 0.1% SDS) and transferred to a
polyvinylidene difluoride membrane with transfer buffer (25 mM Tris, 192 mM
glycine) at 200 mA for 2 hr at 4°C. Following blocking with 5% skimmed milk in
PBST (10 mM phosphate buffer pH 7.6, 150 mM NaCl, 0.05% Tween-20) for 3 hr
at room temperature, the membranes were incubated with 55 µg/ml anti-Oatp4c1
polyclonal antibody (PA1343) or 14.5 µg/ml anti-β-actin in 5% skimmed milk in
PBST at 4°C. After three 10 min washes with PBST, the membranes were
incubated with 0.04 µg/ml HRP conjugated goat anti-rabbit (for Oatp4c1) or antimouse IgG (for β-actin) in 5% skimmed milk in PBST for 1 hr at room
temperature. Following three 10 min PBST washes, the membranes were
visualized by Supersignal® West Pico chemiluminescent kit and imaged on an
Image Station 2000 MM (Eastman Kodak).

9. Immunohistochemistry
MDCKII-Oatp4c1 and MDCKII-pcDNA cells were grown in two T-75 flasks
to confluence. Following a wash with PBS, cells were scraped and centrifuged at
300 g for 5 min. Cell pellets were encapsulated with HistoGelTM and then fixed in
4% paraformaldehyde for 6 hr at room temperature. The cell pellets were
embedded in paraffin at UK Histology Laboratory of the Imaging Facility, and cut
as 6 µm-thick sections using Microm HM325 microtome (Thermo Scientific).
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Sections were heated at 60°C on Barnstead Lab-Line slide warmer (Dubuque,
IA) to affix the tissues on the slides. Sections were deparaffinized with 3 changes
of xylene for 5 min each, and rehydrated with 3 changes of 100% ethanol, 1
change of 95% ethanol, and 1 change of 70% ethanol for 2 min each. Then, the
antigen was retrieved by pressure-cooking in 10 mM citrate buffer, pH 6.0.
Sections were blocked with 3% H2O2 in PBS for 5 min, avidin and biotin blocking
reagent for 15 min each, 2% normal goat serum in PBST for 30 min, and
subsequently incubated with PA1343 (for Oatp4c1, 220 µg/ml) for 24 hr at room
temperature. Following three 5 min washes with PBST, sections were incubated
with 5 µg/ml biotinylated goat anti-rabbit IgG for 30 min at room temperature.
Sections were washed with PBST for 5 min four times, and incubated with
streptavidin-HRP reagent for 20 min. After five more 5 min PBST washes,
sections were incubated with NovaRED chromogen substrate for 5 min for
visualization. Sections were then washed with H2O for 5 min three times, and
counterstained with hematoxylin to visualize nuclei. After washing with running
tap water for 5 min, sections were dehydrated with 1 change of 70% ethanol, 1
change of 95% ethanol, 3 changes of 100% ethanol for 2 min each. Glass
coverslips were then mounted onto the glass slides with Vecta Mount.

10. Immunofluorescence microscopy
Oatp4c1-expressing and vector-transfected MDCKII and LLC-PK1 cells (5 x
105 cells/well) were seeded on polycarbonate #3407 snapwell (0.4 µm pore size,
1.12 cm2 growth area) and grown for 4 days to allow for polarization.
Transepithelial electrical resistance (TEER) was measured every day with a
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Millicell ohmmeter and a Millicell-ERS probe (Millipore, Bedford, MA) until > 200
Ω•cm2 was achieved.
Cell containing inserts were washed with ice-cold PBS. Filter membranes
were then cut and transferred to 24 well plates for staining. Cells were fixed with 20°C methanol for 10 min, rehydrated with room temperature PBS for 5 min,
permeabilized with 0.2% Triton X-100/PBS for 15 min, blocked with 10% goat
serum for 1 hr, and then incubated with PA1343 (for Oatp4c1, 110 µg/ml) and
anti-Zo-1 (5 µg/ml) for 2 hr at room temperature. Following three 5 min washes
with 0.2% Triton X-100/PBS, cells were incubated with 4 µg/ml Alexa Fluor 568
anti-rabbit IgG and Alexa Fluor 488 anti-mouse IgG in blocking solution for 1 hr at
room temperature. Cells were washed with 0.2% Triton X-100/PBS three times
and mounted on glass slides with Prolong Gold containing DAPI solution to
visualize nuclei. The fluorescence emission was visualized using Axiovert 200M
confocal microscope (Carl Zeiss, Thornwood, NY).

11. Surface protein biotinylation assay
MDCKII-Oatp4c1 and MDCKII-pcDNA cells (1 x 106 cells/well) were grown
on polycarbonate #3414 transwell (3 µm pore size, 4.67 cm2 growth area) for 4
days to achieve TEER > 200 Ω•cm2. Cells were washed with ice-cold PBSMg/Ca buffer (PBS buffer containing 0.1 mM CaCl2 and 1.0 mM MgCl2). Freshly
prepared Sulfo-NHS-SS-Biotin (1 mg/ml in PBS-Mg/Ca) was added to either the
apical or basolateral chamber and incubated with slow rocking at 4°C for 20 min.
Cells were then washed and incubated with quenching buffer (5 mM glycine in
PBS-Mg/Ca) with slow rocking at 4°C for 20 min to remove unreacted biotin.
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Following washing with PBS-Mg/Ca, the cells were lysed with 700 µl lysis buffer
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, pH 7.4)
with the protease inhibitor cocktail for 30 min at 4°C with shaking. Cell lysates
were centrifuged at 10,000 g for 2 min at 4°C, and the supernatants were
incubated with streptavidin agarose beads with end-over-end rotation for 1 hr at
4°C. Samples were washed three times with lysis buffer, and incubated with 50 µl
2X Laemmli Buffer (125 mM Tris, 10% glycerol, 2% SDS, 5% 2-βmercaptoethanol, pH 6.8) for 30 min at room temperature. 2-β-mercaptoethanol
was used to break the disulfide (SS) bond between the biotin and the protein
reactive group, releasing the biotinylated membrane proteins from the beads.
The samples were centrifuged at 10,000 g for 2 min, and the supernatants were
subjected to Western blot analysis as described in Section B-8 Western blot.

C. Determination of Oatp4c1 expression and subcellular localization in rat tissues
1. Quantitative real time polymerase chain reaction (qRT-PCR)
RNA isolation from rat tissues and reverse-transcription were performed as
described in Section B-2 Construction of plasmid vector. Quantification of the
expression level of Slco4c1 and the house-keeping gene 18s rRNA was
performed using the qRT-PCR on the iCycler Multicolor Real-Time PCR
Detection System (Bio-Rad, Hercules, CA).

Slco4c1 primer sequences were

obtained from published literature (79), and 18s rRNA primers were designed
using reference sequences deposited in NCBI’s Entrez Gene with the software
assistance of PrimerQuest (Integrated DNA Technologies, Coralville, IA).
Reference accession numbers, primer sequences, and product sizes are
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provided in Table 3-1. PCR reaction master mixes (50 µL) were made using the
SYBR® Green PCR Core Reagents kit and contained 200 nM of each primer,
1.25 mM dNTPs, 1x SYBR Green buffer, 0.025 U/μl Taq polymerase, and 4 mM
MgCl2, 20 nM fluorescein. Amplification conditions were as follows: 95°C (5 min),
[95°C (45 sec), 61.6°C (1 min), 72°C (1 min)] × 50 cycles. No-template (water)
reaction mixtures were prepared as negative control. To confirm the generation
of a single product of appropriate size, all amplification products were separated
by 3% agarose gel electrophoresis in 1 x TBE running buffer for 50 min at 150 V.
The gel was visualized by staining with ethidium bromide, and imaged on an
Image Station 2000 MM (Eastman Kodak). Relative copy number of each gene
in the samples was determined in triplicate and normalized to relative copy
number of the housekeeping gene 18s rRNA within each sample. The fold
change in Slco4c1 expression relative to reference tissue (FC) was calculated
with 2-∆∆Ct method using the following equation:

2

Equation 3-1

The error propagation was as follows:

Equation 3-2

,

2

,

2

2

Equation 3-3

Equation 3-4
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Table 3-1: Slco4c1 and 18s rRNA primers information.

Gene

Reference
sequence

Forward primer (5’  3’)
Reverse primer (5’  3’)

Product
size (bp)

Ref.

127

(79)

GCAAGGTATTGTAGTAAATGGCCTAG
Slco4c1

NM_001002024
AGACAACACGCAAAAGGAGATGT

18s
rRNA

CGCCGCTAGAGGTGAAATTCTT
X03205.1

101
CGAACCTCCGACTTTCGTTCTT

2. Western blot
Crude membrane fractions were prepared from Sprague-Dawley female rat
tissues (kidney, liver, lactating and non-lactating MG). The tissues were disrupted
in Dounce Buffer (10 mM Tris, pH 7.6, 0.5 mM MgCl2 with protease inhibitor
cocktail) with brief pulses of sonication using a probe ultrasonic processor
(Thermo Fisher Scientific) at 4°C and the tonicity was restored to 150 mM with
sodium chloride. Following 300 g centrifugation for 5 min, EDTA was added to
the supernatant to a final concentration of 5 mM. The samples were centrifuged
at 100,000 g for 1 hr at 4°C. Pellets were resuspended in Resuspension Buffer
(0.2 M mannitol, 0.07 M sucrose, 50 μM Tris HCl, 1 μM EDTA). Protein
concentrations were measured using the BCA Protein Assay Kit. Crude
membrane fractions were stored at -80°C until use. Procedures for Western blot
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analysis of Oatp4c1 expression in rat tissues were the same as those described
in Section B-8 Western blot.

3. Immunohistochemistry
Female Sprague-Dawley rat liver, kidney and MG were isolated and fixed in
4% paraformaldehyde for 6 hr at room temperature. The tissues were embedded
in paraffin at UK Histology Laboratory of the Imaging Facility, and cut as 6 µmthick sections. Procedures for immunohistochemical analysis of Oatp4c1
localization

in

rat

tissues

were

as

described

in

Section

B-9

Immunohistochemistry.
To further study the localization of Oatp4c1, rat tissue sections were double
stained with anti-Oatp4c1 antibody (PA1343, 110 µg/ml) and the following
antibodies: anti-E-cadherin (2 µg/ml), anti-AQP1 (10 µg/ml), and anti-calbindinD28k (40 µg/ml), anti-Abcg2 (BXP-53, 12.5 µg/ml), anti-Mrp4 (3 µg/ml), anti-P-gp
(2.5 µg/ml). For visualization, the sections were incubated with fluorescence
conjugated secondary antibodies for 30 min at room temperature and mounted
with glass coverslips using Prolong Gold containing DAPI solution. Fluorescence
was visualized using Axiovert 200M confocal microscope (Carl Zeiss).

4. BBM (brush-border membrane) and BLM (basolateral membrane) isolation
The BBM and BLM were isolated by Percoll density gradient centrifugation
according to procedures described by Goldinger et al. with some modifications
(113). Briefly, two male Sprague-Dawley rats were anesthetized with isoflurane
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and euthanized by cervical dislocation. The kidneys were excised and frozen
immediately. Kidney cortex tissues were excised and homogenized in sucrose
buffer (250 mM sucrose, 10 mM triethanolamine, pH 7.4, protease inhibitor
cocktail) with a motorized homogenizer. Samples were centrifuged at 2,500 g for
15 min at 4°C. The resultant supernatant was centrifuged at 20,000 g for 20 min
at 4°C. The less dense top layer of the pellet was collected and the lower dark
segment of the pellet was discarded. The pellet was resuspended in 26.5 ml
sucrose buffer with 10 strokes of a tight plunger in a Dounce homogenizer.
Following addition of 3.5 ml Percoll, the suspension was mixed by inversion and
centrifuged at 48,000 g for 30 min at 4°C. Two distinct bands were formed and
carefully isolated. The upper band was BLM and the lower one was BBM (113).
An equal volume of sucrose buffer was added to each fraction, and the Percoll
was removed by centrifuging at 93,000 g for 1 hr at 4°C. The single band of
membrane proteins was collected and the glassy Percoll pellet was discarded.
The BLM was resuspended in mannitol buffer (150 mM mannitol, 2.5 mM EGTA,
6 mM HEPES, pH 7.4). The BBM pellet was further purified by magnesium
precipitation (114). Briefly, following resuspension of the BBM pellet in a buffer
(100 mM mannitol, 1.6 mM EGTA, 0.3 mM PMSF, 0.3 mM sodium
orthovanadate, 4 mM HEPES, pH 7.4), MgCl2 was added to yield a final
concentration of 12 mM. The mixture was incubated on ice for 15 min with
intermittent and gentle mixing. Remaining cellular debris were removed by
centrifuging at 3,000 g for 10 min at 4°C, and the resultant supernatant was
centrifuged at 30,000 g for 40 min at 4°C to isolate membrane proteins. The BBM
pellet was resuspended in mannitol buffer and again precipitated by addition of
12 mM MgCl2 as described above. The final pellet was resuspended in mannitol
buffer. The BBM and BLM were stored at -80°C until use.
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Separation efficiency was evaluated by Western blot analysis following
procedures described in Section B-8 Western blot. Procedures were the same
but with different antibodies. Na+/K+-ATPase was used as a basolateral marker
and was labeled with anti-Na+/K+-ATPase (1:1000). Mrp4 and Abcg2 served as
apical markers and were labeled with anti-Mrp4 (3 µg/ml) and rabbit polyclonal
anti-Abcg2 (150 µg/ml), respectively. The rabbit polyclonal anti-Abcg2 antibodies
were

generated

(Open

Biosystems)

against

Walker

A

peptide

(GKSSLLDVLAARKD) of rat Abcg2 (115).

5. Protein trypsin digestion and LC-MS/MS analysis
Approximately 100 µg of proteins from the BBM and BLM were subjected to
10% SDS-PAGE separation. The protein gel bands at 65-100 and 100-150 kDa
were excised and underwent DTT reduction, iodoacetamide (IAA) alkylation, and
in-gel trypsin digestion using a standard protocol as previously reported (116,
117). The resulting tryptic peptides were extracted, and concentrated to 15 µl
each using a SpeedVac, and 5 µl was injected for nano-LC-MS/MS analysis. LCMS/MS data were acquired on an LTQ Velos Orbitrap mass spectrometer
(Thermo Fisher Scientific) coupled with a Nano-LC Ultra/cHiPLC-nanoflex HPLC
system (Eksigent) through a nano-electrospray ionization source. The tryptic
peptides sample was injected by an autosampler, desalted on a trap column, and
subsequently separated by reverse phase C18 column (75 µm i.d. x 150 mm) at
a flow rate of 250 nl/min. The HPLC gradient was linear from 5% to 60% mobile
phase B for 30 min using mobile phase A (H2O, 0.1% formic acid) and mobile B
(90% acetonitrile, 0.1% formic acid). Eluted peptides were analyzed using datadependent acquisition: peptide mass spectrometry was obtained by Orbitrap with
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a resolution of 100,000. The seven most abundant peptides were subjected to
collision induced dissociation (CID) and MS/MS analysis in LTQ linear trap. The
LC-MS/MS data were submitted to a local MASCOT server for MS/MS protein
identification search via the ProteomeDiscoverer software. The mass error
tolerance was 5 ppm for peptide MS and 0.8 Da for MS/MS. All peptides were
required to have an ion score greater than 30 (P < 0.05). The false discovery rate
(FDR) in each LC-MS/MS analysis was set to be less than 1%.

D. Functional characterization of Oatp4c1 in MDCKII-Oatp4c1 cells
1. [3H]-E3S uptake and inhibition studies
MDCKII-Oatp4c1 and MDCKII-pcDNA cells (5 x 105 cells/well) were grown
in 6-well plates. The cell culture medium was replaced with that containing 5 mM
sodium butyrate to induce transporter expression 24 hr prior to uptake. The
uptake buffer used in all transport experiments contained 118 mM NaCl, 23.8
mM NaHCO3, 4.83 mM KCl, 0.96 mM KH2PO4, 1.20 mM MgSO4, 5.0 mM glucose
and 1.53 mM CaCl2. Buffer pH was adjusted to 7.4 by supplementation with 12.5
mM HEPES and pH adjustment with 1M Tris-base. Alternatively, the buffer was
supplemented with 12.5 mM 2-(N-morpholino)ethanesulfonic acid (MES) and pH
was adjusted to 4.5 or 5.5 with 1M Tris-base. Before the study, cells were
washed once and pre-incubated with uptake buffer for 15 min at 37°C. Uptake
was initiated by replacing the uptake buffer with that containing [3H]-E3S. After
incubation for designated time at 37°C, cells were washed three times with icecold PBS, lysed with 0.5 ml of 0.5 N NaOH and neutralized with 0.1 ml of 2.5 N
HCl. The intracellular radioactivity was determined by transferring 0.5 ml of lysate
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into scintillation cocktail for liquid scintillation counting with a Packard 2200CA
Tri-Carb (PerkinElmer, Waltham, MA) liquid scintillation counter. Protein
concentrations were measured using the BCA Protein Assay Kit. Net uptake was
calculated as the difference between [3H]-E3S uptake into MDCKII-Oatp4c1 cells
and uptake into MDCKII-pcDNA cells. For [3H]-E3S uptake under ATP-depletion
conditions, cells were pre-incubated for 20 min prior to the experiment and during
the experiment (1 min) with uptake buffer containing 20 mM 2-deoxy-D-glucose
and 10 mM NaN3 without D-glucose (69). For the inhibition study, cells were preincubated for 15 min prior to and during the experiment with 100 µM of various
compounds (T3, T4, digoxin, ouabain, MTX, kynurenic acid, indoxyl sulfate,
hippuric acid and trans-aconitic acid, uric acid, citric acid, and riboflavin)
compounds at pH 5.5 or 7.4. Based on model fitting criteria, transport parameters
were estimated using a sigmoid-Emax equation:
/

)

Equation 3-5

Where, V, S, Tmax, S50, and n represent the initial uptake velocity, substrate
concentration, maximum uptake velocity, Michaelis-Menten constant equivalent,
and Hill slope, respectively. The model was fitted to the data (obtained in
triplicate) by nonlinear regression using GraphPad Prism (GraphPad Software,
San Diego, CA).
Values are presented as means ± S.D. Statistical analysis was performed
by an unpaired Student’s t-test or two-way ANOVA and Bonferroni post-hoc test
for multiple comparisons as indicated with p < 0.05 as the criterion of
significance. The software program GraphPad Prism was used for statistical
analysis (GraphPad Software, San Diego, CA)
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2. [3H]-MTX uptake and inhibition studies
Time dependent 1 μM [3H]-MTX uptake studies as well as the inhibition
studies at pH 5.5 or pH 7.4 were performed. Procedures were the same as
described above in [3H]-E3S uptake and inhibition studies.

E. Creation and validation of human OATP4C1-expressing cell lines
1. MDCKII cells
i. Plasmid vector construction and transfection
Human SLCO4C1 DNA purchased from OriGene (Rockville, MD) was
amplified by PCR using Phusion High-Fidelity PCR kit with forward (5’CACCATGAAGAGCGCCAAAGGTATTG-

3’)

and

reverse

(5’-

CTACCCTTCTTTTACTATTTTGTTGAG-3’) primers. Amplification conditions
were as follows: 98°C (1 min), [98°C (10 sec), 63°C (30 sec), 72°C (40 sec)] ×
25 cycles, 72°C (10 min). The amplified fragment of appropriate size was
examined on 1% agarose gel, and further purified. The subsequent sequence
was cloned into pENTR vector and transformed into competent One Shot
TOP10 E. coli. The competent cells were grown in an agar plate with 50 µg/ml
kanamycin.

The

plasmid

DNA

(pENTR/SLCO4C1)

from

positive

transformants was validated by EcoRI restriction enzyme digestion and by
PCR with M13 forward (5’-GTTTTCCCAGTCACGAC-3’) and M13 reverse (5’CAGGAAACAGCTATGAC-3’) primers with following amplification conditions:
98°C (1 min), [98°C (10 sec), 52°C (30 sec), 72°C (45 sec)] × 25 cycles, 72°C
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(5 min). The restriction enzyme product and PCR product were examined on
0.8% agarose gel. The plasmid DNA sequence was also confirmed (Davis
sequencing) to share 100% identity with human SLCO4C1 sequence
(GeneBank accession number NM_180991). The plasmid DNA was
subcloned into pcDNA6.2/EmGFP-Bsd/V5-DEST vector. The construct was
transformed into XL1-Blue Supercompetent cells and the competent cells
were grown in an agar plate with 100 µg/ml carbenicillin. The plasmid
construct (pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1, Figure 3-4) was
validated by PCR with T7 forward (5’- TAATACGACTCACTATAGGG-3’) and
SLCO4C1 reverse (5’-CTACCCTTCTTTTACTATTTTGTTGAG-3’) primers
with following amplification conditions: 98°C (1 min), [98°C (10 sec), 53°C (30
sec), 72°C (30 sec)] × 25 cycles, 72°C (10 min). The PCR product was
examined on 0.8% agarose gel. The detailed procedures are described in
Section Chapter 3B2 Construction of plasmid vector. The plasmid construct
(pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1) and vector (pcDNA6.2/EmGFPBsd/V5-DEST) were transfected into MDCKII cells as described in Section
Chapter 3B3 Cell culture and transfection.
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Figure

3-4:

pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1

plasmid

construct.

ii. Validation of OATP4C1 expression and subcellular localization
Transfection efficiency was evaluated by Western blot analysis and
immunohistochemistry following procedures described in Section Chapter 3B8
Western blot and Section B9 Immunohistochemistry, respectively. Subcellular
localization of OATP4C1 in MDCKII-OATP4C1 cells was assessed by
immunofluorescence microscopy and surface protein biotinylation assay as
described in Section B10 Immunofluorescence microscopy and Section B11
Surface protein biotinylation assay, respectively. Procedures were the same
but with different antibodies: rabbit polyclonal antibodies against human
OATP4C1 generated against amino-terminus [DPQRENSQPQELQKPQEPQK
(PA1243)] and carboxyl-terminus [VLAEQDLNKIVKEG (PA1245)] sequence
51

peptides (Figure 3-5). Antibodies development was as described in Section B1
Development of rat Oatp4c1 antibody.

Figure 3-5: Human OATP4C1 antibody antigen peptide sequence and
location.

iii. Validation of OATP4C1 function in MDCKII-OATP4C1 cells
OATP4C1 function was evaluated with [3H]-ouabain or [3H]-E3S uptake
studies. Procedures were the same as described in Section D1 [3H]-E3S
uptake and inhibition studies.

2. Spodoptera frugiperda (Sf9) insect cells
i. Plasmid vector construction
The construction of pENTR/SLCO4C1 was described in Section .
Plasmid vector construction and transfection. The plasmid construct was
cloned into pDEST8 vector and transformed into XL1-Blue Supercompetent
cells. The competent cells were grown in an agar plate with 100 µg/ml
carbenicillin. The plasmid construct (pDEST8/SLCO4C1, Figure 3-6) was
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validated by Bsu361 restriction enzyme digestion and 0.8% agarose gel
electrophoresis. The plasmid DNA was then recombined in MAX Efficiency®
DH10BacTM competent E. Coli containing baculovirus genome. The competent
cells were grown in an agar plate with 100 µg/ml carbenicillin. For background
control, the empty vector (pDEST8) was also recombined as above. The
plasmid DNA from positive transformants was verified by PCR with M13
forward

(5’-GTTTTCCCAGTCACGAC-3’)

CAGGAAACAGCTATGAC-3’)

primers

with

and
the

M13
following

reverse

(5’-

amplification

conditions: 94°C (1 min), [94°C (30 sec), 54°C (30 sec), 68°C (1 min)] × 30
cycles, 68°C (10 min). The PCR product was examined on 0.8% agarose gel.

Figure 3-6: pDEST8/SLCO4C1 plasmid construct.
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ii. Cell culture, transfection and infection
Sf9 cell suspensions were grown in Sf-900 II SFM medium
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin at 27°C
with constant shaking in Barnstead® MaxQTM 4000 incubated shaker
(Dubuque, IA). Sf9 cells (9 × 105 cells/well) were seeded in a 6-well plate and
incubated at 27°C for 1 hr for cells to be attached. The recombinant bacmids
(pDEST8/SLCO4C1 and pDEST8) were transfected into Sf9 cells with
Cellfectin reagent as directed by manufacturer’s protocol. After 48 hr, cells
were scraped and centrifuged at 500 g for 5 min. The supernatant containing
the recombinant baculovirus (P1 viral stock) was harvested.
To minimize experimental variability from protein expression and insideout ratio of membrane vesicles, a large batch of membranes was prepared
for all subsequent transport studies. The recombinant baculovirus stock was
amplified by infecting Sf9 cell suspensions (1 × 106 cells/ml, log phase) with
P1 viral stock at a 1:4 (v/v ; viral stock: Sf9 cell suspensions) at 27°C for 48 hr
with constant shaking. The supernatant (P2 viral stock) was harvested by
centrifugation at 500 g for 5 min. Sf9 cells were infected with P2 viral stock at
27°C for 48 hr and again with P3 viral stock as described above. After
incubation at 27°C for 48 hr, cells were centrifuged at 500 g for 5 min. The
supernatant (P4 viral stock) was dispensed in aliquots and stored at −80°C
until use. Cell pellets for membrane vesicle preparation were stored at –80°C
until use.
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iii. Membrane vesicle preparation
The cell pellets were thawed on ice and resuspended in ice-cold
hypotonic buffer (0.5 mM Na2HPO4, 0.1 mM EDTA, pH 7.4) supplemented
with protease inhibitor cocktails and incubated for 90 min at 4°C. The
suspension was centrifuged at 100,000 g for 40 min at 4°C, and the pellet
was homogenized in ice-cold TS buffer (50 mM Tris-HCl, 250 mM sucrose,
0.25 mM CaCl2, pH 7.4) using a tight-fitting Dounce homogenizer. After
centrifugation at 500 g at 4°C for 10 min, the supernatant was centrifuged at
100,000 g for 40 min at 4°C. The pellet was resuspended in TS buffer and
passed through a 27-gauge needle 25 times. The vesicles were dispensed in
aliquots and stored at −80°C until use. The membrane protein concentrations
were determined by BCA Protein Assay Kit. OATP4C1 expression was
determined by Western blotting as described in Section Chapter 3E1.ii.
Validation of OATP4C1 expression and subcellular localization.

iv. Vesicular transport assay
Sf9 membrane vesicles (40 μg) containing OATP4C1 or vector were
incubated with the indicated concentrations of [3H]-ouabain in 50 μl of TS
buffer supplemented with 10 mM creatine phosphate, 0.1 mg/ml of creatine
phosphokinase, 10 mM MgCl2 and 4 mM ATP at 37°C. At the designated
time, the reaction was stopped by adding 1.5 ml of ice-cold stop buffer (10
mM Tris-HCl, 250 mM sucrose, 100 mM NaCl, pH7.4) and immediately
vacuum filtered onto a cellulose acetate filter (0.45-μm pore size, OE67). The
filter was washed twice with 1.5 ml of ice-cold stop buffer, and the
radioactivity retained on the filter was measured by liquid scintillation
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counting. Procedures for [3H]-E3S were the same as described above but
with regenerated cellulose filters (0.45-μm pore size, RC55). The filters were
selected due to their minimal binding of ouabain or E3S. OATP4C1-mediated
uptake was calculated after subtraction of nonspecific uptake by vector
membrane vesicle.

F. Validation of OATP4C1 expression in human kidney and cancer cells
1. Immunohistochemical analysis in human kidney sections
De-identified human kidney sections were obtained from Markey Cancer
Center Biospecimen Core (IRB#05-0155-X1G). Subcellular localization of
OATP4C1 was assessed by immunohistochemical analysis as described in
Section Chapter 3B9 Immunohistochemistry. Procedures were the same but with
a different antibody. MRP4 was served as a positive control and was labeled with
3 µg/ml of M4I10. OATP4C1 was detected with 550 µg/ml of PA1243 or PA1245.

2. qRT-PCR analysis for SLCO4C1 expression in cancer cells
Prostate cancer cell lines (LnCap, DU145, PC3) and lung cancer cell line
H1299 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Lung cancer cell lines
(A549, H460), breast cancer cell line MCF7 and glioblastoma cell line U118 were
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Breast
cancer cell line MDA-MB-231 and melanoma cell line MDA-MB-435 were
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cultured in Improved Minimum Essential Medium (IMEM) with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Cancer cell lines were grown in a T-25 flask to confluence. Cells were
trypsinized and pelleted by centrifugation at 300 g for 5 min. RNA isolation from
cell pellets and reverse-transcription were performed as described in Section
Chapter 3B2 Construction of plasmid vector. Procedures for qRT-PCR were the
same as described in Section Chapter 3C1 Quantitative real time polymerase
chain reaction (qRT-PCR) with different primers (Table 3-2).

Table 3-2: SLCO4C1 and 18s rRNA primers information.

Gene

Reference
sequence

Forward primer (5’  3’)
Reverse primer (5’  3’)

Product
size (bp)

GAGAAGCTCCGGTCACTGTC
SLCO4C1

NM_180991

149
ACTACAATACCTTGCGTGAC
CGCCGCTAGAGGTGAAATTCTT

18s rRNA

X03205.1

101
CGAACCTCCGACTTTCGTTCTT
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3. OATP4C1/SLCO4C1 expression in lung tumor and adjacent normal lung tissue
sections
i. qRT-PCR
Human lung tumor and adjacent normal lung tissue sections were
obtained from the Markey Cancer Center Biospecimen Core (IRB#05-0155X1G). The tissues were rinsed with 20 µl of xylene, scraped from the slides
with blades and transferred to microcentrifuge tubes for RNA isolation. RNA
isolation was performed with RecoverALLTM total nucleic acid isolation kit as
directed by manufacture’s protocol. Total RNA quality was verified by an
OD260/OD280 absorption ratio within a range of 1.8-2.1. Reversetranscription of 100 ng RNA to cDNA was performed with reverse
ThermoScriptTM RT-PCR kit with oligo (dT)20 primers using Peltier Thermal
Cycler. PCR was conducted using TaqMan® Gene Expression Assay (Table
3-3) and TaqMan® Universal PCR Master mix in a total volume of 20 µl using
ABI PRISM® 7000 sequence detection system (Applied Biosystems, Foster
city, CA). Amplification conditions were as follows: 50°C (2 min), 95°C (10
min), [95°C (15 sec), 60°C (1 min)] × 40 cycles. No-template (water) reaction
mixtures were prepared as negative control.
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Table 3-3: TaqMan® Gene Expression Assay for SLCO4C1 and 18s rRNA.

Gene

SLCO4C1

18s rRNA

Reference
sequence

NM_180991

X03205.1

Assay ID

Exon
Boundary

Amplicon
length (bp)

Hs00698884_m1

4-5

77

Hs01030668_m1

7-8

58

Hs01030660_m1

10-11

64

Hs03003631_g1

-

69

ii. Immunohistochemistry
Procedures

were

as

described

in

Section

Chapter

3B9

Immunohistochemistry. OATP4C1 was detected with 110 µg/ml of PA1243 or
PA1245.

Copyright © Kuei-Ling Kuo 2012
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CHAPTER 4 : RESULTS
A. Creation and validation of a rat Oatp4c1-expressing cell line
1. Specific Aim 1a: To develop and validate rat Oatp4c1 antibodies amenable for
immunoblotting, immunohistochemistry and immunofluorescence.
To investigate the expression and subcellular localization of rat Oatp4c1 in
the in vitro cell models or rat tissues, four rabbit polyclonal antibodies were
generated against either amino-terminus or carboxyl-terminus of rat Oatp4c1.
The

antibody

specificities

were

determined

by

Western

blotting,

immunohistochemical analysis, and immunofluorescence staining in the in vitro
cell models developed in Specific Aim 1b. Among the four antibodies, PA1343
was affinity-purified and used for subsequent experiments.

2. Specific Aim 1b: To create and validate a stably transfected rat Oatp4c1expressing cell line with appropriate characteristics for uptake studies.
To study the role of rat Oatp4c1 in drug disposition, we generated rat
Oatp4c1-expressing MDCKII cells. Rat Slco4c1 mRNA was isolated from rat
kidney and amplified by PCR. The amplified fragment of appropriate size was
examined by agarose gel electrophoresis. As shown in Figure 4-1 A, rat Slco4c1
mRNA was successfully isolated from rat kidney. The amplification product was
further purified and cloned into pENTR vector. The plasmid construct was
validated by KpnI, SalI and EcoRV restriction enzyme digestion (Figure 4-1 B)
and DNA sequencing which had 100% identity with the published rat Slco4c1
sequence (GeneBank accession number NM_001002024). The plasmid DNA
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was then subcloned into pcDNA6.2/GFP-DEST vector and was validated by
EcoRV, SspI and KpnI restriction enzyme digestion (Figure 4-1 C).
The

plasmid

DNA

(pcDNA6.2/GFP-DEST/Slco4c1)

and

vector

(pcDNA6.2/GFP-DEST) were transfected into MDCKII and LLC-PK1 cells.
Transfection efficiency was examined by Western blotting using the antibody
generated in Specific Aim 1a (PA1343) (Figure 4-2 A). Oatp4c1 expression was
detectable as a band at ~80 kDa in MDCKII-Oatp4c1 cells, but not in MDCKIIpcDNA

(empty

vector)

paraformaldehyde-fixed

cells.

Expression

paraffin-embedded

was
cell

also
pellet

confirmed

in

sections

by

immunohistochemical analysis (Figure 4-2 B). Oatp4c1 was observed on the cell
membrane (Figure 4-2 B, inset) in the MDCKII-Oatp4c1 cells, and no staining
was observed in the negative control (rabbit IgG) or in the MDCKII-pcDNA cells.
This demonstrated that the transfection was successful and that the antibody
was specific.
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Figure 4-1: Validation of Slco4c1 plasmid constructs.
PCR products of Slco4c1 isolated from rat kidney and the restriction enzyme digestion
products of the plasmid construct were examined by agarose gel electrophoresis.

62

Figure 4-2: Validation of Oatp4c1 expression and subcellular localization in
MDCKII-Oatp4c1 cells.
(A) Western blot of Oatp4c1 (~ 80 kDa) and β-actin (~42 kDa) in 50 µg cell lysates. (B)
Immunohistochemical analysis of Oatp4c1 expression in paraformaldehyde-fixed
paraffin-embedded cell sections. (C) Confocal microscopy of Oatp4c1 (red) expression
and localization in polarized MDCKII cells. Center image in the Oatp4c1 panel is a single
optical section of the x-y plane while top and right images represent x-z and y-z planes,
respectively, reconstructed from image stacks. The apical and basal sides can be
demarcated by Zo-1 (green) and the nuclei (DAPI, blue), respectively, in both x-z and y-z
sections. (D) Western blot of Oatp4c1 in proteins isolated from either the apical (AP) or
basolateral (BL) membranes of polarized MDCKII cells. Na+/K+-ATPase served as a BL
marker to demonstrate the relative efficiency of AP and BL membrane separation.
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Subsequently, we sought to determine the subcellular localization of
Oatp4c1 in polarized cell monolayers by confocal immunofluorescence laser
scanning microscopy (Figure 4-2 C). A tight-junction protein, Zo-1, was used as
an apical marker. As shown in Figure 4-2 C, Oatp4c1 localized at the apical
membrane, along with Zo-1, in MDCKII-Oatp4c1 cells. This result was also
confirmed by the surface membrane protein biotinylation method. The surface
proteins on either apical or basolateral membranes of polarized MDCKII-Oatp4c1
cells were labeled with biotin and isolated from streptavidin agarose beads.
Western blot analysis of a basolateral marker Na+/K+-ATPase demonstrated the
efficient separation of the apical and basolateral membranes. Western blot
analysis of Oatp4c1 demonstrated that the transporter was enriched in the apical
membrane fraction, but not in the basolateral membrane (Figure 4-2 D).
Collectively, these data verified the apical expression of the transporter in
Oatp4c1-expressing MDCKII cells. However, there is precedent showing that a
transporter can mislocalize in MDCKII cells. Expression studies in MRP4transfected MDCKII cells show that MRP4 traffics to the basolateral membrane
due to low expression of an adaptor protein, Na+/H+ exchanger regulatory factor
1 (NHERF1), in these cells (118, 119). However, MRP4 polarized correctly in
NHERF1 expressing LLC-PK1 cells. While the adaptor proteins facilitating
Oatp4c1 trafficking are not known, we transfected LLC-PK1 with pcDNA6.2Oatp4c1 and determined its polarity. As observed in MDCKII cells, Oatp4c1 also
localized to the apical membrane in LLC-PK1 cells (Figure 4-3)
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Figure 4-3: Confocal microscopy of Oatp4c1 expression and subcellular
localization in LLC-PK1-Oatp4c1 cells.
Center image in the Oatp4c1 (red) panel is a single optical section of the x-y plane while
top and right images represent x-z and y-z planes, respectively, reconstructed from
image stacks. The apical and basal sides can be demarcated by Zo-1 (green) and the
nuclei (DAPI, blue), respectively, in both x-z and y-z sections.
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Despite successful transfection, our immunofluorescence studies showed
that expression was not detectable in at least 97% of the cells (Figure 4-4).
Therefore, we attempted to generate a single clone with homogenous high
Oatp4c1 expression. Our initial attempt was to sort individual live cells into a 96well plate by FACS analysis with transient C-terminal-tagged GFP. MDCKIIOatp4c1 cells were treated with Tag-On-DemandTM Suppressor Supernatant,
which decodes the stop codon as serine, allows translation to continue through
the downstream reading frame and produces transient C-terminal tagged GFP
fusion protein. In this initial attempt, 70 clones were obtained. However,
immunofluorescence staining showed none of them exhibited Oatp4c1
expression.
The second attempt was to sort the cells by immunofluorescence labeling.
Oatp4c1-expressing cells were labeled with PA1343 (rabbit polyclonal antiOatp4c1) and Alexa Fluor 488 goat anti-rabbit IgG, and then sorted with Alexa
Fluor 488 fluorescence by FACS analysis. However, none of 110 clones showed
Oatp4c1 expression by immunofluorescence staining. The third attempt was to
randomly seed individual live cells in 96-well plates. Unfortunately, none of 220
clones showed Oatp4c1 expression by immunofluorescence staining. It has
previously been demonstrated that the expression of foreign protein in
recombinant cells decreases the cell proliferation rate (120, 121). Expressing
foreign protein utilizes host cell’s resources and imposes a metabolic burden
(metabolic load) on the host cells, which may change the physiology and
biochemistry of the cells.

This led us to hypothesize that the expression of

Oatp4c1 decreases the cell proliferation rate and this effect is magnified when
expanding from a single cell. In this case, single cells expressing the protein
were perhaps not dividing during the time we were expanding the single clones.
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Therefore, the fourth attempt was to generate the clones starting from more than
one cell using the serial dilution method. Finally, out of 100 clones, 15 showed
Oatp4c1 expression by immunofluorescence staining. Among them, clone 94
(c94) had more cells exhibiting Oatp4c1 expression as compared to the pooled
cells (Figure 4-4). This clone was selected to use for uptake studies in Specific
Aim 3a and Specific Aim 3b.
Despite multiple efforts and approaches to generate this single clone of
Oatp4c1-expressing MDCKII cells (c94), immunofluorescence staining showed
that expression was detectable in only ~11% of the cells determined by manual
counting. To increase Oatp4c1 expression, we sought to treat the cells with
sodium butyrate, simvastatin, glycerol, MG132 or increase the concentration of
the selection antibiotic, blasticidin. Oatp4c1 expression was determined by PCR,
Western blotting and immunofluorescence staining.
Sodium butyrate is commonly used to induce protein expression (122, 123).
In this study, MDCKII-pcDNA and MDCKII-Oatp4c1 pooled cells were treated
with 0.1 - 5 mM sodium butyrate for 24 hr. Oatp4c1 expression was increased by
sodium butyrate in a concentration-dependent manner at mRNA (Figure 4-5 A)
and protein (Figure 4-5 B) levels. However, the number of cells exhibiting
Oatp4c1 expression was not remarkably increased with sodium butyrate
treatment (Figure 4-5 C). In addition, since sodium butyrate was reported to
disrupt basolateral localization of overexpressed Na+/K+-ATPase β1- and β2
subunits in MDCK I cells (124), we wanted to ensure that induced expression did
not interfere with the subcellular localization of Oatp4c1. Immunofluorescence
staining was performed and demonstrated that the apical polarity was maintained
(Figure 4-5 D).
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Figure 4-4: Immunofluorescence staining for Oatp4c1 expression in MDCKIIOatp4c1 pooled cells and c94.
Oatp4c1 and nuclei were stained with PA1343 (red) and DAPI (blue), respectively.
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Figure 4-5: Effect of 24 hr sodium butyrate (NaB) treatment on Oatp4c1 expression
and subcellular localization in MDCKII-Oatp4c1 pooled cells.
(A) PCR and agarose gel electrophoresis of Slco4c1 and 18s rRNA (loading control). (B)
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein).
(C) Immunofluorescence staining for Oatp4c1 expression (red). (D) Confocal microscopy
of Oatp4c1 (red) expression and localization in polarized cells. Center image in the
Oatp4c1 panel is a single optical section of the x-y plane while top and right images
represent x-z and y-z planes, respectively, reconstructed from image stacks. The apical
and basal sides can be demarcated by Zo-1 (green) and the nuclei (DAPI, blue),
respectively, in both x-z and y-z sections.
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The second approach to enhance Oatp4c1 expression was to increase the
selection antibiotic, blasticidin, concentration from 5 μg/ml to 10 or 30 μg/ml.
MDCKII-pcDNA

and

MDCKII-Oatp4c1

cells

were

grown

in

designated

concentration of blasticidin for 2 passages. Oatp4c1 expression was higher in the
cells grown in 10 or 30 μg/ml blasticidin than those in 5 μg/ml blasticidin at
mRNA (Figure 4-6 A) and protein (Figure 4-6 B) levels, and achieved a maximum
at 10 μg/ml. The number of cells exhibiting Oatp4c1 expression was slightly
enhanced with increasing blasticidin concentration (Figure 4-6 C).
A promoter analysis showed SLCO4C1 promoter region has xenobioticresponsive element (XRE) motifs (106), which are generally recognized by aryl
hydrocarbon receptors (AhR) and AhR nuclear translocator heterodimer (108).
Simvastatin, an inducer of nuclear AhR, can enhance promoter activity and
upregulate SLCO4C1 expression (106). MDCKII-pcDNA and MDCKII-Oatp4c1
cells were treated with 10 or 20 μM of simvastatin for 24 hr. Slco4c1 mRNA
expression was increased by simvastatin in a concentration-dependent manner
(Figure 4-7 A), but this did not lead to changes in protein expression (Figure 4-7
B). Additionally, the number of cells exhibiting Oatp4c1 expression was not
changed with simvastatin treatment (Figure 4-7 C).
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Figure 4-6: Effect of increasing blasticidin (Bsd) concentration for two passages
on Oatp4c1 expression in MDCKII-Oatp4c1 pooled cells.
(A) PCR and agarose gel electrophoresis of Slco4c1 and 18s rRNA (loading control). (B)
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein).
(C) Immunofluorescence staining for Oatp4c1 expression (red).
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Figure 4-7: Effect of 24 hr simvastatin (Sim) treatment on Oatp4c1 expression in
MDCKII-Oatp4c1 pooled cells.
(A) PCR and agarose gel electrophoresis of Slco4c1 and 18s rRNA (loading control). (B)
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein).
(C) Immunofluorescence staining for Oatp4c1 expression (red).

72

Primary amino acid sequence of rat Oatp4c1 showed a considerably higher
number of cysteine residues (27 cysteine/724 amino acids) as compared with
other transporters, such as ABCG2 (12 cysteine/655 amino acids), p-glycoprotein
(7 cysteine/1279 amino acids) or MRP4 (11 cysteine/859 amino acids). Disulfide
bonds between cysteine residues in proteins play a key role in protein folding.
More cysteine residues may cause more turns or folding, and the protein may be
more difficult to be properly folded. Therefore, we hypothesized that most of
Oatp4c1 in the transfected MDCKII cells is misfolded so that scarce number of
cells exhibit Oatp4c1 expression. Misfolded proteins fail to traffic from
endoplasmic reticulum (ER) via the Golgi apparatus to plasma membrane, and
are targeted for degradation via the ubiquitin/proteasome-dependent pathway. In
an attempt to rescue misfolded proteins, we treated the cells with the chemical
chaperone, glycerol or the proteasome inhibitor, MG132.
Glycerol is a chemical chaperone, and stabilizes misfolded proteins into
conformations that are not targeted for degradation and can escape the ER (125,
126). In this study, MDCKII-pcDNA and MDCKII-Oatp4c1 cells were treated with
0.5 - 1.5 M glycerol for 48 hr. However, glycerol decreased Oatp4c1 expression,
and did not change the number of cells exhibiting Oatp4c1 expression (Figure
4-8).
N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) is a proteasome
inhibitor, and can prevent misfolded proteins, which are retained in the ER from
being targeted for premature proteolysis. In this study, MDCKII-pcDNA and
MDCKII-Oatp4c1 cells were treated with MG132 (0.1 μM for 24 hr or 10 μM for
12 hr). However, MG132 decreased Oatp4c1 expression, and did not change the
number of cells exhibiting Oatp4c1 expression (Figure 4-9).
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Figure 4-8: Effect of 48 hr glycerol treatment on Oatp4c1 expression in MDCKIIOatp4c1 pooled cells.
(A) Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg
protein). (B) Immunofluorescence staining for Oatp4c1 expression (red).
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Figure 4-9: Effect of MG132 treatment on Oatp4c1 expression in MDCKII-Oatp4c1
pooled cells.
(A) Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg
protein). (B) Immunofluorescence staining for Oatp4c1 expression (red).
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In summary, Oatp4c1 expression was enhanced by sodium butyrate
treatment or increasing blasticidin concentration, but not by simvastatin, glycerol
or MG132 treatment. To optimize growth conditions to obtain the highest
Oatp4c1 expression, MDCKII-Oatp4c1 pooled cells and c94 were treated with 5
mM sodium butyrate or 30 μg/ml blasticidin or both. As shown in Figure 4-10, the
impact of sodium butyrate on inducing Oatp4c1 expression was substantial, so
that the effect of blasticidin was negligible. The substantially higher Oatp4c1
expression in c94 than in pooled cells was also demonstrated. Finally, after
multiple efforts and approaches, as compared with the pooled cells, the number
of cells exhibiting Oatp4c1 expression in c94 with sodium butyrate treatment was
substantially higher (Figure 4-11). Therefore, to achieve the highest Oatp4c1
expression, c94 prior treated with sodium butyrate were applied for the following
uptake studies described in Specific Aim 3a and Specific Aim 3b.
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Figure 4-10: Effect of sodium butyrate (NaB, 5 mM) and blasticidin (Bsd, 30 μg/ml)
on Oatp4c1 expression in MDCKII-Oatp4c1 pooled cells and c94.
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein).

Figure 4-11: Immunofluorescence staining for Oatp4c1 expression in MDCKIIOatp4c1 pooled cells and sodium butyrate (NaB) treated c94.
Oatp4c1 and nuclei were stained with PA1343 (red) and DAPI (blue), respectively.
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B. Determination of Oatp4c1 expression and subcellular localization in rat tissues
1. Specific Aim 1c: To determine the expression and subcellular localization of
Oatp4c1 in the rat tissues (liver, kidney, lactating and non-lactating mammary
gland).
Microarray analysis of various transporters expressed in lactating MEC
isolated from breast milk and non-lactating MEC isolated from surgical reduction
mammoplasty specimen showed that human SLCO4C1 is increased 70-fold in
lactating MEC relative to non-lactating MEC. The upregulation of SLCO4C1
expression during lactation has been confirmed by qRT-PCR (30). This
phenomenon was also confirmed in rats by qRT-PCR (Figure 4-12 A) and
Western blotting (Figure 4-12 B). Liver and kidney served as a negative and
positive control, respectively, and has been demonstrated by Northern analysis
(79). Oatp4c1 was expressed in the rat kidney and lactating MG, but not in the
rat liver and non-lactating MG. This result was confirmed by Western blotting
(Figure 4-12 B). A single band was detected at ~80 kDa in the rat kidney, and at
a slightly lower molecular weight in the rat MG, and both of the bands were
reduced to ~65 kDa after deglycosylation. In accord with the mRNA expression,
no protein band was detected in the rat liver and non-lactating MG. The specific
band reactivity was confirmed by pre-absorbing the antibody with antigen peptide
(STITVEEDLNKIENEG) prior to use. The bands were abolished after antigen
peptide blocking (Figure 4-12 C).
In addition, the ontogeny of Oatp4c1 in rat kidney (Figure 4-13) and liver
(Figure 4-14) was investigated. In rat kidney, Slco4c1 mRNA expression was
minimal at birth and then gradually increases to adult levels (Figure 4-13 A), and
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this was confirmed by Western blotting (Figure 4-13 B). This phenomenon was
consistent with the ontogenic expression of Slco4c1 in mouse kidney (52). In
addition, higher Oatp4c1 expression was observed in non-lactating female rat
kidney as compared with males at both mRNA and protein levels, but it was
inconsistent with the previous finding showing no gender differences of Slco4c1
mRNA expression in the rat kidney (79). Neither Slco4c1 mRNA (Figure 4-14 A)
nor Oatp4c1 protein (Figure 4-14 B) were detected in rat livers of pups or adults
across the ages.

79

Figure 4-12: Oatp4c1 expression in female adult rat liver, kidney, lactating and
non-lactating MG.
(A) i. qRT-PCR and agarose gel electrophoresis analysis for Slco4c1 mRNA and 18s
rRNA (loading control) expression in rat tissues. ii. Relative Slco4c1 mRNA expression
normalized with 18s rRNA. Each bar represents the mean ± S.D (n=2 (liver) or 3). (B)
Western blot of native (~80 kDa), deglycosylated (~60 kDa) Oatp4c1 and β-actin (~42
kDa) in rat tissue crude membrane fractions (40 µg protein). PNGaseF was used for
deglycosylation. (C) Western blot of Oatp4c1 and β-actin in rat tissue crude membrane
fractions (40 µg protein) with and without antigen peptide blocking. Lac: lactating, Nonlac: non-lactating
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Figure 4-13: Ontogeny of Oatp4c1 in rat kidney.
(A) Relative Slco4c1 mRNA expression calculated with 2-∆∆Ct method. Relative copy
number of SLCO4C1 in the samples was normalized to 18s rRNA within each sample
and values were then normalized with those in lac-d16 kidney. Each dot represents the
mean of three determinations from one rat. (B) Western blot of Oatp4c1 (~80 kDa) and
β-actin (~42 kDa) in rat tissue crude membrane fractions (40 µg protein). Lac-d16: rats
had been lactating for 16 days, Lac-d21: rats had been lactating for 21 days, Non-lac:
non-lactating, F: female, M; male
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Figure 4-14: Ontogeny of Oatp4c1 in rat liver.
(A) Relative Slco4c1 mRNA expression calculated with 2-∆∆Ct method. Relative copy
number of SLCO4C1 in the samples was normalized to 18s rRNA within each sample
and values were then normalized with those in lac-d16 kidney. Each dot represents the
mean of three determinations from one rat. (B) Western blot of Oatp4c1 (~80 kDa) and
β-actin (~42 kDa) in rat tissue crude membrane fractions (40 µg protein). Lac-d16: rats
had been lactating for 16 days, Lac-d21: rats had been lactating for 21 days, Non-lac:
non-lactating, F: female, M; male.
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The

subcellular

localization

of

Oatp4c1

was

then

assessed

by

immunohistochemical analysis in paraformaldehyde-fixed paraffin-embedded
liver, kidney and MG tissue sections. To assure the quality of the tissue
specimens, the rat liver and MG sections were stained with anti-Abcg2 antibody,
and the rat kidney sections were stained with anti-Mrp4 antibody. All tissues
showed specific staining. Consistent with the PCR and Western blot results
(Figure 4-12 A, B), Oatp4c1 was not detected in the rat liver, but Oatp4c1 stained
strongly in apical membranes of kidney tubules and MG (Figure 4-15). No
staining was observed in tissue sections exposed to rabbit IgG, instead of
primary antibody, and Oatp4c1 staining was abolished when probing with
antibody that was pre-adsorbed with antigen peptide (Figure 4-16). The distinct
apical expression of Oatp4c1 in rat kidney was also demonstrated using dual
staining for a basolateral marker E-cadherin (127) and Oatp4c1 (Figure 4-17).
Because these results were in contrast to the reported expression pattern
of Oatp4c1 in the rat kidney, we developed additional antibodies, including the
polyclonal antibody reported previously (79). As shown in Figure 4-16, apical
expression was confirmed using three different antibodies (PA1254, F3608 and
PA1562), however, we were not able to observe any staining, above background
levels, with the antibody reported previously (79).
In rat MG, the apical expression of Oatp4c1 was demonstrated by
colocalization of Oatp4c1 and an apical marker Abcg2 (10) and distinct
localization of Oatp4c1 and a basolateral marker E-cadherin (128) (Figure 4-18).
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Figure 4-15: Oatp4c1 localization in rat liver, kidney and lactating MG.
Immunohistochemical analysis for Oatp4c1 subcellular localization in paraformaldehydefixed paraffin-embedded rat tissue sections. Oatp4c1 was detected with PA1343. Rabbit
IgG was used as a negative control. Magnification: 40x.
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Figure 4-16: Verification of apical Oatp4c1 localization in rat renal tubules by four
different antibodies.
Immunohistochemical analysis for Oatp4c1 subcellular localization in paraformaldehydefixed paraffin-embedded rat kidney sections with rabbit polyclonal anti-Oatp4c1
antibodies as indicated. A. Antibody specificity (PA1343) was demonstrated by preabsorbing PA1343 with antigen peptide (STITVEEDLNKIENEG) overnight at 4°C prior to
use. Magnification: 40x.
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Figure 4-17: Double immunofluorescence staining for Oatp4c1 (green) and Ecadherin (red) in rat kidney.
E-cadherin served as a basolateral marker. Magnification: 40x.

Figure 4-18: A. Double immunofluorescence staining for Oatp4c1 (green) and
Abcg2 (A, red) or E-cadherin (B, red) in rat lactating MG.
Abcg2 and E-cadherin served as apical and basolateral marker, respectively.
Magnification: 40x.
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2.

Specific Aim 2a: To verify the apical localization of Oatp4c1 in the rat kidney
cortex by proteomic analysis in the isolated brush-border membrane (BBM) and
basolateral membrane (BLM).
Concurrently with the studies outlined in Figure 4-16, we wanted to
definitively demonstrate the specificity of our PA1343 antibody used for Western
blot and immunolocalization of Oatp4c1. Proteomic analysis was performed on
proteins collected from BBM and BLM, which were isolated from rat kidney cortex
by Percoll density gradient. Western blotting (Figure 4-19 A) and proteomic
analysis (Figure 4-19 B) were applied to analyze the proteins in these two
fractions. Abcg2 and Mrp4 were used as apical markers, which were enriched in
BBM. Na+/K+-ATPase, a basolateral marker (127), was detectable in both
membrane fractions, but more so in BLM than BBM. Oatp4c1 was detected in
BBM

but

not

in

BLM

(Figure

4-19

A),

which

was

consistent

with

immunohistochemistry results (Figure 4-15).
To validate the specificities of our antibodies, the proteome in BBM and
BLM were each analyzed by LC-MS/MS following separation by SDS-PAGE. The
gel bands of proteins eluting at 65-100 and 100-150 kDa were excised, and
underwent reduction, alkylation, and in-gel trypsin digestion (116, 117). The
abundance of the identified proteins was determined by the total number of
spectra identified from a protein (spectral counts, SC) (129, 130), and SC > 2
was used as the cutoff. The proteins with molecular weight less than 65 kDa or
more than 150 kDa were excluded. The LC-MS/MS analysis identified 6 proteins
unique to the BBM, 19 proteins unique to the BLM, and 56 proteins were either
enriched in one membrane or equally distributed in both membrane preparations.
Among them, the spectral counts of the SLC and ABC family with reported
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localization, along with the apical marker (meprin) and basolateral marker
(Na+/K+-ATPase) are shown in Figure 4-19 B. Eleven apical proteins were
predominantly in the BBM, four basolateral proteins were enriched in the BLM,
and three proteins with previously reported apical localization were found in both
fractions

(ambiguous).

Four

(GVENPAFVPSSPDTPRR;

unique

peptides

of

Oatp4c1

RASASPSQVEVSAVASR;

TSQTHQNNSTSFQHMDENFGK; KVDITSTAXSPDFEAR) were found only in the
BBM and not in the BLM. These qualitative data provide additional and
conclusive evidence that Oatp4c1 localizes at the apical membrane in the rat
kidney cortex.
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Figure 4-19: Expression of Oatp4c1 in isolated kidney brush border membrane
(BBM) and basolateral membrane (BLM) fractions.
(A) Western blot of Oatp4c1 in BBM and BLM fractions (20 µg protein) isolated from rat
kidney cortex. Na+/K+-ATPase α 1 was used as a basolateral marker. Abcg2 and Mrp4
served as apical markers. Oatp4c1 was detected with PA1343. (B) Spectral counts
detected in protein digests obtained from ~65-150 kDa sections excised from the SDSPAGE gel. Proteins with 3 or more spectral counts in one fraction are presented as
“Apical” or “Basolateral” based on previously published literature. Spectral counts
indicate the number of unique peptides detected in each fraction.
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3.

Specific Aim 2b: To determine the precise expression pattern of Oatp4c1 at the
organ and nephron level.
To further gain insight on the potential physiological role of Oatp4c1, we
assessed its precise expression pattern at the organ and nephron level.
Immunohistochemical analysis (Figure 4-20) showed that Oatp4c1 is expressed
densely in the renal tubules located in the juxtamedullary cortex. To ascertain its
location within the tubule, we used double immunofluorescence to stain for
Oatp4c1 and the proximal tubule marker, aquaporin 1 (AQP1) (131), or a distal
tubule marker, calbindin-D28K (132). As shown in Figure 4-21, Oatp4c1
colocalized with AQP1, but not with calbindin-D28K. Therefore, Oatp4c1 is
expressed in the proximal tubule within the juxtamedullary cortex, which
suggests that it localizes in the proximal straight tubules (S3). Double
immunofluorescence staining was also used to access the location of Oatp4c1
relative to major apical efflux transporters in the rat kidney. As shown in Figure
4-22, Mrp4 was expressed in the superficial cortex (S1, S2) and did not
colocalize with Oatp4c1. P-gp was expressed in the juxtamedullary cortex (S3)
and colocalized with Oatp4c1. Abcg2 was expressed in the whole cortex (S1, S2,
S3) and partially colocalized with Oatp4c1.
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Figure 4-20: Oatp4c1 location in rat kidney.
Immunohistochemical analysis for Oatp4c1 (red) location in paraformaldehyde-fixed
paraffin-embedded rat kidney sections with PA1343. Magnification: 4x.
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Figure 4-21: Double immunofluorescence staining for Oatp4c1 (red) and the
proximal tubule marker AQP1 (A, green) or the distal tubule marker calbindin-D28K
(B, green).
Yellow color in merged panels indicates colocalization. Nuclei (blue) were stained with
DAPI. Magnification: 10x.
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Figure 4-22 (part 1 of 2): Oatp4c1 colocalization with major efflux transporters in
the kidney cortex.
(A) Paraformaldehyde-fixed paraffin-embedded rat kidney sections were stained for
Oatp4c1 (red), Mrp4 (red), P-gp (green), and Abcg2 (red). The images were stitched
from six individual images using Image J with Fiji plug-in (National Institute Health,
Bethesda, MD). Magnification: 4x.
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Figure 4-22 (part 2 of 2) Oatp4c1 colocalization with major efflux transporters in
the kidney cortex.
(B-D) Sections were double stained for Mrp4 (red) and Oatp4c1 (green) (B); P-gp
(green) and Oatp4c1 (red) (C); Abcg2 (red) and Oatp4c1 (green) (D). Yellow/orange
color in merged panels indicates colocalization. Nuclei (blue) were stained with DAPI.
Magnification: 10x (B-D).
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C. Functional characterization of Oatp4c1 in MDCKII-Oatp4c1 cells
1.

Specific Aim 3a: To investigate Oatp4c1 transport characteristics and driving
force.
To validate the functional activity of rat Oatp4c1 in MDCKII cells generated
in Specific Aim 1b and to gain further insight on its role in the transport of
physiological substrates, we performed uptake and inhibition studies using E3S,
which was previously shown to be a human OATP4C1 substrate (110, 111). In
preliminary studies, MDCKII-pcDNA and MDCKII-Oatp4c1 c94 cells were
incubated with 0.5 µM [3H]-E3S in the absence (control) and presence of 100 µM
unlabeled E3S for 1 min at pH 5.5 and pH 7.4. As shown in Figure 4-23, the
uptake of [3H]-E3S in MDCKII-Oapt4c1 c94 cells was susceptible to inhibition by
100 µM unlabeled E3S and transport appeared to be more efficient in cells
exposed to media with pH 5.5 than pH 7.4. These data demonstrated the
functionality of the in vitro model and provided evidence that E3S is also a
substrate of rat Oatp4c1.
The transport kinetics of [3H]-E3S in MDCKII-Oatp4c1 (c94) cells were
studied further to determine the pH dependent differences in transport. From a
physiological perspective, relating to the expression of Oatp4c1 in the kidney,
this could be important as the pH in urine is in the acidic range under normal
conditions, but can be basic (pH > 7) under pathological conditions. The time
dependent uptake of [3H]-E3S (0.5 μM) was more efficient in Oatp4c1 cells as
compared to vector-transfected cells at pH 4.5, 5.5 and 7.4 (Figure 4-24 A).
Oatp4c1-mediated uptake, obtained by subtracting transport in vector-transfected
cells, was more efficient at pH 4.5 and 5.5 than at pH 7.4 (Figure 4-24 B).
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Figure 4-23: Inhibition of Oatp4c1-mediated 0.5 μM [3H]-E3S uptake by 100 μM E3S
at 1 min at pH 5.5 and pH 7.4.
Oatp4c1-mediated uptake was calculated after subtraction of nonspecific uptake by
pcDNA cells. Each column represents the mean ± S.D. of triplicate determinations from
one representative experiment. Statistical analysis was performed by unpaired student’s
t-test. * p<0.05, significant differences from control.
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Figure 4-24: Time-dependent Oatp4c1-mediated [3H]-E3S (0.5 μM) transport in
MDCKII-Oatp4c1 c94 cells at pH 4.5, pH 5.5 and pH 7.4.
(A) [3H]-E3S intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94
cells. (B) Oatp4c1-mediated uptake was calculated after subtraction of nonspecific
uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate
determinations from one representative experiment.
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To obtain quantitative estimates of the pH dependent differences in
transport, we examined the concentration dependent uptake of 1 - 150 µM [3H]E3S, and estimated transport kinetic parameters under conditions of linearity with
respect to time (1 min). [3H]-E3S uptake in MDCKII-Oatp4c1 c94 and MDCKIIpcDNA cells at pH 4.5, pH 5.5 and pH 7.4 is shown in Figure 4-25 A, and the net
uptake is shown in Figure 4-25 B. A Michaelis-Menten or a modified MichaelisMenten model, incorporating Hill slope, (Sigmoid-Emax) was fitted to the net
Oatp4c1 transport data, and Sigmoid-Emax model was selected because of lower
AIC (Table 4-1). Transport kinetic parameters were estimated by nonlinear
regression (Table 4-2). The Michaelis-Menten Km-equivalent parameter, S50, at
pH 7.4 (21.5 ± 3.6 µM) was comparable to the reported Km (26.6 ± 4.9 µM) for
human OATP4C1 at pH 7.4 (110). There was a trend toward increasing S50 with
a decrease in pH. Similarly, the estimated Tmax was 5- and 4-fold higher at pH 4.5
and pH 5.5, respectively, than the Tmax estimate at pH 7.4. Accordingly, increased
E3S transport activity at acidic extracellular pH could be ascribed to the
increased maximum transport rate. In addition, the estimated Hill slope value of
2.6 at pH 7.4 suggests positive cooperativity.
Using the estimated transport parameters we then determined the uptake
transport clearance as a function of [3H]-E3S concentration. As shown in Figure
4-26, the uptake transport clearance ( / ) was constant at concentrations below
the S50 value, but decreased rapidly as the substrate concentration saturated the
transporter. This analysis also demonstrated that the transporter uptake
clearance was 10-20 fold higher at acidic pH conditions.
The relationship between proton concentration and E3S uptake velocity
was also examined. E3S uptake velocity was estimated from the parameter
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estimates in Table 4-2. In a log-log scale, the function of y = axb appears as a
straight line, in which b is the slope. At 0.3 µM E3S, the slope was 1, indicating
E3S uptake velocity was linear with proton concentration (Figure 4-27). At higher
concentrations of E3S, the slope was less than 1, indicating that E3S uptake
velocity reached a plateau faster with increasing proton concentration,
suggesting that proton concentration plays a role in Oatp4c1-mediated E3S
uptake.
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Figure 4-25: Concentration-dependent Oatp4c1-mediated [3H]-E3S transport in
MDCKII-Oatp4c1 c94 cells at pH 4.5, pH 5.5 and pH 7.4.
(A) [3H]-E3S intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94
cells at 1 min. (B) Oatp4c1-mediated uptake was calculated after subtraction of
nonspecific uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate
determinations from one representative experiment.

Table 4-1: Akaike Information Criterion (AIC) of model selection for transport
kinetic parameter estimation of Oatp4c1-mediated E3S transport at pH 4.5, 5.5 and
7.4.
Model selection was performed using WinNonlin.

pH 4.5

pH 5.5

pH 7.4

Michaelis-Menten

62.3

57.3

53.2

Sigmoid-Emax

60.5

49.8

37.4
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Table 4-2: Transport kinetic parameters of Oatp4c1-mediated E3S transport at pH
4.5, 5.5 and 7.4 (mean ± S.E.).
The parameters were estimated by fitting a Sigmoid-Emax to the data by GraphPad.
Statistical analysis was performed by two-way ANOVA with Bonferroni post-hoc test for
all pairwise comparisons. *, **, *** p<0.05 indicate significant differences between pH 4.5
and 5.5, pH 4.5 and 7.4, and pH 5.5 and 7.4, respectively.

pH 4.5

pH 5.5

pH 7.4

612.6 ± 109.7*

484.0 ± 50.4***

129.3 ± 11.0**

S50 (µM)

60.5 ± 22.7

49.3 ± 8.8

21.5 ± 3.6

Hill Slope

1.1 ± 0.2

1.5 ± 0.2

2.6 ± 1.0

Tmax
(pmol/mg protein/min)
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Figure 4-26: The effect of pH on uptake transport clearance.
The uptake clearance v/S was simulated using the parameter estimates in Table 4-2.
The solid lines show the best fit to the data using v/S=Vmax×Sn-1/(S50n+Sn) obtained from
[3H]-E3S uptake.

Figure 4-27: The relationship between proton concentration and E3S uptake.
E3S uptake velocity was simulated at 0.3, 1, 3 and 10 µM using the parameter
estimates in Table 4-2. The solid lines show the best fit to the data using V=aHs, where
V, H and s represent E3S uptake velocity, proton concentration, and slope, respectively.
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Examination of the reported Oatp4c1 and OATP4C1 primary amino acid
sequences had revealed the presence of a potential ATP binding site (Walker A
motif) (79). However, an ATP-depletion assay revealed that OATP4C1 mediated
transport of T3 was not ATP-dependent at pH 7.4 (79). To examine whether
Oatp4c1-mediated [3H]-E3S transport was ATP-dependent, the effect of ATP
depletion on its accumulation was assessed. Twenty minutes prior to the
transport experiment, and for the duration (1 min) of transport, cells were
incubated with either uptake buffer or buffer lacking glucose, but supplemented
with 20 mM 2-deoxy-D-glucose and 10 mM NaN3 at pH 5.5 and pH 7.4. Oatp4c1mediated [3H]-E3S (0.5 µM) uptake did not change under ATP-depleted condition
at both pH 5.5 and pH 7.4 (Figure 4-28 B). In addition, [3H]-E3S intracellular
concentrations in Oatp4c1-expressing and vector-transfected MDCKII cells were
higher under ATP-depleted condition at pH 5.5 (Figure 4-28 A), suggesting the
presence of an endogenous ATP-dependent efflux transporter in the MDCKII
cells.
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Figure 4-28: Effect of ATP depletion on [3H]-E3S uptake (0.5 μM) via Oatp4c1.
(A) [3H]-E3S intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94
cells. ATP-depletion was achieved by incubating the cells in uptake buffer containing 20
mM 2-deoxy-D-glucose and 10 mM NaN3 without D-glucose at pH 5.5 and pH 7.4. (B)
Oatp4c1-mediated uptake was calculated after subtraction of nonspecific uptake by
pcDNA cells. Each column represents the mean ± S.D. of triplicate determinations from
one representative experiment.
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2.

Specific Aim 3b: To identify potential Oatp4c1 substrates.
Having validated E3S as an Oatp4c1 substrate, we next attempted to
determine the interaction of Oatp4c1 with potential physiological substrates by
studying their capacity to inhibit transport of this prototypical substrate. OATP4C1
was reported to transport T3, T4, ouabain, digoxin and MTX (79). In addition, in
vivo studies suggested that OATP4C1/Oatp4c1 is involved in the elimination of
uremic toxins (106). [3H]-E3S (0.5 µM) uptake was determined in the absence
and presence of 100 µM of putative substrates for 1 min at pH 5.5 (Figure 4-29
A, B) or pH 7.4 (Figure 4-29 C, D). Oatp4c1-mediated [3H]-E3S uptake was
significantly inhibited by T4 at pH 5.5, and significantly stimulated in the presence
of T3 at both pH 5.5 and pH 7.4 (Figure 4-29 B, D). In addition, [3H]-E3S
accumulation was significantly higher in the presence of T3 in both Oatp4c1expressing and vector-transfected cells (Figure 4-29 A, C). Neither reported
OATP4C1 substrates (digoxin, ouabain, MTX), nor putative substrates (kynurenic
acid, indoxyl sulfate, hippuric acid and trans-aconitic acid, uric acid, citric acid,
riboflavin) affected Oatp4c1-mediated E3S uptake at either pH 5.5 or pH 7.4.

105

Figure 4-29: Effect of putative substrates on [3H]-E3S uptake at pH 5.5 and 7.4.
MDCKII-pcDNA and MDCKII-Oatp4c1 c94 cells were incubated with 0.5 µM [3H]-E3S in
the absence (control) and presence of various compounds (100 µM) for 1 min at pH5.5
(A, B) and 7.4 (C, D). Oatp4c1-mediated uptake was estimated after subtracting the
nonspecific uptake measured in pcDNA cells (B, D). Each bar represents the mean ±
S.D. of triplicate determinations from one representative experiment. Statistical analysis
was performed by two-way ANOVA with Bonferroni post-hoc test compared with
control.* p<0.05, significant differences from control.
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Human OATP4C1 has been proposed to possess multiple substrate
recognition sites. In accord with a previous report demonstrated in MDCKIIOATP4C1 cells (110), Oatp4c1-mediated E3S uptake was not inhibited by
digoxin and ouabain. Therefore, Oatp4c1 may also have multiple substrate
binding sites. If so, the unchanged Oatp4c1-mediated E3S uptake by putative
substrates (Figure 4-29) may be because they interact with a different site than
that of E3S. To verify these putative substrates, we used another reported
OATP4C1 substrate, MTX (79), as a prototype substrate. As shown in Figure
4-30 A, time dependent uptake of [3H]-MTX (1 μM) was more efficient in Oatp4c1
cells as compared to vector-transfected cells at pH 5.5 and pH 7.4, suggesting
MTX is Oatp4c1 substrate. However, Oatp4c1-mediated MTX uptake was
comparable at pH 5.5 and pH 7.4 (Figure 4-30 B), which is unlike the pH effect
observed with E3S uptake.
The capacity of the putative substrates to inhibit MTX transport was
examined. [3H]-MTX (1 µM) uptake was determined in the absence and presence
of 100 µM various compounds for 1 min at pH 5.5 (Figure 4-31 A, B) or pH 7.4
(Figure 4-31 C, D). Oatp4c1-mediated [3H]-MTX uptake was significantly
stimulated by the presence of trans-aconitic acid and uric acid at pH 5.5 (Figure
4-31 B). Oatp4c1-mediated [3H]-MTX uptake was significantly inhibited by T3 at
pH 7.4. (Figure 4-31 D). Additionally, as observed in [3H]-E3S inhibition studies,
[3H]-MTX accumulation was significantly higher in the presence of T3 in both
Oatp4c1-expressing and vector-transfected cells (Figure 4-31 A, C). Neither
reported OATP4C1 substrates (T4, digoxin, ouabain, and E3S), nor putative
substrates (kynurenic acid, indoxyl sulfate, riboflavin) changed Oatp4c1mediated MTX uptake at either pH 5.5 or pH 7.4.
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Figure 4-30: Time-dependent Oatp4c1-mediated [3H]-MTX (1 μM) transport in
MDCKII-Oatp4c1 c94 cells at pH 5.5 and pH 7.4.
(A) [3H]-MTX intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94
cells. (B) Oatp4c1-mediated uptake was calculated after subtraction of nonspecific
uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate
determinations from one representative experiment.
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Figure 4-31: Effect of putative substrates on [3H]-MTX uptake at pH 5.5 and 7.4.
MDCKII-pcDNA and MDCKII-Oatp4c1 c94 cells were incubated with 1 µM [3H]-MTX in
the absence (control) and presence of various compounds (100 µM) for 1 min at pH5.5
(A, B) and 7.4 (C, D). Oatp4c1-mediated uptake was estimated after subtracting the
nonspecific uptake measured in pcDNA cells (B, D). Statistical analysis was performed
by two-way ANOVA with Bonferroni post-hoc test compared with control. Each bar
represents the mean ± S.D. of triplicate determinations from one representative
experiment. * p<0.05, significant differences from control.
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D. Creation and validation of human OATP4C1-expressing cell lines
1.

Specific Aim 4a: To develop and validate human OATP4C1 antibodies amenable
for immunoblotting, immunohistochemistry and immunofluorescence.
To investigate the expression and subcellular localization of human
OATP4C1 in the in vitro cell models and human tissues, two rabbit polyclonal
antibodies were generated against either amino-terminus (PA1243) or carboxylterminus (PA1245) of human OATP4C1. The antibodies specificities were
validated

by

Western

blotting,

immunohistochemical

analysis,

and

immunofluorescence staining in the in vitro cell models developed in Specific Aim
4b.

2.

Specific Aim 4b: To create and validate human OATP4C1-expressing cells with
appropriate characteristics for functional studies.
To study the role of human OATP4C1 in drug disposition, we generated
OATP4C1-expressing MDCKII cells and OATP4C1-expressing Sf9 cells. Human
SLCO4C1 DNA purchased from OriGene was amplified by PCR reaction. The
amplified fragment of appropriate size was confirmed by agarose gel
electrophoresis (Figure 4-32 A). The amplification product was purified and
cloned into pENTR vector. The plasmid construct was verified by EcoRI
restriction enzyme digestion and by PCR with M13 forward and M13 reverse
primers, which bound to ~110 bp upstream and ~150 bp downstream of the gene
insertion site, respectively, in the pENTR vector (Figure 4-32 B). This sequence
was confirmed with 100% identity as compared to the published human
SLCO4C1 sequence (GeneBank accession number NM_180991). The plasmid
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DNA was then subcloned into pcDNA6.2/EmGFP-Bsd/V5-DEST vector and was
verified by PCR with T7 forward primer, which bound to 50 bp upstream of gene
insertion site in the vector, and SLCO4C1 reverse primers (Figure 4-32 C).
The SLCO4C1 plasmid DNA (pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1)
and empty plasmid DNA (pcDNA6.2/EmGFP-Bsd/V5-DEST) were transfected
into MDCKII cells. Transfection efficiency was examined by Western blotting
using the antibody generated in Specific Aim 4a (PA1245) (Figure 4-33 A).
OATP4C1 expression was detectable as a band at ~60 kDa in MDCKIIOATP4C1 cells, but not in MDCKII-pcDNA (empty vector) cells. Human kidney
served as a positive control with a band detected at ~70 kDa. OATP4C1 was
also detectable as a broad band at 60-70 kDa in OATP4C1-expressing Sf9 cells,
which will be described later. In addition, validation of antibody PA1243 for
Western blotting is shown in Figure 4-33 B. OATP4C1 was detected at ~60 and
80 kDa in human kidney and at ~60 kDa in Sf9-OATP4C1 cells, but not in Sf9vector cells. After antigen peptide blocking, the specific bands in human kidney
(~80 kDa) and Sf9-OATP4C1 cells (~60 kDa) were abolished, demonstrating the
antibody specificity.
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Figure 4-32: Validation of SLCO4C1 plasmid constructs.
PCR products and the restriction enzyme digestion products of SLCO4C1 and plasmid
DNA were examined by agarose gel electrophoresis.
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OATP4C1 expression in MDCKII-OATP4C1 cells was also confirmed in
paraformaldehyde-fixed

paraffin-embedded

cell

pellet

sections

by

immunohistochemical analysis using antibody PA1243 (Figure 4-33 C).
OATP4C1 was observed on the cell membrane in the MDCKII-OATP4C1 cells,
and the staining was abolished when probed with antibody that was preadsorbed with antigen peptide. Despite some background staining detected in
the negative control (rabbit IgG), no staining was observed in the MDCKII-pcDNA
cells. This demonstrated that the transfection was successful and that the
antibody was specific.
The subcellular localization of OATP4C1 in polarized cell monolayers was
assessed by confocal immunofluorescence laser scanning microscopy (Figure
4-33 D) and surface protein biotinylation assay (Figure 4-33 E). As observed for
rat Oatp4c1, OATP4C1 localized at the apical membrane in MDCKII-OATP4C1
cells (Figure 4-33 D). As shown in Figure 4-33 E, surface biotinylation assay
demonstrated that OATP4C1 was enriched in the apical membrane fraction as
compared to the basolateral membrane. Collectively, these data verified the
apical localization of the transporter in OATP4C1-expressing MDCKII cells.
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Figure 4-33: Validation of OATP4C1 expression and subcellular localization in
MDCKII-OATP4C1 cells.
(A) Western blot of OATP4C1 and β-actin. OATP4C1 was detected with PA1245. (B)
Western blot of OATP4C1 and β-actin with and without antigen peptide blocking.
OATP4C1 was detected with PA1243. (C) Immunohistochemical analysis of OATP4C1
expression in paraformaldehyde-fixed paraffin-embedded cell sections. OATP4C1 was
detected with PA1243. (D) Confocal microscopy of OATP4C1 (red) expression and
localization in polarized MDCKII cells. Center image is a single optical section of the x-y
plane while top and right images represent x-z and y-z planes, respectively,
reconstructed from image stacks. The apical and basal sides can be demarcated by Zo114

1 (green) and the nuclei (DAPI, blue), respectively, in both x-z and y-z sections.
OATP4C1 was detected with PA1245. (E) Western blot of OATP4C1 in proteins isolated
from either the apical (AP) or basolateral (BL) membranes of polarized MDCKII cells.
Na+/K+-ATPase served as a BL marker to demonstrate the relative efficiency of AP and
BL membrane separation. OATP4C1 was detected with PA1245.
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To validate the functional activity of OATP4C1 in MDCKII cells, the uptake
studies of reported OATP4C1 substrates, ouabain and E3S (79, 110, 111), was
performed. Ouabain transport kinetics were determined by [3H]-ouabain uptake
for concentrations ranging from 1 to 150 µM at 5 min. OATP4C1-mediated
uptake (net) was calculated after subtraction of nonspecific uptake by pcDNA
cells. As shown in Figure 4-34, [3H]-ouabain uptake was higher in MDCKIIOATP4C1 as compared to MDCKII-pcDNA cells, and a saturable concentrationdependent OATP4C1-mediated ouabain uptake was observed. It confirmed
ouabain as an OATP4C1 substrate and showed the functional activity of
OATP4C1 in the transfected cells. Michaelis-Menten and sigmoid-Emax were fitted
to the net OATP4C1 transport data. The transport kinetic parameters were
estimated by nonlinear regression (
Table 4-3). The AIC for the two models were comparable. Therefore, the
simpler Michaelis-Menten model was selected. The estimated S50 (0.19 ± 0.09
µM) was in the similar range of the reported Km (0.38 ± 0.1 µM) (79).
The functional activity of OATP4C1 in MDCKII cells was also validated with
E3S. [3H]-E3S uptake was determined at 0.5 and 1 µM for 5 min. As shown in
Figure 4-35, [3H]-E3S uptake was higher in MDCKII-OATP4C1 than that in
MDCKII-pcDNA cells, and the net uptake was increased with concentration.
Despite that the concentrations were not high enough to reach saturation, the
data suggest that E3S is an OATP4C1 substrate.
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Figure 4-34: Concentration-dependent OATP4C1-mediated [3H]-ouabain transport
in MDCKII-OATP4C1 cells at pH 7.4.
[3H]-ouabain intracellular concentration (5 min) in MDCKII-pcDNA and MDCKIIOATP4C1 cells. OATP4C1-mediated uptake (net) was calculated after subtraction of
nonspecific uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate
determinations from one representative experiment.

Table 4-3: Transport kinetic parameters of OATP4C1-mediated [3H]-ouabain
transport at pH 7.4 (mean ± S.E.).
The transport parameters were estimated by GraphPad, and AIC for model selection
was estimated by WinNonlin.

Michaelis-Menten

Sigmoid-Emax

0.17 ± 0.03

0.26 ± 0.24

S50 (µM)

0.19 ± 0.09

0.70 ± 2.02

Hill Slope

-

0.67 ± 0.36

AIC

-34.00

-34.23

Tmax
(pmol/min/mg protein)
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Figure

4-35:

Concentration-dependent

OATP4C1-mediated

[3H]-E3S

transport in MDCKII-OATP4C1 cells at pH 7.4.
[3H]-E3S intracellular concentration (5 min) in MDCKII-pcDNA and MDCKIIOATP4C1 cells. OATP4C1-mediated uptake (net) was calculated after
subtraction of nonspecific uptake by pcDNA cells. Each point represents the
mean ± S.D. of triplicate determinations from one representative experiment.
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In addition to MDCKII cells, we also overexpressed OATP4C1 in Sf9 cells.
Sf9 can express higher level of recombinant protein and is easily scaled up for
substrate screening to study the role of human OATP4C1 in drug disposition.
pENTR/SLCO4C1 construct was generated as previously described in
developing OATP4C1-expressing MDCKII cells, and was subcloned into pDEST8
vector. The size of the plasmid construct was confirmed by Bsu361 restriction
enzyme digestion (Figure 4-36 A). The plasmid DNA was then recombined in
DH10BacTM competent E. Coli. containing baculovirus genome. For background
control, the empty vector (pDEST8) was also recombined as above.
Recombinant bacmid DNA was verified by PCR with M13 forward and M13
reverse primers (Figure 4-36 B).
The recombinant bacmids (pDEST8/SLCO4C1 and pDEST8) were
transfected into Sf9 cells, and the supernatant containing recombinant
baculovirus stock was harvested after 48 hr. The viral stock was amplified by
infecting a large volume of Sf9 cell suspensions. The infected Sf9 cells were
centrifuged to collect cell pellets for membrane vesicle preparation. Successful
infection was confirmed by Western blotting for OATP4C1 expression in the
membrane vesicles. As shown in Figure 4-37, OATP4C1 was detected in Sf9OATP4C1 membrane vesicles but not in Sf9-vector.
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Figure 4-36: Validation of pDEST8-SLCO4C1 plasmid construct.
Restriction enzyme digestion products and PCR products of pDEST8-SLCO4C1 were
examined by agarose gel electrophoresis.

Figure 4-37: Validation of OATP4C1 expression in Sf9-OATP4C1 membrane
vesicles.
Western blot analysis for OATP4C1 expression in Sf9-pDEST8 and Sf9-OATP4C1
membrane vesicles (0.2 μg protein). OATP4C1 was detected with PA1245.
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To validate the functional activity of OATP4C1 in Sf9 cells, vesicular
transport studies of [3H]-ouabain and [3H]-E3S were performed. As shown in
Figure 4-38, the time dependent uptake of [3H]-ouabain (0.5 μM) was higher in
Sf9-OATP4C1 as compared to Sf9-pDEST8 membrane vesicles at pH 7.4.
Based on this result, the 3 min time point was chosen to determine the initial rate.
To evaluate [3H]-ouabain transport kinetics, the initial rate of [3H]-ouabain uptake
were determined for concentrations ranging from 0.01 to 1 µM (Figure 4-39 A
and B). However, the nonspecific adsorption determined by incubation in cold
uptake buffer was substantial. At 1 µM, the nonspecific adsorption was 55% of
the total radioactivity remaining on the filter. After subtracting the nonspecific
adsorption, [3H]-ouabain uptake in Sf9-pDEST8 showed saturation transport
kinetics, indicating the presence of an endogenous uptake transporter (Figure
4-39 B). OATP4C1-mediated ouabain uptake was calculated after subtraction of
nonspecific uptake in Sf9-pDEST8. Michaelis-Menten and sigmoid-Emax models
were fitted to the net OATP4C1 transport data. The transport kinetic parameters
were estimated by nonlinear regression (Table 4-4). The simpler MichaelisMenten model was selected because the AIC of the two models were
comparable. The estimated S50 (0.18 ± 0.09 µM) was comparable with the S50
estimated from MDCKII-OATP4C1 cells (0.19 ± 0.09 µM) and was in the similar
range of the reported Km (0.38 ± 0.1 µM) (79). However, the high nonspecific
adsorption decreased the sensitivity, therefore another substrate with low
adsorption was needed to study OATP4C1 function.
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Figure 4-38: Time-dependent OATP4C1-mediated [3H]-ouabain (0.5 μM) transport
in Sf9-OATP4C1 membrane vesicles at pH 7.4.
[3H]-ouabain accumulation in Sf9-pDEST8 and Sf9-OATP4C1 membrane vesicles.
OATP4C1-mediated uptake was calculated after subtraction of nonspecific uptake by
Sf9-pDEST8. Each point represents the mean ± S.D. of triplicate determinations from
one representative experiment.

Figure 4-39: Concentration-dependent OATP4C1-mediated [3H]-ouabain transport
in Sf9-OATP4C1 membrane vesicles at pH 7.4.
(A) [3H]-ouabain accumulation (3 min) in Sf9-pDEST8 and Sf9-OATP4C1 membrane
vesicles. Nonspecific adsorption on the filter was measured by incubation in cold buffer.
(B) Data from panel A with nonspecific adsorption subtraction. OATP4C1-mediated
uptake was calculated after subtraction of nonspecific uptake by Sf9-pDEST8. Each
point represents the mean ± S.D. of triplicate determinations from one representative
experiment.

122

Table 4-4: Transport kinetic parameters of OATP4C1-mediated [3H]-ouabain
transport in Sf9-OATP4C1 membrane vesicles at pH 7.4 (mean ± S.E.).
The transport parameters were estimated by GraphPad, and AIC for model selection
was estimated by WinNonlin.

Michaelis-Menten

Sigmoid-Emax

0.15 ± 0.02

0.37 ± 0.90

S50 (µM)

0.18 ± 0.09

2.76 ± 20.80

Hill Slope

-

0.55 ± 0.39

AIC

-30.83

-30.70

Tmax
(pmol/min/mg protein)
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Because of the high nonspecific adsorption on the filter membrane of
ouabain, which interfered with data interpretation, another substrate, E3S, was
used to investigate OATP4C1 transport characteristics. Preliminary studies
showed that nonspecific adsorption of E3S was only 0.3% of the total
radioactivity. The time dependent uptake of [3H]-E3S (30 μM) was higher in Sf9OATP4C1 as compared to Sf9-pDEST8 membrane vesicles at pH 7.4, and the 5
min time point was chosen to determine the initial rate (Figure 4-40 A). To
evaluate [3H]-E3S transport kinetics, the initial rate of [3H]-E3S uptake was
determined for concentrations ranging from 1 to 30 µM (Figure 4-40 B). The net
uptake was increased with concentration, but did not reach a plateau, implying
that the transporter was not saturated at these concentrations. In addition, the pH
effect on OATP4C1-mediated E3S transport was examined. [3H]-E3S (20 μM)
accumulation in Sf9-pDEST8 and Sf9-OATP4C1 for 5 min at pH 6.5 and pH 7.4
was determined (Figure 4-41 A). As shown in Figure 4-41 B, there was a trend
toward increasing net uptake with a decrease in pH.
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Figure 4-40: Time-dependent and concentration-dependent OATP4C1-mediated
[3H]-E3S transport in Sf9-OATP4C1 membrane vesicles at pH 7.4.
(A) Time-dependent 30 μM [3H]-E3S accumulation in Sf9-pDEST8 and Sf9-OATP4C1
membrane vesicles. (B) Concentration-dependent [3H]-E3S accumulation in Sf9pDEST8 and Sf9-OATP4C1 membrane vesicles at 5 min. Nonspecific adsorption on the
filter was measured by incubation in cold buffer and was subtracted as background.
OATP4C1-mediated (net) uptake was calculated after subtraction of nonspecific uptake
by Sf9-pDEST8. Each point represents the mean ± S.D. of triplicate determinations from
one representative experiment.
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Figure 4-41: Effect of pH on OATP4C1-mediated [3H]-E3S transport in Sf9OATP4C1 membrane vesicles.
(A) [3H]-E3S (20 μM) accumulation in Sf9-pDEST8 and Sf9-OATP4C1 membrane
vesicles for 5 min at pH 6.5 and pH 7.4. (B) OATP4C1-mediated uptake was calculated
after subtraction of nonspecific uptake by Sf9-pDEST8. Each point represents the mean
± S.D. of triplicate from one representative experiment.
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E. Validation of OATP4C1 expression in human kidney and cancer cells
1.

Specific Aim 4c: To determine the expression and subcellular localization of
OATP4C1 in the human kidney.
OATP4C1 expression in human kidney by Western blotting was shown in
Figure 4-33 A and B. The subcellular localization of OATP4C1 was then
assessed by immunohistochemical analysis in paraformaldehyde-fixed paraffinembedded human kidney tissue sections. To assure the quality of the kidney
specimens, sections were stained with anti-MRP4 antibody (clone M4I10), which
showed specific staining (Figure 4-42). However, no staining was observed using
the PA1243 and PA1245 anti-OATP4C1 antibodies, despite several attempts to
improve antigen recovery and to maximize reaction time (prolonged incubations).
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Figure 4-42: Immunohistochemical analysis for OATP4C1 subcellular
localization in human kidney sections.
OATP4C1 was detected with rabbit polyclonal anti-OATP4C1 antibodies as
indicated. Rabbit IgG was used as a negative control. MRP4, a positive control,
was detected with M4I10. Magnification: 40x.
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2.

Specific Aim 4d: To determine the expression of OATP4C1 in cancer cells.
Microarray analysis showed a 18-fold increase of SLCO4C1 expression in
lung tumor relative to normal lung (104). In addition, SLCO4C1 expression in
lung tumor was 2-fold higher than that in human kidney. To screen SLCO4C1
expression in different type of cancer cells, qRT-PCR was performed in 10
cancer cell lines, including prostate cancer, glioblastoma, breast cancer and
melanoma cells. As shown in Figure 4-43, SLCO4C1 expression in H1299 (nonsmall cell lung cancer cells) was 20-fold higher than that in human kidney,
whereas SLCO4C1 expression in other cell lines was not significantly different
from that in human kidney.
SLCO4C1 was also observed in human formalin fixed paraffin embedded
lung cancer specimens. SLCO4C1/OATP4C1 expression in these tissues was
determined by qRT-PCR and immunohistochemical analysis. Because tissue
fixation and storage typically cause nucleic acid fragmentation and chemical
modification, three primers were used in qRT-PCR to prevent false negative
interpretation from unsuccessful amplification. 18s rRNA was used as an internal
control, and relative SLCO4C1 expression was normalized with normal lung
tissue from the same patient calculated by the 2-∆∆Ct method. Compared with
adjacent normal lung tissue, SLCO4C1 expression was higher in the tumor for
five patients (2451, 2492, 2506, 2508 and 2509), but lower for four patients
(2493, 2497, 2507 and 2534) (Figure 4-44). Two patients from each group were
chosen for immunohistochemical analysis to confirm OATP4C1 expression in
tumor and normal lung tissue. Unlike the qRT-PCR results, OATP4C1 staining
was stronger in the tumor than in the normal lung in all of four patients (Figure
4-45). Despite this discrepancy between immunohistochemistry and qRT-PCR
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results, these data collectively suggested that OATP4C1 is highly expressed in
lung tumors.
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Figure 4-43: Relative SLCO4C1 expression in cancer cells calculated with the 2-∆∆Ct
method.
Relative copy number of SLCO4C1 in the samples was normalized to 18s rRNA within
each sample and values were then normalized with those in human kidney. Each bar
represents mean of triplicate determinations. Statistical analysis was performed by oneway ANOVA with Dunnett’s test. * p<0.05, significant difference from control (human
kidney).
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Figure 4-44: Relative SLCO4C1 expression in lung tumor and adjacent normal
lung tissue of 9 patients calculated with the 2-∆∆Ct method.
Relative copy number of SLCO4C1 in the samples was normalized to 18s rRNA within
each sample and values were then normalized with those in adjacent normal lung tissue
of each patient. Each bar represents mean of triplicate determinations. The amplicon
length of the primer is denoted in the parentheses. Four patients selected for
immunohistochemical analysis are indicated by the blue underline.
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Figure 4-45: OATP4C1 expression in the lung tumor and adjacent normal lung
tissue of 4 patients.
Immunohistochemical analysis of OATP4C1 expression in paraformaldehyde-fixed
paraffin-embedded lung tumor and adjacent normal lung tissue slides. OATP4C1 was
detected with PA1243. Magnification: 10x (inset 40x).
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CHAPTER 5 : DISCUSSION
A. Creation and validation of a rat Oatp4c1-expressing cell line
Despite the well documented benefits of breastfeeding, limited data regarding the
risk of drug transfer into breast milk and the possibility of exposing infants to drugs
poses a dilemma for lactating mothers and their physicians. To identify the transporters
involved in drug transfer into the milk, a comprehensive microarray analysis examining
xenobiotic

transporter

genes

regulation

during

lactation

was

performed

and

demonstrated that SLCO4C1 expression was upregulated 70-fold in LMEC as compared
to MEC. This suggests its potential role in drug transfer into the milk. In accord with the
published literature, ABCG2 expression was upregulated during lactation 164-fold (10).
OATP4C1/Oatp4c1 had been demonstrated to localize at the basolateral membrane in
the kidney (79, 106). Therefore, we hypothesized that OATP4C1/Oatp4c1 localized at
the basolateral membrane in the mammary gland and coupled with ABCG2/Abcg2, an
apical efflux transporter, to facilitate the transfer of their common substrates into breast
milk.
To examine the expression and subcellular localization of rat Oatp4c1 in the cells
and tissues, antibodies amenable to immunohistochemistry, immunofluorescence, and
immunoblotting were generated and validated. Rat Oatp4c1-expressing MDCKII cell
lines were generated to study the role of Oatp4c1 in drug disposition. The MDCKII cell
line was selected because of its extensive use in the published literature, ease of
transfection and subsequent selection, ability to form a polarized monolayer and tight
junctions. The successful transfection was demonstrated by a distinct band at
appropriate molecular weight by Western blotting and specific membrane localization by
immunohistochemical analysis. Unexpected results from immunofluorescence confocal
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microscopy and surface protein biotinylation assay both showed that the transporter
localized at the apical rather than the basolateral membranes (Figure 4-2). Although this
result was unexpected, it is not without precedent, as others demonstrated that
apical/basolateral sorting depends on the host cell (35). Previous results by Lai and Tan
showed that MRP4 localized in the basolateral membrane of MDCKII cells (118).
However, MRP4 localizes at the apical membrane of human and rodent renal proximal
tubules (133). This discrepancy was later attributed to species differences in NHERF1
expression, an adaptor protein that determines the trafficking of MRP4 (119). Therefore,
Oatp4c1-expressing LLC-PK1 cells were generated to confirm the subcellular
localization of Oatp4c1. As observed in MDCKII cells, Oatp4c1 also localized at the
apical membrane in LLC-PK1 cells (Figure 4-3).
Apical/basolateral sorting of newly synthesized proteins typically occurs in the
trans-Golgi network, where apical and basolateral components are selectively packaged
into specific transport vesicles mediated by sorting signals (134, 135). Apical sorting
signals localized to all the portions of apical proteins (extracellular, transmembrane and
cytoplasmic domain) include the glycosylphosphatidylinositol (GPI) anchor or N- and Olinked protein glycosylation. Basolateral sorting signals usually located in the
cytoplasmic tail of basolateral proteins include tyrosine-based YXXØ, NPXY motifs
(where X can be any amino acid and Ø is a bulky hydrophobic residue) and dileucinebased motifs. The trafficking of basolateral proteins containing the tyrosine-based or
dileucine-based sorting signals is via adaptor proteins. AP1-µ1B is a well-characterized
adaptor protein associated with basolateral sorting. It is expressed in various polarized
epithelial cell lines, including MDCKII, Caco-2, but not in LLC-PK1 cells. Lack of AP1µ1B in LLC-PK1 cells results in missorting of many basolateral proteins to the apical
membrane, but stable expression of AP1-µ1B restores the basolateral trafficking (136).
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Although Oatp4c1 localized at the apical membrane in both of MDCKII and LLC-PK1
cells, we can not rule out the possibility that the adaptor protein for Oatp4c1 trafficking is
lacking in both cells. Therefore, it was necessary to determine the subcellular
localization of Oatp4c1 in the kidney to confirm this result.
Although

transfection

led

to

detectable

protein

by

Western

blot,

immunofluorescence studies showed that the transfection efficiency was very low (~ 3%)
in MDCKII cells (Figure 4-4). Therefore, we attempted to obtain a single clone with
homogenous high Oatp4c1 expression. Our initial attempt was to sort individual live cells
into a 96-well plate by FACS analysis with transient C-terminal-tagged GFP, which was
produced by adding Tag-On-DemandTM Suppressor Supernatant. However, none of the
subsequent clones showed Oatp4c1 expression. Tag-On-DemandTM Suppressor
Supernatant is a replication-incompetent adenovirus containing human tRNAser
suppressor, which has been mutated to recognize the TAG stop codon and decode it as
serine. Translation is thereby continued through the downstream reading frame and
produces a transient C- terminal tagged GFP fusion protein. The sorting gate
(fluorescence channel boundaries) was set based on the fluorescence intensity, which
was determined by the efficiency of Tag-On-DemandTM Suppressor Supernatant.
Observed low GFP intensity was probably due to low efficiency of Tag-On-DemandTM
Suppressor Supernatant, and resulted in a wide sorting gate which may have
compromised the purity of sorted cells. Therefore, some of the sorted cells may not have
contained the Slco4c1 gene.
The second attempt was to sort the cells by immunofluorescence labeling. Oatp4c1
was labeled with rabbit polyclonal antibody PA1343 and Alexa 488 anti-rabbit IgG.
Individual live cells were then sorted into a 96-well plate by FACS analysis with Alexa
488 fluorescence. However, none of the subsequent clones exhibited Oatp4c1
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expression. The labeling of Oatp4c1 needs the C-terminal primary antibody and the
secondary antibody to penetrate into the cells, and that may be difficult to achieve
without permeabilization agent, Triton-X 100. Therefore, low fluorescence intensity was
observed and resulted in a wide sorting gate, which compromised the purity of sorted
cells.
The third attempt was to randomly seed individual live cells in 96-well plates.
Unfortunately, none of the subsequent clones showed Oatp4c1 expression. These
failures lead us to hypothesize that the expression of Oatp4c1 decreases the cell
proliferation rate and this effect is magnified when expanding from a single cell. The
decreased cell proliferation rate is probably because of the metabolic burden created
from expressing a foreign protein in recombinant host cells (121). Therefore, the fourth
attempt was to generate the clones starting from more than one cell using the serial
dilution method. Although the homogeneity of Oatp4c1 expression was compromised,
but we finally obtained one clone (c94) that showed higher Oatp4c1 expression by
Western blotting (Figure 4-10) and more cells exhibiting Oatp4c1 expression as
compared to the pooled cells (11% vs. 3%) by immunofluorescence staining (Figure
4-4).
To increase Oatp4c1 expression, we sought to treat the cells with sodium butyrate,
simvastatin, glycerol, MG132, or to increase the selection antibiotic, blasticidin,
concentration. Sodium butyrate is commonly used to induce protein expression (122,
123). It is a short-chain fatty acid that has been recognized to function as a transcription
activator due to its ability to influence chromatin structure via inhibition of histone
deacetylase activity (137). However, sodium butyrate was reported to disrupt the protein
trafficking in Na+/K+-ATPase β1- and β2 subunits-overexpressed MDCK-I cells (124). A
concentration-dependent upregulation of Oatp4c1 expression was observed at mRNA
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and protein levels, while apical polarity was maintained (Figure 4-5). The upregulation of
Oatp4c1 expression, as well as increased number of cells exhibiting Oatp4c1
expression, were also observed in high concentrations of selection antibiotic, blasticidin
(Figure 4-6). However, the effect of blasticidin was negligible when co-treating Oatp4c1expressing MDCKII c94 cells with sodium butyrate and blasticidin (Figure 4-10).
Several HMG-CoA reductase inhibitors (statins) have been shown to enhance
SLCO4C1 promoter activity by inducing nuclear AhR, which binds to the XRE motifs on
SLCO4C1 promoter region. However, our data showed that simvastatin induced Slco4c1
mRNA expression, but this did not result in increased protein expression in the MDCKIIOatp4c1 cells (Figure 4-7). This is inconsistent with a previous report, which showed that
pravastatin/fluvastatin increased SLCO4C1 expression as well as protein function, T3
uptake, in ACHN cells (renal carcinoma cells) (106). However, other transporters
expressed in ACHN cells (107), which transport T3, may also be regulated by
pravastatin/fluvastatin and thereby increase T3 uptake. Although a direct relationship
between mRNA and protein levels is often expected, several reports have demonstrated
weak correlation between mRNA and protein levels (138, 139). This may be the result of
differences in regulatory controls, translation rates, posttranslational modification and
protein degradation. In fact, simvastatin was shown to decrease androgen receptor
protein expression, while its mRNA expression was not changed (140). Whether the
discrepancies in Oatp4c1 mRNA and protein expression by simvastatin treatment are
due to protein degradation will have to be investigated further.
The primary amino acid sequence of rat Oatp4c1 contains a high number of
cysteine residues as compared to other transporters, such as ABCG2, P-gp, and MRP4.
Disulfide bonds between cysteine residues play a key role in protein folding, which is
important for protein trafficking and function. The high number of cysteine residues in
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Oatp4c1 may lead to a higher degree of folding, which may not be possible in the
MDCKII cells. In turn, misfolded proteins fail to traffic out of the endoplasmic reticulum
(ER) via the Golgi apparatus to the plasma membrane, and are targeted for degradation
via the ubiquitin/proteasome-dependent pathway. Glycerol is a chemical chaperone, and
has protein-stabilizing properties in vitro, due to its ability to increase protein hydration
(126). Glycerol has been shown to stabilize misfolded ∆F508 cystic fibrosis
transmembrane conductance regulator protein (CFTR) mutant protein into conformations
that are not targeted for degradation and can escape ER and degradation (125).
Treatment of ∆F508 CFTR-expressing cells with high concentrations (1 - 1.25 M) of
glycerol for 2 or 3 days increased the stability of fully glycosylated matured form of CFTR
on Western blotting and restored the ability of forskolin-dependent (cAMP-activated)
chloride transport (141). MG132 is a proteasome inhibitor that can prevent misfolded
proteins, which are retained in ER, from being targeted for premature proteolysis. Its
effect on misfolded protein rescue has been demonstrated in ABCG2 mutant C592G- or
C608G-expressing Flp-In-293 cells. MG132 increased the expression of the fully
glycosylated mature form of ABCG2 mutant by Western blotting, membrane localization
by immunofluorescence staining, and also protein function as cellular resistance to
ABCG2 substrate, SN-38 (142). However, treatment with glycerol or MG132 did not
increase Oatp4c1 expression (Figure 4-8, Figure 4-9). This suggests that Oatp4c1 was
properly folded in MDCKII cells and the low number of cells exhibiting Oatp4c1
expression (~11%) was not due to misfolded proteins. The potential cause for low
Oatp4c1-expressing cells is that Oatp4c1 expression decreases the cell proliferation
rate, and therefore the majority of the cell population doesn’t express Oatp4c1. The slow
growth rate of Oatp4c1-expressing cells is possibly due to the metabolic burden created
from expressing foreign protein or protein toxicity caused from overexpressing proteins
at levels higher than the physiological level (121). Recombinant protein expression
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introducing a foreign protein in host cells utilizes host cell’s resources, such as ATP or
amino acids, imposes a metabolic burden on the host cells, and may decrease the
growth rate of the host cells. The recombinant protein expression is usually significantly
higher than that in physiological environment, which may not need for the host cells and
cause toxicity in the host cells. In addition, Oatp4c1 functions as an uptake transporter,
which may increase intracellular concentrations of substances that slow the growth rate
or cause cell death.
Overall, although the number of cells exhibiting Oatp4c1 expression is low, we
believe that Oatp4c1 expression with sodium butyrate induction is adequate to study
Oatp4c1 function.

B. Determination of Oatp4c1 expression and subcellular localization in rat tissues
The upregulation of human SLCO4C1 expression in MG during lactation was also
observed in rats by RT-PCR analysis, and protein upregulation was confirmed by
Western blotting (Figure 4-12). In accord with the published literature, Slco4c1/Oatp4c1
was expressed in the kidney, but not in the liver (79). The expression of Slco4c1 in rat
kidney was lower than that in rat MG at the mRNA level, but was higher at the protein
level. The discrepancies in Slco4c1 mRNA and protein expression in kidney and MG
may

be

due

to

tissue-dependent

regulatory

controls

and/or

posttranslational

modification. An ontogenic study showed that Slco4c1 mRNA expression in rat kidney
increases with age, whereas liver expression was absent in rats of all ages (Figure 4-13,
Figure 4-14). However, our observation is inconsistent with the previous findings that
showed no gender differences of Slco4c1 mRNA expression in the rat kidney (79). In
terms of gender differences, higher Oatp4c1 expression was observed in non-lactating
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female rat kidney as compared with males at both mRNA and protein levels (Figure
4-13). The expression of Slco4c1 in non-lactating female rat kidney was higher than that
in lactating female rat kidney at the mRNA level, but was the same at the protein level.
The discrepancies may be due to differences in regulatory controls and/or
posttranslational modification during lactation. However, these results were not
conclusive because of the small sample size (one).
The subcellular localization of Oatp4c1 in rat tissues was determined by
immunohistochemical analysis and showed apical localization in both rat kidney and MG
(Figure 4-15), which was inconsistent with a previous report showing that Oatp4c1
localized at the basolateral membrane in the rat proximal tubule (79). The
immunohistochemistry result was verified with four different antibodies, which were
raised against unique C- and N-terminal peptides (Figure 4-16). The apical localization
was also demonstrated by distinct localization of Oatp4c1 and a basolateral marker Ecadherin (Figure 4-17), and colocalization of Oatp4c1 and an apical marker pglycoprotein (Figure 4-22 C). In addition, biochemical separation of BBM and BLM from
proximal rat kidney tubules confirmed the location of Oatp4c1 at the apical/brush border
membranes by Western blot and proteomic analyses (Figure 4-19). Furthermore, the
proteomic analyses provide additional validation for the Oatp4c1 antibody specificity.
This extensive validation of the in vitro and in vivo subcellular localization was
deemed necessary as our results were not in accordance with previous reports, which
showed that Oatp4c1 localizes at the basolateral membrane in the rat proximal tubule
(79), as did human OATP4C1 in the transgenic rat harboring human SLCO4C1 (106).
These authors hypothesized that basolateral expression of Oatp4c1 worked in tandem
with an apical efflux transporter to efficiently transport substrates across the kidney
epithelium and into the urine (79, 106). The contradictory finding in the original report by
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Mikkaichi and colleagues may have been a result of limited validation performed with the
antibody used in that study. Our attempt to develop this polyclonal antibody (79), using
the reported 11 amino acid peptide antigen, did not yield a reagent that was amenable to
immunohistochemistry (Figure 4-16). The results of the transgenic OATP4C1 expression
pattern reported by Toyohara et al., however, are more difficult to reconcile (106). In
their publication, they present evidence that OATP4C1 localizes in the basolateral
membrane of renal tubule epithelium in transgenic rats. Provided that the anti-OATP4C1
antibody recognized the correct transgenic protein, one potential explanation for the
observed differences in the subcellular localization could be abnormal trafficking of the
human OATP4C1 protein in the transgenic rat.
It is not without precedent that antibodies used to detect transporter proteins result
in controversial findings. For instance while both BXP-9 and BXP-21 are well-validated
antibodies, ABCG2 was only recently detected in human kidney using BXP-9 (57), but
not with BXP-21 (143). Similarly, numerous examples can be found in the literature
demonstrating the cross-reactivity of several P-glycoprotein antibodies including the
C219 antibody used in this study (144). In fact, close examination of the P-gp staining
obtained in Figure 4-22 A showed that both membrane and intracellular expression
pattern. However, the knowledge that P-gp is expressed on the membrane allows for the
correct interpretation of its expression across the kidney structures. To avoid potential
misinterpretation of results due to antibody immunoreactivity, we also applied twodimensional LC/MS-MS analysis to identify the proteome in BBM and BLM isolated from
the rat kidney cortex and indirectly validate our Western blot results. Methods for
separation of the BBM from the BLM have been developed based on the fact that these
membranes have distinct lipid and carbohydrate compositions, so that their density and
net charge are different (145). Density gradient centrifugation (146), phase partitioning,
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differential centrifugation (147), and free flow electrophoresis (148) have all been
described to separate BBM from BLM. In this study, differential and density gradient
centrifugation were applied for the separation, and BBM were further purified by
magnesium precipitation. Some of the most abundant proteins, such as Na+/K+-ATPase
or rBat, SGLT2, TSC or NKCC2, were detectable in both membrane fractions, showing
lack of absolute efficiency in the separation of the two membrane fractions. Crosscontamination between the two fractions was also observed in previous reports using the
same method (145, 149, 150). However, these proteins were sufficiently enriched in the
appropriate fraction, suggesting adequate separation of basolateral and apical
membranes. In all, the LC-MS/MS analyses detected 81 proteins in both the apical and
basolateral membranes. Among those, eighteen were either in the SLC or ABC
transporter families (Figure 4-19 B). Based on the literature, fourteen of these proteins,
not including Oatp4c1, were enriched or uniquely identified in the appropriate fraction
(apical or basolateral) and three proteins (ambiguous) were equally present in both
preparations. Four unique Oatp4c1 sequence peptides were found only in BBM but not
in BLM. These results are in agreement with the findings from Western blotting and
immunohistochemical analyses and definitively demonstrate that Oatp4c1 localized at
the apical membrane in the rat proximal tubule.
The expression of Oatp4c1 at the apical membrane in the kidney suggests its
potential role in renal reabsorption of its substrates as other apically expressed organic
anion transporters (OATs or OATPs) do. As examples, Oatp1a1 expressed at the apical
membrane of rat proximal straight tubule in the outer medulla is responsible for renal
reabsorption of perfluorocarboxylates (PFO) (63, 64). Oatp2a1 localized at the apical
surface of rat collecting ducts is responsible for renal reabsorption of prostanoids (78).
OAT4 expressed at the apical membrane in the proximal tubule is involved in E3S and
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urate reabsorption (97, 98). URAT1 expressed at the apical membrane in the proximal
tubule plays a key role in urate homeostasis via a renal reabsorption mechanism (99).
OATP1A2 expressed at the apical membrane in the distal tubule may participate in the
saturable reabsorption of MTX (67).
The upregulation of Oatp4c1 in MG during lactation indicates that Oatp4c1 may
play a role in determining the final concentrations of endogenous and exogenous
substances into milk. The apical localization of Oatp4c1 in rat MG was demonstrated by
immunohistochemical analysis (Figure 4-15) and confirmed further by the distinct
localization of Oatp4c1 and the basolateral marker E-cadherin, and colocalization of
Oatp4c1 with the apical marker Abcg2 (Figure 4-18). The apical localization of Oatp4c1
suggests that it is involved in xenobiotic reuptake from the milk to reduce exposure to
the suckling infants, or that it functions as a scavenger system, as Pept2 does. Pept2 is
expressed at the apical membrane in MG and has been suggested to transport the
hydrolyzed milk protein product, as well as some peptide-like drugs, such as
cephalosporins, back into the mammary epithelium (23).

C. Functional characterization of Oatp4c1 in MDCKII-Oatp4c1 cells
The apical localization of Oatp4c1 in the proximal straight tubule suggests its
potential role in renal reabsorption of its substrates. Several human OATP4C1
substrates have been reported, including cardiac glycosides (digoxin, ouabain), thyroid
hormones (T3, T4), cAMP, MTX, sitagliptin and E3S (79, 109, 110). To explore the
physiological role of Oatp4c1, several uptake studies and inhibition studies were
performed in MDCKII-Oatp4c1 cells. In agreement with previous studies with OATP4C1
(110, 111), we showed that E3S is an Oatp4c1 substrate (Figure 4-23, Figure 4-24 and
Figure 4-25). Oatp4c1-mediated E3S uptake was inhibited by T4 and enhanced by T3
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(Figure 4-29 B and D), suggesting that T4 is a substrate/inhibitor and T3 is an enhancer.
However, a previous report showed that OATP4C1-mediated E3S transport was
decreased by T3 at pH 7.4 (110). The discrepancies may be attributable to differences
between the rat Oatp4c1 and human OATP4C1, which share 80.4% homology. It is
interesting to note that E3S accumulation was significantly higher in the presence of T3
in both Oatp4c1-expressing and vector-transfected cells (Figure 4-29 A and C). This
suggests the presence of a T3-inhibitable endogenous transporter involved in E3S efflux
in the MDCKII cells.
OATP4C1 has been suggested to possess multiple substrate recognition sites. In a
previous study it was shown that digoxin does not inhibit OATP4C1-mediated T3 (79) or
E3S (110) uptake and vice versa, while E3S and T3 have mutual inhibition. Consistent
with that report (110), our results showed that digoxin and ouabain did not change
Oatp4c1-mediated E3S uptake, nor did MTX (Figure 4-29). These data provide initial
evidence that Oatp4c1 possess multiple substrate recognition sites. One interacts with
E3S/T4, and another with digoxin/ouabain, and possibly MTX. Therefore, to verify
putative substrates, multiple prototypical substrates recognized by different binding sites
need to be used for future inhibition studies. In addition to E3S, the capacity of putative
substrates to inhibit MTX transport was examined. MTX was shown to be an Oatp4c1
substrate (Figure 4-30). However, neither digoxin nor ouabain inhibited Oatp4c1mediated MTX uptake (Figure 4-31 B and D), suggesting that they do not share the
same binding site. In contrast, Oatp4c1-mediated MTX uptake was inhibited by T3, which
was suggested to be an enhancer for E3S uptake (Figure 4-29). Both MTX and T3 may
bind to the same site to modulate Oatp4c1 function, but the affinity of MTX was too low
to change Oatp4c1-medaited E3S uptake. In addition, MTX accumulation was also
significantly higher in the presence of T3 in both Oatp4c1-expressing and vector-
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transfected cells (Figure 4-31 A and C). This suggests the presence of a T3-inhibitable
endogenous transporter involved in MTX efflux in the MDCKII cells. However, the low
value/percentage of the net MTX uptake (0.2-0.5 pmol/min/mg protein corresponding to
0.0002-0.0005 %) indicated that Oatp4c1 transported MTX at a low efficiency as
compared to E3S (~0.074 %). Therefore, additional inhibition studies with digoxin as a
model substrate and by direct measurement of putative substrates, such as uremic
toxins, are needed to definitively determine if these are substrates and/or inhibitors of
Oatp4c1. These studies are necessary so that physiological role of Oatp4c1, as well as
its function in the renal disposition of drugs and/or their metabolites, can be understood.
Overall, we demonstrated that Oatp4c1 transports E3S and MTX. Both molecules are
known to be reabsorbed in the tubules (151, 152), and this process is possibly mediated
by Oatp4c1. The increased uremic toxin plasma concentrations observed in wild-type
rats in the 5/6 nephrectomy renal failure model were reduced in OATP4C1 transgenic
rats (106), consistent with a model of basolateral uptake by OATP4C1 and apical efflux
by another transporter. However, our data demonstrated that Oatp4c1 was expressed at
the apical membranes and functions as an uptake transporter, thereby implying a
function in renal reabsorption, not tubular secretion. Therefore, there may be other
basolateral uptake or apical efflux transporters involved in renal elimination of uremic
toxins. Oat1 and Oat3, which are expressed at the basolateral membrane in the proximal
tubule (91), have been shown to be responsible for indoxyl sulfate and hippuric acid
uptake from blood into tubular cells (153). Moreover, the down-regulation of Oat1 and
Oat3 expression in a chronic renal failure model may result in the uremic toxin
accumulation (154). As for apical efflux transporters, hippuric acid, indoxyl sulfate and
kynurenic acid have been shown to inhibit MRP4-mediated MTX uptake and ABCG2mediated E3S uptake in inverted membrane vesicles (155). Furthermore, ABCG2mediated transport is more efficient under acidic conditions (156, 157), which are likely
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to prevail under normal physiological conditions in the proximal tubules. Thus, impaired
efflux by an ABC transporter may also provide an explanation for increased uremic toxin
accumulation in the blood of animals in the renal failure models. Clearly, more studies
are required to elucidate the role of different transporters in human kidney
pathophysiology and in the animal models of renal failure.
The driving force responsible for Oatp4c1 mediated transport is not fully
understood. Mikkaichi et al. showed that pH did not affect OATP4C1-mediated uptake
(79), while Leuthold et al. showed that E3S and T3 uptake were significantly higher at
extracellular pH 6.5 than pH 8.0 in Xenopus laevis oocytes expressing OATP4C1 (111).
The pH-dependent transport has been also demonstrated in rat Oatp1a1, Oatp1a4,
Oatp1a5,

Oatp1b2

and

human

OATP1A2,

OATP1B1,

OATP1B3,

OATP2B1,

OATP3A1_v1, OATP3A2_v2, OATP4A1 (111, 158-160). In this study, we demonstrated
that Oatp4c1-mediated E3S uptake was pH dependent. In our estimates, Vmax and
transport uptake clearance ( / ) were 4- and 10-fold higher, respectively, at pH 5.5 than
at pH 7.4 (Figure 4-25 B, Figure 4-26, Table 4-2). The observed pH-dependent Oatp4c1mediated uptake may be a consequence of changed intrinsic transport activity at
different pH and/or altered ionization state of the substrate molecules and thus different
substrate-transporter protein interaction. With a pKa of 2 (156), in our experiments (pH
4.5, 5.5 and 7.5) the ionization state of E3S is essentially constant. Therefore, any
changes in E3S uptake from pH 7.4 to 4.5 could be a result of pH gradient as the driving
force or changes in the protein structure. As shown in Figure 4-27, Oatp4c1-mediated
E3S uptake reached a plateau with increasing H+, suggesting that H+ plays a role in E3S
transport, either directly by E3S/H+ cotransport mechanism, or indirectly by E3S/HCO3exchange mechanism. The increasing extracellular H+ concentration leads to a
conversion of HCO3- and H+ into H2O and CO2, causing an outwardly directed HCO3-
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gradient across cell membranes. The outwardly HCO3- gradient facilitates the substrate
uptake, which suggests that Oatp4c1 may be a HCO3- exchanger as are other OATPs
(Oatp1a1, OATP1B3 and OATP2B1 (111)). Further studies examining substrate uptake
in HCO3- replete and depleted conditions are needed to confirm a potential organic
anion/HCO3- exchange mechanism. In addition, the pH in renal proximal tubules of rats
is acidic (6.68-6.87 (161-164)) and may provide the driving force for Oatp4c1 function.
Furthermore, pH-dependent changes in the protein structure may also be important for
substrate transport (111, 156). A conserved histidine amino acid in the third TMD has
been proposed to be critical for pH dependent transport by OATPs/Oatps. However, this
histidine is only present in rat and mouse Oatp4c1, but not in human OATP4C1, which
showed pH-dependent E3S and T4 uptake (111). Therefore, this histidine in the rodent
proteins may not be important for Oatp4c1-mediated transport.
Interestingly, the primary amino acid sequence of rat Oatp4c1 and human
OATP4C1 contain one and two potential ATP binding sites, respectively, characteristic
of the Walker A motif found in ABC transporters, but not in OATP family proteins (79).
Upon investigation, Mikkaichi et al. showed that ATP depletion by sodium azide and 2deoxyglucose decreases, but does not significantly affect T3 transport in MDCKIIOATP4C1 cells (79). Similarly, our results showed that ATP depletion did not affect E3S
transport in MDCKII-Oatp4c1 cells, suggesting that ATP is not involved in Oatp4c1mediated transport (Figure 4-28). In addition, E3S accumulation in Oatp4c1-expressing
and vector-transfected MDCKII cells were higher under ATP-depleted condition at pH
5.5 but not at pH 7.4 (Figure 4-28 A), suggesting the presence of an endogenous ATPdependent efflux transporter, which has increased transport activity at pH 5.5 in MDCKII
cells. Interestingly, increased E3S accumulation in Abcg2-expressing and vectortransfected MDCKII cells was also observed after GF120918 treatment at pH 5.5 but not
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pH 7.4 (Figure A-1), suggesting the existence of a GF120918-inhibitable endogenous
efflux transporter, which has increased transport activity at pH 5.5 in MDCKII cells. The
indicated endogenous transporters may be the same. There are three endogenous ABC
transporters identified in MDCKII cells: p-glycoprotein, Mrp1 and Mrp2 (165). Pglycoprotein is inhibitable by GF120918, but there is no evidence that it transports E3S
(166, 167). Mrp1 can transport E3S, but is not inhibitable by GF120918 (168-170). Mrp2
can transport E3S, but its inhibition by GF120918 is controversial (43, 165, 167, 169,
171). Therefore, there may be other GF120918-inhibitable ATP-dependent endogenous
transporter present in MDCKII cells or these two phenomena are governed by different
transporters.
Most of the OATPs/Oatps are bidirectional transporters. However, a previous
report showed that OATP4C1-mediated T3 transport is unidirectional from outside to
inside (79). To investigate the transport direction of Oatp4c1, further studies examining
E3S efflux in E3S pre-loaded cells or examining E3S flux from apical to basolateral or
from basolateral to apical in a polarized monolayer are needed.
D. Creation and validation of human OATP4C1-expressing cell lines
Although the primary sequence homology between human and rat Oatp4c1 is
80.4%, it is possible that species differences exist in subcellular localization. Human
OAT2 and rat Oat2 share 79% homology, but human OAT2 localizes at the basolateral
membrane of proximal tubules (92), whereas rat Oat2 localizes at the apical surface of
proximal tubule S3 segments, medullary thick ascending limb of Henle’s loop and the
collecting ducts (91, 93). To examine the expression and subcellular localization of
human

OATP4C1

in

cells

and

tissues,

two

antibodies

amenable

to

immunohistochemistry, immunofluorescence, and immunoblotting were generated and

149

validated. To study the role of OATP4C1 in drug disposition, two human OATP4C1expressing cell lines were generated. The MDCKII cell line was selected because of its
ability to form a polarized monolayer and tight junctions for directional transport study.
Sf9 cells were selected because of their higher expression level of recombinant proteins
and ease of scaling up for substrate screening. The successful transfection in MDCKII
cells was demonstrated as a distinct band at ~60 kDa in MDCKII-OATP4C1 cells but not
in MDCKII-pcDNA cells by Western blotting (Figure 4-33 A). The apparent molecular
weight was lower than the calculated molecular weight (79 kDa) which may be
attributable to absent glycosylation or misfolded truncated protein. The successful
transfection was also verified by immunohistochemical analysis showing specific
membrane localization in OATP4C1-expressing cells, but not in vector-transfected cells.
The specific staining was abolished when probing with antibody that was pre-absorbed
with antigen peptide, but some background staining was observed in sections exposed
to rabbit IgG instead of primary antibody (Figure 4-33 C). As observed in rat Oatp4c1,
OATP4C1 localized at the apical membrane in MDCKII-OATP4C1 cells (Figure 4-33 D).
Surface biotinylation assay demonstrated that OATP4C1 was enriched in the apical
membrane fraction as compared with the basolateral membrane (Figure 4-33 E).
Although efficient separation between apical and basolateral membrane was
demonstrated by Na+/K+-ATPase, the membrane fractions may be contaminated with
cytosol, which contains partially processed or misfolded OATP4C1 in the ER/Golgi
system. Functional activity of OATP4C1 in MDCKII-OATP4C1 cells was probed with
ouabain and E3S by uptake studies. A saturable concentration-dependent OATP4C1mediated ouabain uptake was observed and the transport parameters were estimated
(Figure 4-34, Table 4-3). The estimated Km (0.19 ± 0.09 µM) was in the similar range of
the reported Km (0.38 ± 0.1 µM) (79). In addition, a concentration-dependent OATP4C1mediated E3S uptake was observed, despite the concentrations we used were not high
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enough to show saturation kinetics (Figure 4-35). Further studies with higher
concentrations are needed to show saturation kinetics and obtain transport parameters.
These data confirmed that ouabain and E3S were OATP4C1 substrates (79, 110) and
showed the functional activity of OATP4C1 in MDCKII-OATP4C1 cells, although its
apparent molecular weight was lower than the calculated one. Collectively, OATP4C1
expression and function were validated in MDCKII-OATP4C1 cells which can be used to
investigate the driving force and transport direction of OATP4C1-mediated transport and
explore the potential substrates and the role of OATP4C1 in drug disposition.
In addition to MDCKII cells, OATP4C1 was overexpressed in Sf9 cells with a
baculovirus expression system. The successful infection was demonstrated as a broad
band at ~60 kDa as observed in MDCKII-OATP4C1 cells (Figure 4-37). The recombinant
protein expressed in Sf9 cells commonly appears as a deglycosylated form, however, no
reports indicate any functional consequence of different glycosylation patterns (172,
173). Functional activity of OATP4C1 in Sf9-OATP4C1 cells was probed with ouabain
and E3S by vesicular transport assay. Selecting membrane filters with minimal drug
adsorption is important for this assay. High background adsorption may decrease the
sensitivity and interfere with data interpretation. This was the case with ouabain studies
using the OE67 filter membrane. Although the estimated Km (0.18 ± 0.09 µM) of
OATP4C1-mediated ouabain uptake was comparable with the Km estimated from
MDCKII-OATP4C1 cells (0.19 ± 0.09 µM) and in the similar range of the reported Km
(0.38 ± 0.1 µM) (79) (Figure 4-39, Table 4-4), the high background adsorption may
decrease the sensitivity of the capacity to be inhibited for substrate screening during
inhibition studies. The nonspecific adsorption of E3S on RC55 filter membrane was
relatively low (~0.3%). A concentration-dependent OATP4C1-mediated E3S uptake was
observed, but the concentrations we used were not high enough to saturate the
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transporter (Figure 4-40 B). Further studies with higher concentrations are needed to
show saturation kinetics and obtain transport parameters. The pH effect on OATP4C1mediated E3S transport was also examined (Figure 4-41). There was a trend toward
increasing net uptake with a decrease in pH. Additional studies at more than two pH
conditions are needed to confirm the pH-dependency of OATP4C1-mediated E3S
transport. Vesicular transport assay is a good tool to study ATP-dependent transport for
efflux transporters, but not for uptake transporters such as OATP4C1. Extracellular ATP
is not able to penetrate into cells and bind to the intracellular ATP-binding site of
OATP4C1 to function. Therefore, to examine if ATP is the driving force for OATP4C1,
determining E3S uptake in the presence and absence of a cell-permeable ATPanalogue, formycin A (174, 175), is needed. Collectively, OATP4C1 expression and
function were validated in Sf9-OATP4C1 cells and the system can be used to further
investigate the role of OATP4C1 in drug disposition.

E. Validation of OATP4C1 expression in human kidney and cancer cells
OATP4C1/Oatp4c1 was isolated from human/rat kidney (79) and its basolateral
localization in the renal proximal tubules was determined in the transgenic rat harboring
human SLCO4C1 and in the rat (79, 106). However, we have definitively demonstrated
that rat Oatp4c1 localized at the apical membrane in the kidney, and thereby its
physiological function implies a role in renal reabsorption, not tubular secretion. We also
attempted to determine OATP4C1 subcellular localization in human kidney by
immunohistochemical analysis. Despite multiple approaches and efforts, no staining was
observed using our anti-OATP4C1 antibodies, whereas the quality of tissue specimens
was verified with MRP4 expression (Figure 4-42) and the amenability of our anti-
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OATP4C1 antibodies in immunohistochemistry was validated in MDCKII-OATP4C1 cells
(Figure 4-33 C) and in lung tumor specimens (Figure 4-45). It is not without precedent
that well-validated antibodies failed to detect transporter proteins in tissues which were
later detected by other antibodies. For instance, ABCG2 was not detected in human
kidney with BXP-21 (143), but was recently detected with BXP-9 (57). In addition, the
antibodies used in immunohistochemical analysis of OATP4C1 in human kidney may
have been degraded because it was performed one year later than that in MDCKIIOATP4C1 cells and in lung tumor specimens. Further studies with different antibodies or
performing Western blot analysis on isolation BBM and BLM from human kidney are
needed to verify the subcellular localization in human kidney.
Microarray analysis has shown that SLCO4C1 was highly expressed in lung tumor,
and its expression in lung tumor was 18- and 2- fold higher than in normal lung, and
normal kidney, respectively (104). SLCO4C1 was also detected in several cancer cell
lines, including renal carcinoma cells (ACHN, SN12C), ovarian cancer cells (OVCAR-8,
OVCAR-3), leukemia cells (HL-60, RPMI-8226, CCRF-CEM), lung cancer cells (H322M,
H23, HOP-62, H460), glioblastoma (SF-539) and breast cancer cells (BT-549) (107).
The high SLCO4C1 expression in lung tumor was confirmed in non-small cell lung
cancer cells H1299 and in lung tumor specimens. Our data demonstrated a 20-fold
increase of SLCO4C1 expression in H1299 cells relative to human kidney (Figure 4-43).
Further studies need to confirm this message with Western blotting.
RT-PCR and immunohistochemical analysis were performed in the lung tumor and
adjacent normal lung tissue specimen isolated from patients. Total RNA isolated from
formaldehyde-fixed paraffin-embedded (FFPE) slides is typically fragmented and
chemically modified. During tissue fixation process, formaldehyde reacts with the
nitrogen atoms of lysine, arginine, and histidine, resulting in extensive cross-linking of
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the proteins within each cell. Nucleic acids are subsequently trapped and modified by
extensive protein-protein and protein-nucleic acid crosslinks. Even after protease
treatment, some of the nucleic acid bases are still crosslinked, which cannot be
recognized as templates and be amplified by polymerases. During storage, atmospheric
oxygen, water and light cause nucleic acid degradation and fragmentation over time.
Samples that have been stored over five years typically yield nucleic acids with only
~100 nt (176-178). Therefore, successful amplification is limited to small fragments and
less sensitivities in template detection. Our samples were stored for over 2.5 years so
that the isolated RNA was possibly fragmented. To prevent false negative interpretation
from unsuccessful amplification due to fragmented and chemically modified RNA, three
primers were utilized in RT-PCR analysis. Results from only one of three primers
demonstrated higher SLCO4C1 expression in the tumor than in the adjacent lung tissue
in five out of nine patients (Figure 4-44). Two patients with either higher or lower
SLCO4C1 expression in tumor relative to adjacent normal lung were selected to
examine OATP4C1 expression by immunohistochemical analysis. All of four patients
showed stronger OATP4C1 staining in the tumor than in the adjacent normal lung tissue
(Figure 4-45). The discrepancies from RT-PCR and immunohistochemistry results may
be due to unsuccessful amplification of the fragmented RNA. Collectively, these data
demonstrated highly OATP4C1 expression in lung tumor and possibly higher than in
normal lung. The high OATP4C1 expression in the lung tumor may facilitate the uptake
of physiological substrates that facilitate tumor cell survival but may also uptake
anticancer drugs, such as MTX, and these functions may have implications in cancer
therapy. Clearly, more studies are required to elucidate the role of OATP4C1 in the
treatment for lung cancer.
Copyright © Kuei-Ling Kuo 2012
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CHAPTER 6 : CONCLUSIONS
This dissertation focused on validation of the subcellular localization of
OATP4C1/Oatp4c1 in in vitro models and in human/rat tissues and on its transport
characteristics.

Multiple

immunofluorescence,

and

antibodies

amenable

immunoblotting

were

to

immunohistochemistry,

developed

and

validated

with

OATP4C1/Oatp4c1-expressing in vitro models. The expression of Slco4c1/Oatp4c1 in
Oatp4c1-expressing MDCKII cells was increased with sodium butyrate or blasticidin
treatment, but was not changed with glycerol or MG132 treatment. Simvastatin
enhanced Oatp4c1 expression only at the mRNA level, but not at the protein level. A
single clone with highest Oatp4c1 expression (c94) was obtained by serial dilution
method. The effect of blasticidin on increasing Oatp4c1 expression was negligible when
co-treating sodium butyrate and blasticidin in c94 cells. Therefore, for in vitro functional
studies, c94 cells were first treated with sodium butyrate to induce Oatp4c1 expression.
Oatp4c1 expression in rat kidney was increased with age, while it was not detected
in rat liver at any age. Higher Slco4c1/Oatp4c1 expression was observed in female rat
kidney as compared with males. To determine the subcellular localization of Oatp4c1 in
the in vitro models and in rat tissues, a comprehensive approach was undertaken, and
these studies definitively demonstrated that Oatp4c1 is expressed at the apical
membrane in the rat proximal tubule and mammary epithelium. Our approach included a
variety of complementary methods to verify this observation. Western blotting
demonstrated that the antibody used recognized a protein of appropriate molecular
weight. Immunofluorescence and immunohistochemical analysis revealed that the
protein localizes at the apical membrane of polarized epithelium in vitro (Oatp4c1expressing

MDCKII,

LLC-PK1

cells)

and

in

vivo

(rat

kidney,

MG).

The

immunohistochemistry results were verified with four different antibodies, which were
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raised against unique C- and N-terminal peptides, and also confirmed by double
immunofluorescence staining with apical or basolateral markers. In addition, biochemical
separation of apical and basolateral membranes from polarized cells in vitro and
proximal rat kidney tubules confirmed the location of Oatp4c1 at the brush border
membranes by Western blot and proteomic analyses. Furthermore, the proteomic
analyses provide additional validation for the Oatp4c1 antibody specificity. In addition,
double immunofluorescence staining and immunohistochemical analysis showed that
Oatp4c1 localized in the proximal straight tubule (S3 segment) in the juxtamedullary
cortex, and colocalized with P-gp and Abcg2, but not with Mrp4.
The apical localization of rat Oatp4c1 in the kidney suggests its potential role in
tubular reabsorption of its substrates. Although we did not perform extensive studies to
identify potential Oatp4c1 substrates, we demonstrated that most human OATP4C1
substrates were rat Oatp4c1 substrates, including E3S, MTX and possibly T4 (79, 110).
T3 was an enhancer for Oatp4c1-mediated E3S uptake, but was an inhibitor for Oatp4c1mediated MTX uptake. This suggests that T3 and MTX shared the same binding site
while the affinity of MTX was too low to change Oatp4c1-mediated E3S uptake. In
accord with the previous finding of OATP4C1 (110), ouabain and digoxin did not inhibit
Oatp4c1-mediated E3S uptake, which provides corroborating evidence that Oatp4c1
possesses multiple binding sites. In addition, previously purported uremic toxin
substrates failed to inhibit Oatp4c1-mediated E3S uptake, suggesting that they were not
substrates or that they interact with a different binding site. The Oatp4c1-mediated E3S
uptake was ATP-independent and pH-dependent, suggesting that the pH gradient is the
driving force for Oatp4c1-mediated transport. The increased E3S transport activity at
acidic extracellular pH was ascribed to the increased maximum transport rate (Vmax). In
addition, our data indicated the presence of an ATP-dependent and/or GF120918-
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inhibitable endogenous E3S efflux transporter with increased transport activity at acidic
pH in MDCKII cells.
In accord with previous microarray data demonstrating that human SLCO4C1
expression was upregulated during lactation, rat Slco4c1/Oatp4c1 expression was
increased in lactating MG as compared with non-lactating MG, indicating a potential role
of Oatp4c1 in endogenous or exogenous substances transport into the milk. The apical
localization of Oatp4c1 suggests that it is involved in reuptake of xenobiotic from the
milk, resulting in their reduced exposure to the suckling infants, or that it functions as a
scavenger system.
Human OATP4C1 was demonstrated to localize at the apical membrane in the in
vitro model (MDCKII cells). However, the determination of the subcellular localization of
OATP4C1 in human kidney was not possible, even though that the antibody we
developed was amenable for immunohistochemistry and the quality of tissue specimens
was verified. Further studies with different antibodies or performing Western blot
analysis on isolation BBM and BLM from human kidney are needed to verify the
subcellular localization in human kidney. Uptake study in MDCKII-OATP4C1 cells and
vesicular transport study in Sf9-OATP4C1 cells confirmed that ouabain and E3S were
OATP4C1 substrates (79, 110). In addition, our data demonstrated that OATP4C1 was
highly expressed in lung cancer cells (H1299) and lung tumor specimens by RT-PCR
and immunohistochemical analysis, respectively.
For future studies, generating OATP4C1-knockout mice will be useful to gain more
insight of the physiological role of OATP4C1 and its impact on the pharmacokinetics of
drugs. Metabolomic analysis of urine from OATP4C1-knockout mice will be applied in an
attempt to identify endogenous substrates without prior knowledge of transport studies.
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In addition, to determine the role of OATP4C1 in lung cancer cells, cell viability will be
first examined in the OATP4C1-transfected cells or in the SLCO4C1 siRNA-silencing
lung cancer cells (H1299) with treatment of anticancer drugs which are also OATP4C1
substrates, such as MTX. To examine if OATP4C1 confers cell death through apoptotic
pathways, the apoptotic outcome will be examined by terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) assay or
Annexin V assay.
Overall, the apical localization of Oatp4c1 in the rat kidney and MG is a highly
novel finding of this study, and thereby implies its physiological role in renal
reabsorption, not tubular secretion. Further studies to identify Oatp4c1 substrates will
explore the physiological role and significance of Oatp4c1.

Copyright © Kuei-Ling Kuo 2012
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APPENDICES
Appendix 1: Lists of abbreviations

CFTR

Cystic fibrosis transmembrane conductance regulator protein

ER

Endoplasmic reticulum

AB

From apical to basolateral

ABC

ATP-binding cassette

AE

Apical efflux

AhR

Aryl hydrocarbon receptors

AIC

Akaike Information Criterion

ANOVA

Analysis of variance

AP

Apical

AQP1

Aquaporin 1

ATP

Adenosine triphosphate

AU

Apical uptake

BA

From basolateral to apical

BBM

Brush-border membrane

BCRP

Breast cancer resistance protein

BL

Basolateral

BLM

Basolateral membrane

Bsd

Blasticidin

C

Substrate concentration

c94

Clone 94

cAMP

Cyclic adenosine monophosphate

cGMP

Cyclic guanosine monophosphate

D

Diffusion

DMEM

Dulbecco's modified Eagle's medium

dNTP

Deoxyribonucleotide triphosphate

DTT

Dithiothreitol

E3S

Estrone-3-sulfate

FACS

Fluorescence-activated cell sorting

GF

GF120918

GFP

Green fluorescent protein
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HMG-CoA

Hydroxymethylglutaryl–CoA

HRP

Horseradish peroxidase

IgG

Immunoglobulin G

Km

Michaelis-Menten constant

LMEC

Lactating mammary epithelial cells

MDCKII

Madin-Darby canine kidney II

MDR

Multidrug resistance protein

MEC

Non-lactating mammary epithelial cells

MEM

Minimum essential medium

MG

Mammary gland

MG132

N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal

MRP

Multidrug resistance-associated protein

MTX

Methotrexate

n

Hill slope

NaB

Sodium butyrate

NBD

Nucleotide binding domains

NHERF1

Na+/H+ exchanger regulatory factor 1

NSAIDs

Non-steroidal anti-inflammatory drugs

OAT

Organic anion transporter

OATP

Organic anion transporting polypeptide

OCT

Organic cation transporter

OCTN

Zwitterion/cation transporters

PAH

Para-aminohippurate

PC

Paracellular transport

PEPT

Peptide transporter

PFO

Perfluorocarboxylates

P-gp

P-glycoprotein

PS

Permeability-surface area product

RT-PCR

Real-time polymerase chain reaction

S50

Michaelis-Menten constant equivalent

SC

Spectral counts

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

Sim

Simvastatin

SLC

Solute carrier
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SLCO

Solute carrier organic anion transporter

T3

Triiodothyronine

T4

Thyroxine

TEER

Transepithelial electrical resistance

Tmax

Maximum uptake velocity

TMD

Transmembrane domains

URAT

Urate transporter

V

Initial uptake velocity

Vmax

Maximum transport rate

XRE

Xenobiotic-responsive element
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Appendix 2: Identification of Abcg2 as a potential transporter of uremic toxins
Introduction:
OATP4C1 has been proposed to be involved in the elimination of uremic toxins
and its expression in a transgenic rat model was shown to decrease the concentration of
uremic toxins in a 5/6 nephrectomy renal failure model (106). However, we
demonstrated that Oatp4c1 is expressed at the apical membrane in the kidney, which
suggests that Oatp4c1 is involved in renal reabsorption but not tubular secretion as
previously suggested (79, 106, 110). Lack of E3S transport inhibition by uremic toxins
led us to probe the interaction of uremic toxins with other transporters as a way to
reconcile previous observations in a renal failure model (106). Recent evidence
suggests that human ABCG2 and MRP4 may also transport uremic toxins (155).
Therefore, we hypothesized that impaired uremic toxin clearance could result from
impaired transport by an efflux pump in the renal tubules. This hypothesis is consistent
with previous work demonstrating that the function of ABCG2 is less efficient at pH 7.4
than in acidic pH, while the urine pH ranges in the acidic range under normal conditions,
but can be basic (> pH 7) under pathological situations. (156, 157). In this study, the
capacity of uremic toxins to inhibit Abcg2 –mediated Hoechst 33342 efflux was
determined by at pH 5.5 and pH 7.4.

Methods:
Rat Abcg2- and pcDNA3.1 (vector)-transfected MDCKII cells generously provided
by Dr. McNamara’s lab (13) were grown in MEM supplemented with 5% fetal bovine
serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 500 µg/ml geneticin.
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Functional activity of Abcg2 in MDCKII-Abcg2 cells was preliminary assessed by
[3H]-E3S uptake studies in the presence and absence of 10 µM GF120918 at pH 5.5 and
pH 7.4. The procedures were the same as described in Chapter 3 -D -1 [3H]-E3S uptake
and inhibition studies.
Functional activity of Abcg2 in MDCKII-Abcg2 cells was also assessed by Hoechst
33342 efflux. MDCKII-pcDNA and MDCKII-Abcg2 cells were grown in 6-well plates (1 x
106 cells/well) and allowed to become confluent overnight. Cells were washed once and
pre-incubated in OptiMEM in the presence and absence of 10 µM GF120918, 2 mM
MTX, and 1 mM uremic toxins (kynurenic acid, indoxyl sulfate, hippuric acid and transaconitic acid) for 15 min and during the duration of the Hoechst 33342 incubation. The
experiment was initiated by incubating cells with 2 µM Hoechst 33342 for 45 min at
37°C. Cells were washed twice with ice-cold PBS and lysed with 500 µl of 10 mM
HEPES (pH 7.4) containing 0.2% SDS for 30 min. Lysates (200 µl) were transferred to a
96-well plate and the fluorescence of Hoechst 33342 was determined in a microplate
reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) at excitation and emission
wavelengths of 360 and 460 nm, respectively. Protein concentration in cell lysates was
measured by BCA Protein Assay Kit, and used to normalize the fluorescence readings.

Results and Discussion:
To evaluate functional activity of Abcg2 in MDCKII-Abcg2 cells, the uptake studies
of ABCG2 substrate, E3S (179), was performed in the presence and absence of Abcg2
inhibitor GF120918 (13) at pH 5.5 and pH 7.4 . As shown in Figure A-1, there was no
significant difference between [3H]-E3S accumulation in MDCKII-Abcg2 and MDCKIIpcDNA cells at both pH values, suggesting that E3S was not a rat Abcg2 substrate or
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E3S intracellular concentration was not high enough to show a significant Abcg2mediated transport. In addition, [3H]-E3S accumulation in both MDCKII-Abcg2 and
MDCKII-pcDNA cells were substantially higher in the presence of GF120918 at pH 5.5
but not at pH 7.4, suggesting the presence of a GF120918-inhibitable endogenous efflux
transporter in MDCKII cells. This endogenous efflux transporter may interfere Abcg2mediated E3S transport.
Therefore, another ABCG2 substrate, Hoechst 33342 (180), was then used to
access Abcg2 function. Intracellular fluorescence after 45 min incubation with Hoechst
33342 was determined in the absence and presence of GF120918 at pH 5.5 and 7.4
(Figure A-2 A). Abcg2-mediated Hoechst 33342 efflux was calculated by subtracting the
accumulation in Abcg2-expressing cells from that in vector-transfected cells. Transport
specificity was demonstrated by GF120918 inhibition. As shown in Figure A-2 B, Abcg2mediated Hoechst 33342 effluxes were both reduced with GF120918 addition at both pH
values. At pH 7.4, the decreased net accumulation was resulted from the increased
accumulation in MDCKII-Abcg2 cells as GF120918 inhibiting Abcg2-mediated efflux,
However, at pH 5.5, the decreased net accumulation was resulted from the decreased
accumulation in MDCKII-pcDNA cells while the accumulation in MDCKII-Abcg2 cells was
not changed (Figure A-2 A). The decreased accumulation in MDCKII-pcDNA cells in the
presence of GF120918 was probably because of the presence of a GF120918inhibitable endogenous uptake transporter functioned at pH 5.5. In addition, inconsistent
with previous reports showing ABCG2 function was less efficient at pH 7.4 than in acidic
pH (156, 157). Abcg2-mediated Hoechst 33342 efflux was higher at pH 7.4 than at pH
5.5. The discrepancy was probably because of different assay system. Inverted
membrane vesicles were used in previous reports, whereas intact cells were used in this
study which required the substrates penetrated into the cells before being efflux. In
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addition, the endogenous uptake transporter functioned at pH 5.5 may also interfere
Abcg2-mediated Hoechst 33342 transport.
The capacity of uremic toxins to inhibit Hoechst 33342 efflux was also examined.
Among the uremic toxins tested, indoxyl sulfate and trans-aconitic acid inhibited Abcg2mediated Hoechst 33342 efflux at pH 5.5, but not at pH 7.4. This suggests that Abcg2
may transport these uremic toxins only at normal condition (acidic pH) but not at
pathological conditions (pH >7), and therefore, the uremic toxin plasma concentrations is
increased in renal failure model (106). With a predicted pKa of 17.0, the ionization states
of indoxyl sulfate at pH 5.5 and 7.4 are constant. Therefore, the pH-dependent inhibitory
effect was resulted from the drug-protein interactions. However, the predicted pKa for
trans-aconitic acid is 2.8 and 4.46. The unionization ratio is 8.4% and 0.1% at pH 5.5
and pH 7.4, respectively, indicating that the unionized form of 1 mM trans-aconitic acid is
84 μM and 1 μM at pH 5.5 and pH 7.4, respectively. Therefore, the pH-dependent
inhibitory effect was probably resulted from different amount of unionized drug diffused
into the cells. More studies using inverted membrane vesicles or different model
substrates were required to elucidate the role of Abcg2 or other renal transporters in
uremic toxins disposition.
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Figure A-1: The effect of GF120918 on [3H]-E3S uptake in MDCKII-Abcg2 cells at
pH 5.5 and 7.4.
MDCKII-pcDNA and MDCKII-Abcg2 cells were incubated with 5 µM [3H]-E3S in the
absence and presence of 10 µM GF120918 for 15 min at pH 5.5 and 7.4. Each bar
represents the mean ± S.D. of triplicate determinations from one representative
experiment.
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Figure A-2: Inhibition of Hoechst 33342 efflux by various compounds in MDCKIIAbcg2 cells at pH 5.5 and 7.4.
MDCKII-pcDNA and MDCKII-Abcg2 cells were incubated with 2 µM Hoechst 33342 in
the absence (control) and presence of 10 µM GF120918 (GF), 2 mM MTX, and 1 mM
uremic toxins (kynurenic acid, indoxyl sulfate, hippuric acid and trans-aconitic acid) for
45 min at pH5.5 and 7.4. Abcg2-mediated efflux was calculated by subtracting the
accumulation in Abcg2-expressing cells from that in vector-transfected cells (B, D). Each
bar represents the mean ± S.D. of triplicate determinations from one representative
experiment. Statistical analysis was performed by two-way ANOVA with Bonferroni posthoc test comparing with control.* p<0.05, significant differences from control.
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Appendix 3: Creation and validation of human ABCG2-expressing Sf9 cells
Introduction:
ABCG2 also known as breast cancer resistance protein (BCRP) is a halftransporter containing only 6 TMD, and forms a homodimer to acquire transport activity.
ABCG2 is expressed at the apical membrane in multiple tissues, including liver,
intestine, placenta, blood-brain-barrier, lung, mammary gland and kidney proximal tubule
(57, 58). It limits the entry of its substrates into the tissues and facilitates the elimination
of its substrates to the bile and urine. In addition, it is important in nutrients as well as
xenobiotic accumulation in the milk (10). ABCG2 transports a wide range of substrates
including uncharged or amphiphilic compounds, such as MTX, mitoxantrone and
cimetidine (12). To study the role of ABCG2 in drug disposition, ABCG2-expressing Sf9
cells were developed for substrate screening.

Methods:
pFastBac1-ABCG2 plasmid vector construct (Figure A-3) was generated previously
in our lab. Detail procedures for pFastBac1-ABCG2 plasmid vector construct were as
described in Chapter 3-E-2-i. Plasmid vector construction. Briefly, ABCG2 was cloned
into pFastBac1 and recombined in MAX Efficiency® DH10BacTM competent E. Coli.
containing baculovirus genome. The bacmid DNA from positive transformants was
verified by PCR with M13 forward (5’-GTTTTCCCAGTCACGAC-3’) and M13 reverse (5’CAGGAAACAGCTATGAC-3’) primers and agarose gel electrophoresis.
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Figure A-3: pFastBac1-ABCG2 plasmid construct.

Procedures for Sf9 cell culture, transfection, infection, membrane vesicle
preparation and vesicular transport assay were the same as described in Chapter 3-E-2
Spodoptera frugiperda (Sf9) insect cells. The successful infection of AGCG2 was
detected with 0.25 µg/ml BXP-21.
MDCKII-ABCG2 c40 cells generously provided by Dr. McNamara’s lab (30) were
grown in MEM supplemented with 5% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml
streptomycin, and 500 µg/ml geneticin.
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Results and Discussion:
pFastBac1-ABCG2 plasmid vector construct and recombinant bacmid DNA were
generated previously in our lab. Recombinant bacmids were verified by PCR with M13
forward and M13 reverse primers (Figure A-4).
The recombinant bacmids (pFastBac1-ABCG2 and pFastBac1) were transfected
into Sf9 cells, and the supernatant containing recombinant baculovirus stock was
harvested after 48 hr. The viral stock was amplified by infecting a large volume of Sf9
cell suspensions. The infected Sf9 cells were centrifuged to collect cell pellets for
membrane vesicle preparation. Successful infection was validated by Western blotting
for ABCG2 expression in the membrane vesicles. As shown in Figure A-5, ABCG2 was
detected in Sf9-ABCG2 membrane vesicles but not in Sf9-vector. In addition, in accord
with previous reports (172), as compared with the protein band in MDCKII-ABCG2 c40
cells with PNGase F deglycosylation, the overexpressed ABCG2 in Sf9 cells was
unglycosylated.
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Figure A-4: Validation of the pFastBac1-ABCG2 plasmid construct.
PCR product of pFastBac1-ABCG2 with M13 forward and M13 reverse primers by
agarose gel electrophoresis.

Figure A-5: Validation of ABCG2 expression in ABCG2-expressing Sf9 membrane
vesicles.
Western blot analysis for ABCG2 expression in 1 μg MDCKII-ABCG2 c40 cell membrane
fractions, Sf9-vector and Sf9-ABCG2 membrane vesicles. ABCG2 was detected with
BXP-21. PNGase F was used for deglycosylation.
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Functional activity of ABCG2 in Sf9-ABCG2 membrane vesicles was validated with
MTX by vesicular transport assay. MTX transport kinetics were determined by [3H]-MTX
uptake for concentrations ranging from 500 to 3000 µM at 5 min. ATP-dependent uptake
was calculated by subtracting values obtained in the presence of AMP from those in the
presence of ATP. The difference between ATP-dependent uptake in Sf9-vector and in
Sf9-ABCG2 membrane vesicles was ABCG2-mediated uptake. As shown in Figure A-6,
ATP-dependent MTX uptake in Sf9-ABCG2 membrane vesicles was saturable, while
that in Sf9-vector membrane vesicle was a flat line. It confirmed that MTX is an ABCG2
substrate (181). A sigmoid-Emax was fitted to the net ABCG2 transport data. The
transport kinetic parameters were estimated by nonlinear regression (Table A-1). The
estimated Km (1191 ± 380.7) was comparable with the reported Km (~1000 µM) (181). In
addition, the estimated Hill coefficient value of 1.8 suggests positive transport
cooperativity. The transport specificity was demonstrated by ABCG2 inhibitor,
GF120918, inhibition (182). As shown in Figure A-7, ATP-dependent MTX uptake in Sf9ABCG2 membrane vesicles was substantially reduced in the presence of GF120918,
while that in Sf9-vector membrane vesicles was unaltered. Collectively, the expression
and functional activity of ABCG2 in Sf9-ABCG2 membrane vesicles were validated, and
the membrane vesicles can be used for substrate screening to study the role of ABCG2
in drug disposition.
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Figure A-6: Concentration-dependent ABCG2-mediated [3H]-MTX transport in Sf9ABCG2 membrane vesicles at pH 7.4.
[3H]-MTX accumulation (5 min) in Sf9-vector and Sf9-ABCG2 membrane vesicles. ATPdependent uptake was calculated by subtracting values obtained in the presence of
AMP from those in the presence of ATP. ABCG2-mediated uptake was the difference
between ATP-dependent uptake in Sf9-vector and in Sf9-ABCG2 membrane vesicles.
Each point represents the mean ± S.D. of triplicate determinations from one
representative experiment.

Table A-1: Transport kinetic parameters of ABCG2-mediated MTX uptake at pH 7.4
(mean ± S.E.).
The transport parameters were estimated by GraphPad.

Tmax (pmol/min/mg protein)

994.8 ± 220.7

S50 (µM)

1191 ± 380.7

Hill Slope

1.8 ± 0.7
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Figure A-7: Inhibition of GF120918 on ATP-dependent [3H]-MTX uptake in Sf9ABCG2 membrane vesicles at pH 7.4.
ATP-dependent 500 μM [3H]-MTX uptake (5 min) were determined in the absence and
presence of 100 µM GF120918 (GF) in Sf9-ABCG2 and Sf9-vector membrane vesicles
at pH 7.4. ATP-dependent uptake was calculated by subtracting values obtained in the
presence of AMP from those in the presence of ATP. Each bar represents the mean ±
S.D. of triplicate determinations from one representative experiment.
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Appendix 4: Development of a mathematical model to simulate the transport of
common substrate of apical uptake and apical efflux transporters across the renal
proximal tubular cells
Introduction
Double immunofluorescence staining showed that Oatp4c1, as an uptake
transporter, were colocalized with efflux transporters, Abcg2 and p-glycoprotein, at the
apical membrane in rat proximal straight tubule (Figure 4-22 D). For their common
substrates, such as digoxin (Oatp4c1 and p-glycoprotein substrate (183)) and E3S
(Oatp4c1 and Abcg2 substrate (179)), a three compartment mathematical model was
developed to simulate their transport in the renal proximal tubular cells.
Methods
This three compartment system incorporates four transport processes including
apical uptake (AU), apical efflux (AE), paracellular transport between the cells (PC),
passive diffusion across the apical and basolateral membranes in proximal tubule
epithelial cell (D) (Figure A-8). AU and AE were calculated saturable Michaelis-Menten
type transport kinetics.

Figure A-8: A schematic representation of the transport model for flux across
renal proximal tubule monolayer.
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Passive diffusion is assumed to be equal for the apical and basolateral
membranes, and the drug transfer across basolateral membrane is only by passive
diffusion. The kinetic model was simulated using STELLA (Isee systems, Lebanon, NH)
(Figure A-9).

Figure A-9: Schematic representation of the mathematical model for flux across
renal proximal tubule monolayer built by STELLA.
Squares, circles and “pipes” represent compartments, parameters, and transport
processes, respectively. Blue arrows demonstrate the transport direction. Red arrows
signify the determinants of each compartment and transport processes.

The equations and parameter settings were as follows:
Equation A-1
Equation A-2
Equation A-3
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;

;

VmaxU = VmaxE = 15000 pmol/hr, KmU = KmE = 30 μM
;

; PSD = 100 ml/hr

; PSPC = 1 ml/hr
⁄ ;

⁄

;

⁄

Equation A-4
Equation A-5
Equation A-6

; VA = VB = 2000 μl; VC = 20 μl

Equation A-7

where A, B, and C represent apical (urine), basolateral (blood), and cellular (proximal
tubule epithelial cells) compartments, respectively; CA, CB, and CC, represent the
substrate concentrations in each compartment; and VA, VB, and VC, represent the
volume of each compartment. AU, AE DAC, DBC, PC represent apical uptake, apical
efflux, passive diffusion across apical membrane, passive diffusion across basolateral
membrane, and paracellular transport between the cells, respectively. PSAU, PSE, PSD,
PSPC represent permeability-surface area product (PS) of apical uptake, apical efflux,
passive diffusion, paracellular transport, respectively. KmU, VmaxU, KmE, VmaxE represent
the Km and Vmax of uptake and efflux transporters, respectively.
The flux from BA and AB at 10 min (initial rate) were simulated for the
concentrations ranging from 0.1 to 100000 μM. PS were calculated by the following
equation:
Equation A-8

where A, T, C0, and SA represents amount of substrate in recipient compartment (pmol),
time (hr), initial concentration (μM) and surface area (cm2), respectively. The Km and
Vmax of uptake transporter and efflux transporter were changed one at a time to evaluate
the effect of each parameter on transport direction.
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Results and Discussion
In this model, four transport processes were included: apical uptake (AU), apical
efflux (AE), passive diffusion across the apical and basolateral membrane (DAC, DBC),
and paracellular transport between the cells (PC). The substrate flux in each
compartment and the initial rate of BA and AB are derived as follows:
Equation A-9

Equation A-10

Equation A-11
Initial rate BA (represents tubular secretion): assuming initial substrate concentration
in apical compartment is zero (CA = 0), Equation 5-1 becomes:
, →

Equation A-12

and rapid equilibration between the B and C compartments such that dXC/dt = 0,
Equation A-11 can be rearranged as:
Equation A-13

Substitution of Equation A-13 into Equation A-12 yields:
, →

Equation A-14

The permeability surface area product (PS) becomes:
, →

Equation A-15

→

178

while

Initial rate AB (represents renal reabsorption): assuming initial substrate concentration
in basolateral compartment is zero (CB = 0), Equation A-10 becomes:
, →

Equation A-16

and rapid equilibration between the A and C compartments such that dXC/dt = 0,
Equation A-11 can be rearranged as:
Equation A-17

Substitution of Equation A-13 into Equation A-12 yields:
, →

Equation A-18

The PS becomes:
, →

Equation A-19

→

while

,

As shown in Equation A-15, apical uptake (AU) transporter played no role in
PSBA. This was demonstrated in Figure A-10 D and Figure A-11 D showing that the
changes of Km or Vmax of AU transporter did not alter PSBA. Equation 1-11 showed
PSAB was influenced by both PSAU and PSAE (panels E in Figure A-10, Figure A-11,
Figure A-12 and Figure A-13), and PSmax,AB was more sensitive to PSAU than PSAE,
because the effect of PSAE is attenuated by of its scaling by PSD (Equation A-19).
Intuitively, transporter mediated flux of a substrate is determined by the
predominant intrinsic clearance (Vmax/Km) of the AU or AE transporters. Flux from AB
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and BA is neutralized if the intrinsic transporter clearances of AU and AE transporters
are the same. Flux from AB is predominant if the intrinsic transporter clearance of the
AU transporter is higher than that of AE transporter and vice versa. However, that is only
true at low concentrations (panels A, B and C in Figure A-10, Figure A-11, Figure A-12
and Figure A-13). As shown in Equation A-15 and Equation A-19, the only difference
between PSBA and PSAB is the numerator, PSD+PSAE and PSD+PSAU, respectively. At
low concentrations (CC << KmE or CA << KmU), PSAE and PSAU approximately equals to
intrinsic clearance (Vmax/Km). Therefore, the predominance of PSBA or PSAB is
determined by the intrinsic clearance (Vmax/Km) of the AU or AE transporters. At
concentration near the Km, CC and CA is unignorable. For PSBA, substrates cross
basolateral membrane into the cells by passive diffusion down the concentration
gradient. Therefore, CC is lower than the donor concentration, and, supposedly, lower
than CA which is the donor concentration for PSAB. When the Km or Vmax of AU and AE
transporters are equal, PSAE is thereby higher than PSAU, and PSBA is higher than
PSAB (panels B in Figure A-10, Figure A-11, Figure A-12 and Figure A-13). At high
concentrations, transporters become saturated, and PSBA and PSAB gradually
decrease to the same value as passive diffusion (panels A, B and C in Figure A-10,
Figure A-11, Figure A-12 and Figure A-13).
In conclusion, at low concentrations (C << Km), transporter mediated flux of a
substrate is determined by the predominant intrinsic clearance (Vmax/Km) of the AU or AE
transporters. At concentrations near the Km, flux from BA, indicating tubular secretion,
is predominant, despite the intrinsic clearance of AU transporter is higher than that of AE
transporter.
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Figure A-10: The influence of KmU on flux of BA and AB.
VmaxU = VmaxE = 15000 pmol/hr, KmE = 30μM, KmU = 15 (A), 30 (B), 60 (C) μM
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Figure A-11: The influence of VmaxU on flux of BA and AB.
KmU = KmE = 30 μM, VmaxE = 15000 pmol/hr, VmaxU = 7500 (A), 15000 (B), 30000 (C)
pmol/hr

Figure A-12: The influence of KmE on flux of BA and AB.
VmaxU = VmaxE = 15000 pmol/hr, KmU = 30μM, KmE = 15 (A), 30 (B), 60 (C) μM
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Figure A-13: The influence of VmaxE on flux of BA and AB.
KmU = KmE = 30 μM, VmaxU = 15000 pmol/hr, VmaxE = 7500 (A), 15000 (B), 30000 (C)
pmol/hr
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